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ISOLATION AND STRUCTURE ELUCIDATION OF VINCA ALKALOIDS 
FROM VINCA SPECIES AND INVESTIGATION OF CYTOTOXIC 
ACTIVITY OF VINORELBINE LOADED NANODRUG DELIVERY 
SYSTEMS 
SUMMARY 
This thesis study mainly consists of two different parts. The first part forms isolation 
and structure elucidation of Vinca alkaloids from the three Vinca species (Vinca 
major, Vinca minor and Vinca soneri). The second part consists of loading of a 
dimeric Vinca alkaloid, Vinorelbine to three different types of micellar nano drug 
delivery systems (MNDDS) and physical characterization of MNDDS and 
investigation of their cytotoxic activity.  
As it is known, natural products or their derivatives have an important place in 
cancer therapy. Among present chemotherapeutic agents natural drugs or their semi-
synthetic derivatives, namely alkaloids from Taxus, Catharantus and Vinca species 
are the most common drugs. Particularly dimeric Vinca alkaloids which have indeed 
Catharantus alkaloids and their derivatives are used in lung, ovarian and breast 
cancer therapy. However, all of the anti-cancer drugs including Vinca alkaloids have 
numerous side-effects. For this purpose, both isolation and structure elucidation 
studies for the Vinca alkaloids growing in Turkey were carried out, and the three 
micellar drug delivery systems were prepared and investigated for their physical 
properties and cytotoxic activity of the MNDDS with and without Vinorelbine.   
For the phytochemical research, alkaloids’ extracts of the three Vinca species were 
prepared, and structure of alkaloids, isolated by chromatographic methods, were 
determined with modern spectroscopic techniques, namely NMR (1H and 13C NMR, 
BB, APT, DEPT, COSY, gHSQS and gHMBC) and mass spectroscopy. From the 
three Vinca species, Vinca soneri has just been brought to the world of science as a 
new endemic species to Turkey. In fact, there are four species of Vinca in Turkey and 
among them, investigations on V. herbacea have just now published by our group. 
Vallesiachotamine and Picrinine were isolated from Vinca soneri as well as α and β-
Yohimbine. Vallesiachotamine is also isolated from Vinca minor besides iso-
Vallesiachotamine. This is a first isolation of Vallesiachotamine, iso-
Vallesiachotamine, α and β-Yohimbine from Vinca species as known Indole 
alkaloids. It is noteworthy that 11-Hydroxypolyneuridine was obtained from V. 
major as a new Indole alkaloid in this study.  
The studies of the second part is the preparation of the Vinorelbine 
nanoformulations. Vinorelbine is uploaded to one lipid based and two polymeric 
nano-drug delivery systems. The aim of these formulations is to prepare drug 
delivery systems which target cancerous tissue by using Enhanced Permeability and 
Retention (EPR) effect with high efficiency and lesser side effects.  
One of the MNDDS used in this study is a very well known targeting carrier, 
DiStearoyl PhosphatidylEthanolamine-PolyEthyleneGlycol 2000 (DSPE-PEG 2000) 
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which has been used in targeted cancer therapy researches, reported for several 
times.  
We also used two different Polymeric MNDDS to produce Nano-VLB. One of them 
is four arm star-shaped Poly-ε-Caprolactone (PCL), PolyEthyleneGlycol (PEG) 
(PCL4-PEG4), and the other one is Y shaped PCL2-PEG. These polymers have been 
synthesized by Prof. Gurkan HIZAL and Umit TUNCA polymer research group and 
the synthesis procedure was not involved in this study. The structure and synthesis 
pathway of these two polymers are new and we are reporting characterization of 
micelles prepared by these two co-polymers.  
For the characterization of these two polymeric micelles their CMC were 
investigated and gave satisfactory results (CMC is 50 mg/L and 1mg/L for Star and 
Y-Shaped PCL-PEG micelles, respectively) and we are introducing two new drug 
delivery systems for hydrophobic agents by preparing two new Nano-VLB 
formulations.  
As a result, although both polymeric nano-VLB formulations and DSPE-PEG 
formulation showed enhanced in vitro cytotoxic activity, the latter one exhibited 
higher activity and drug loading capacity than the former one. Thus, it can be 
summarized that DSPE-PEG systems can be considered as better drug delivery 
systems, at least based on our experimental results as well as the accumulated 
knowledge.    
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VĐNCA ALKALOITLERININ VĐNCA TÜRLERĐNDEN ĐZOLASYONU VE 
YAPI TAYĐNĐ VE VINORELBINE YÜKLENMĐŞ NANO-ĐLAÇ TAŞIMA 
SĐSTEMLERĐNĐN SĐTOTOKSĐK AKTĐVĐTELERĐNĐN ARAŞTIRILMASI 
ÖZET  
Bu tez çalışması başlıca iki farklı kısımdan oluşmaktadır. Đlk kısım, Türkiye’de 
yetişen üç Vinca türünden (V. minor, V. major ve V. soneri’den) alkaloitlerinin izole 
edilmesi ve yapılarının tayininden oluşmaktadır. Đkinci kısım ise kanser tedavisinde 
kullanılan dimerik Vinca alkaloitlerinden birinin seçilerek ki bu amaçla Vinorelbin 
seçilmiş ve farklı üç misel ile hazırlanan nano-taşıyıcı sistemlere yüklenerek fiziksel  
ve sitotoksik aktivitesi yönüyle incelenmesinden ibarettir. 
Bilindiği gibi kanser tedavisinde doğal ürünler veya onların yarı-sentetik türevleri 
oldukça önemli bir yer almaktadır. Günümüzdeki kemoterapötik ajanların en önde 
gelenlerini yine doğal ürünler veya türevleri  ve özellikle de alkaloitler 
oluşturmaktadır ki başlıcaları Taxol, Catharanthus ve Vinca alkaloitleri veya yarı-
sentetik türevlerinden ibarettir. Bunlardan biri olan dimerik Vinca alkaloitlerinin 
farklı ürünleri akciğer, yumurtalık ve meme kanseri tedavisinde kullanılmakta, fakat 
Vinca alkaloitleri de dahil tüm antikanser ilaçların pek çok yan tesiri bulunmaktadır. 
Bu amaçla bu tez çalışmasında hem Türkiyede yetişen Vinca türlerinin alkaloitleri 
izole edilerek yapıları belirlenmiş ve ilaç olma potansiyelleri araştırılmış, hem de 
Vinca alkaloitlerinden son yıllarda tedavide sıklıkla kullanılan Vinorelbinin vücuttaki 
biyoyararlanımı arttırılarak yan tesirlerinin azaltması için hazirlanan yeni ilaç taşıyıcı 
sistemlerinin misel formu hazırlanarak Vinorelbin yüklemeden ve yüklendikten 
sonraki fiziksel ve kimyasal özellikleri incelenmiş, yanı sıra sitotoksik özelliklerinde 
bir değişlik olup olmadığı araştırılmıştır.    
Yapılan fitokimyasal araştırmada öncelikle toplanan her üç Vinca türünün alkaloit 
ekstreleri hazırlandı ve kromatografik yöntemlerle içerdikleri alkaloitler izole 
edilerek kimyasal yapıları modern NMR (1H ve 13C NMR, BB, APT, DEPT, COSY, 
gHSQC ve gHMBC) ve kütle spektroskopisi başta olmak üzere spektroskopik 
yöntemlerle tayin edildi. Đncelenen üç Vinca türünden Vinca soneri bilim dünyasına 
henüz kazandırılmış Türkiye’ye endemik yeni bir Vinca türü’dür . Zaten Türkiye’de 
4 Vinca türü vardır, bunlardan V. herbacea  grubumuz tarafından yakın geçmişte 
incelenmiştir. Vinca soneri’den α- ve β-Yohimbin alkaloitlerinin yanı sıra 
Vallesiachotamine alkaloidi elde edilmiştir. Bu sonuncu alkaloit Vinca minor 
bitkisinden iso-Vallesiachotaminin yanı sıra Vallesiachotamine de elde edilmiştir, 
Vallesiachotamine’in Vinca türlerindeki mevcudiyeti ilk kez bu çalışma ile 
gösterilmiştir. Sonuç olarak, Vallesiachotamine, iso-Vallesiachotamin, α- ve β-
Yohimbin Vinca türlerinden ilk kez elde edilen indol alkaloitleri, Vinca major 
bitkisinden izole edilerek yapısı aydınlatılan 11-Hydroxypolineuridin ise doğadan ilk 
kez elde edilen bir indol alkaloitidir. 
Tezin ikinci kısmını oluşturan Vinorelbinin nanoformülasyonların hazırlanmasında, 
Vinorelbin (VLB)i lipid bazlı ve ayrıca polimerik miseller oluşturarak hazırladığımız 
nanoilaç taşıyıcı sistemlerine (MNDD) yükleyip kanserli bölgeyi hedef almak, 
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yüksek geçirgenlik ve alıkonma (EPR) özelliklerine sahip yüksek etki ve düşük yan 
etkili bir nanoilaç haline getirmeyi amaçladık. 
Bu amaçla hazırlanılan MNDDs lerden biri hedefli kanser tedaviyi amaçlayan 
çalışmalarda çok iyi bilinen bir hedeflendirme reaktifi olan 
DiStearoylPhosphatidylEthanolamine-PolyEthyleneGlycol 2000 (DSPE-PEG 2000) 
dir. Polimerik Nano-VLB yi hazırlamak için ise iki farklı polimerik misel nano-drug 
delivery (MNDD) sistem  hazırlandı.Onlardan biri dört kollu yıldız şekilli Poly-ε-
Caprolactone  (PCL), PolyEthyleneGlycol (PEG) den ibaret (PCL4-PEG4) ve diğeri 
iseY şekilli PCL2-PEG dir. Bu polimerler Prof. Dr. G. Hızal ve Ü. Tunca’nın 
polimerik sentez araştırma grubunca sentezlendiğinden bu tez çalışmasına dahil 
edilmemiştir. Bu iki polimerin karakterizasyonları için kritik misel konsantrasyon 
(CMC) ları ölçülmüş ve dört kollu yıldız polimer için CMC 50 mg/L ve Y şekilli 
PCL2-PEG miselleri için 1mg/L olarak tatmin edici sonuçlar vermiştir. Sonuçta hem 
Polimerik Nano-VLB formülasyonları, hem de DSPE-PEG-VLB formülasyonları in 
vitro koşullarda sitotoksik aktiviteyi arttırsalarda DSPE-PEG-VLB 
formülasyonlarının hem daha yüksek aktivite göstermesi hem de DSPE-PEG 
sisteminin polimerik sistemlerden daha yüksek miktarda VLB taşıma kapasitesi 
göstermesi en azından bizim sonuçlarımız ve bugüne dek yapılan çalışmalara göre  
lipid bazlı sistemlerin daha iyi ilaç taşıyıcı sistemler olduğunu göstermektedir. 
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1. INTRODUCTION 
1.1 General Introduction: 
Every living organism, from the very beginning of its existence, has to struggle for 
survival. Man has familiarized himself with plants and used them in a variety of 
ways throughout the ages. For search of food, he has distinguished the plants suitable 
for nutritional purposes from others with definite pharmacological actions. Thus the 
drugs of plant origin have served through the ages as the mainstay in the treatment of 
human ailments and preservation of health.  
Plants have been the basis for some of the most effective powerful drugs known to 
man e.g. the Chinese have been using “Ma Huang” (Ephedra), for thousands of years 
for the treatment of nasal congestion, bronchial cough and asthma. In addition, 
almost a quarter of all pharmaceutical used today are of plant origin. 
In the Indo-Pak subcontinent, records of the indigenous system of medicines known 
as “Ayurveda”, go back to 700 B.C. and its systematization is attributed to Charaka 
and Sushurta, who cited about 700 medicinal plants. Thus the “Ayurvedic system 
was developed in India, whereas Srilanka (Ceylon) established the “Bantu System”. 
The many advances made in medicine in the earlier period are examplified by great 
names of Hippocrates [(Finlayson, 1892), (Sigerist, 1934), (Theophrastus and Galen 
Walsh, 1937)].  
Actually the history of modern medicine and pharmacy begins from Hippocrates, the 
“Father of Modern Medicine”. In writings early 400 samples are named as medicinal 
substances. Theophrastus wrote a book “on the History of Plants” in which he 
mentioned 500 drugs. His famous book on “Materica Medica” was first published in 
Greece, which serves as the pharmacological handbook for a long time. Following 
this period, the role of medicine was gratly extended in the Islamic age of Science 
and Medicine. The most famous physician and philosopher of his time, Ibni-Sina 
described 760 herbal drugs in his book “Canon of Medicine” which served as a 
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textbook of Medicine in Europe till 17th century A.D, and formed the base of the 
Greco-Arab System of medicine known as Tibb-e-Unani.(Sultana, 1992)  
In the seventeenth and eighteenth centuries great progress was made in the fields of 
pharmacy and medicinal chemistry. During the nineteenth century pharmaceutical 
chemistry emerged as an important subclass of chemistry. The discovery of the 
alkaloid morphine by serturner in 1805, followed by a whole series of alkaloids from 
herbal drugs e.g. strychnine, papaverine, quinine nicotine and cocaine , may have led 
to greater attention being paid to chemical investigations of medicinal plants(Figure 
 1.1) .  
One of the first important plants on which work was carried out was Rauwolfia 
serpentina which led to the isolation of a whole series of new alkaloids, which 
gained worldwide importance in the treatment of cardiovascular diseases and aental 
ailments e.g. reserpine (Figure  1.2). About 25% of the drugs used today in developed 
countries contain active principles which are extracted from plants and about 2/3 of 
the people in developing countries rely on plants for relief from disease. Morover, 
studies on the structure-function releationship have enriched mankind with a better 
understanding of the biological systems and disease processes. Recently there has 
been increasing interest in the development of bioassay procedures for the selection 
of plants containing novel biologically active substances.(Sultana, 1992)  
Thus a great deal of interest has developed throughout the world in the investigation 
of medicinal plants, most of which grow in the hot and humid regions of the third 
world. Taking into account the facts stated above, the work undertaken for the 
present thesis relates to the isolation of new natural products from Vinca minor, 
Vinca major and Vinca soneri. 
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Figure  1.1: First discovered alkaloids (Sultana, 1992). 
 
Figure  1.2: Chemical Structure of Reserpine (Sultana, 1992). 
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2. ALKALOIDS 
2.1 Definition 
The definition of the term alkaloid is not a simple one, and is in many cases a source 
of academic controversy. Difficulties with the definition of such a group of 
secondary and natural molecules as alkaloids stem from similarities of alkaloids with 
other secondary compounds. Attempts to define the term “alkaloid” originated at the 
time of the discovery of these compounds. 
The term “alkaloid” was first mentioned in 1819 by W. Meißner, an apothecary from 
Halle. He observed that these compounds appeared “like alkali”, and so named them 
alkaloids. 
From the biological point of view, the alkaloid is any biologically active and 
heterocyclic chemical compound which contains nitrogen and may some 
pharmacological activity and, in many cases, medicinal or ecological use. This 
definition, as a relatively wide one based on application, can be criticized as inexact. 
However, it presents a general picture of what kinds of compound are under 
consideration. The biological and chemical nature of this group of compounds leads 
to the conclusion that each definition of alkaloids is either too broad or too narrow. A 
short exact definition is not possible without a long list of exceptions. 
Medicine draws attention to the fact that alkaloids create intense physiological 
action, and they are widely used in the medical fields as curative drugs. Some 
alkaloids can also be highly toxic, even in very small doses. In the database of the 
National Library of Medicine it is possible to find the definition of alkaloids, 
according to which these compounds are nitrogenous bases and occur in animal and 
vegetable kingdoms, while some of them have been synthesized. Another electronic 
database also provides a definition of alkaloids, stating that an alkaloid is a 
nitrogenous organic compound which has pharmacological effects on humans and 
other animals, and whose name is derived from the world alkaline. As can be seen, 
the definition of alkaloids in the field of medicine also offers parameters of “may 
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be”, “often”, “slightly” and “highly”, which are not exact. This is typical of the 
scientific and practical fields, where alkaloids are well known and used in the 
bettering of human health, but where the term remains relatively difficult to define 
exactly and concisely. 
Chemistry has provided a definition of alkaloids in purely chemical terms. Chemists 
stress that alkaloids are any group of complex heterocyclic nitrogen compounds, 
which have strong physiological activity, are often toxic, and retain their own basic 
chemical properties. It is also stated that there are a few exceptions to this definition. 
In another chemical definition, it is stated only that alkaloids are nitrogen-containing 
compounds derived from plants and animals. 
Later, chemists stressed that alkaloids were biogenic, nitrogen-containing and mostly 
N-heterocyclic compounds. In this definition it is also stated that amino acids, 
peptides, nucleosides, amino sugars and antibiotics are not considered as to be 
alkaloids (Cordell, 1981). 
The first modern definition by Winterstein and Trier described alkaloids as basic 
nitrogen containing compounds of either plant or animal origin. “True alkaloids” 
were defined as compounds having four additional qualifications: 
(1)The nitrogen is part of a heterocyclic system 
(2)The compound has a complex molecular structure 
(3)The compound often manifests significant pharmacological activity. 
(4)The compound is restricted to the plant kingdom.  
Alkaloids frequently occur as salts of plant acids such as maleic acid, meconic acid 
or quinic acid some occur as glucosides e.g. solanine whereas others are found as 
amides e.g. piperine or as esters. 
The classical definition mentioned above has been modified because there were 
many examples of compounds which were universally accepted as alkaloids, but 
which violated one or more of the cardinal requirements of a definition of the 
Winterstein-Trier type. For instance basicity can no longer be regarded as a 
necessary property of an alkaloid e.g. colchicines, piperine and amine oxides such as 
indicine are not basic. Moreover alkaloid-type structures have also been isolated 
from animal, fungal and bacterial sources. 
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Alkaloids are therefore better defined as cyclic organic compounds containing 
nitrogen in a negative oxidation state, which are of limited distribution among living 
organisms. The requirement of nitrogen in a negative oxidation states include amines 
(-3), amine oxide (-1), amides (-3) and quaternary ammonium salts (-3), but excludes 
nitro (+3) and nitroso (+1), compounds. 
Alkaloids can be classified in the terms of their (1) biological and ecological activity; 
(2) chemical structures and (3) biosynthetic pathway. From the point of view of 
biological activity, it is possible to divide alkaloids into (1) neutral or weakly basic 
molecules (e.g., lactams such as ricinine, certain N-oxides (such as indicine), (2) 
animal-derived alkaloids (e.g., anuran, mammalian and arthropod alkaloids), (3) 
marine alkaloids, (4) moss alkaloids, (5) fungal and bacterial alkaloids and (6) non-
natural alkaloids (structurally modified or analogues). 
From a structural point of view, alkaloids are divided according to their shapes and 
origins. There are three main types of alkaloids: (1) true alkaloids, (2) protoalkaloids 
and (3) pseudoalkaloids (Cordell, 1981). 
2.2 True Alkaloids 
True alkaloids derive from amino acid and they share a heterocyclic ring with 
nitrogen. These alkaloids are highly reactive substances with biological activity even 
in low doses. All true alkaloids have a bitter taste and appear as a white solid, with 
the exception of nicotine(Figure  1.1) which has a brown liquid. True alkaloids form 
water-soluble salts. Moreover, most of them are well-defined crystalline substances 
which unite with acids to form salts. True alkaloids may occur in plants (1) in the 
free state (2) as salts and (3) as N-oxides. These alkaloids occur in a limited number 
of species and families, and are those compounds in which decarboxylated amino 
acids are condensed with a nonnitrogenous structural moiety. The primary precursors 
of true alkaloids are such amino acids as l-ornithine, l-lysine, l-phenylalanine/l-
tyrosine, l-tryptophan and l-histidine. Examples of true alkaloids include such 
biologically active alkaloids as cocaine, quinine (Figure  1.1), dopamine, morphine 
and usambarensine (Figure  2.1). 
8 
 
 
Figure  2.1 Chemical structure of Usambarensine an example of true alkaloids 
(Cordell, 1981). 
l-tyrosine-derived alkaloid usambarensine has strong anti-malarial potential. 
Usambarensine was extracted from the root bark of African Strychnos usambarensis, 
a small tree in East and South Africa, and a small bush in West Africa. 
2.3 Protoalkaloids 
Protoalkaloids are compounds, in which the N atom derived from an amino acid is 
not a part of the heterocyclic. Such kinds of alkaloid include compounds derived 
from l-Tyrosine and l-tryptophan. Protoalkaloids are those with a closed ring, being 
perfect but structurally simple alkaloids. They form a minority of all alkaloids. 
Hordenine, mescaline (Figure  2.2) and yohimbine are good examples of these kinds 
of alkaloid. 
 
Figure  2.2: Chemical structure of Mescaline (an example of Protoalkaloids) (Cordell, 
1981). 
Mescaline is the alkaloid derived from l-tyrosine and extracted from the Peyote 
cactus (Lophophora williamsii) belonging to the Cactus family (Cactaceae). 
Mescaline has strong psychoactive and hallucinogenic properties. Peyote cactus 
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grows in the desert areas of northern Mexico and the southern parts of the USA. This 
plant was used in Pre-Columbian America in the shamanic practice of local tribes. 
2.4 Pseudoalkaloids 
Pseudoalkaloids are compounds, the basic carbon skeletons of which are not derived 
from amino acids. In reality, pseudoalkaloids are connected with amino acid 
pathways. They are derived from the precursors or postcursors (derivatives the 
indegradation process) of amino acids. They can also result from the amination and 
transamination reactions of the different pathways connected with precursors or 
postcursors of amino acids. 
These alkaloids can also be derived from non-aminoacid precursors. The N atom is 
inserted into the molecule at a relatively late stage, for example, in the case of 
steroidal or terpenoid skeletons. Certainly, the N atom can also be donated by an 
amino acid source across a transamination reaction, if there is a suitable aldehyde or 
ketone. Pseudoalkaloids can be acetate and phenylalaninederived or terpenoid, as 
well as steroidal alkaloids. Examples of pseudoalkaloids include such compounds as 
coniine, capsaicin, ephedrine, solanidine, caffeine, theobromine and pinidine (Figure 
 2.3)(Cordell, 1981). Acetate-derived alkaloid pinidine is extracted from the Pinus 
species, for example, from Pinus penderosa. Pinidine has antimicrobial activity. 
 
Figure  2.3: An example of a pseudoalkaloids (Cordell, 1981). 
2.5 Alkaloid Classification According To Structure: 
2.5.1 Indole alkaloids: 
Indole alkaloids include many compounds which pharmacological activity is well 
established e.g. Morphin (Figure  1.1) derived from Opium poppy by Sertuner in 
1805, is used as analgesic and narcotic, quinine (Figure  1.1) from Cincona bark cures 
or Alleviates malaria , reserpine (Figure  1.2) from Rauwolfia serpentia was once 
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used as an important hypotensive and sedative drug. Vinblastine (Figure 5.2Hata! 
aşvuru kaynağı bulunamadı.)and Vincristine (Figure 5.2) isolated from leaves of 
Catanthus roseus are used as anticancer drugs. Vincristine is highly active in the 
treatment of childhood leukemia. Vinblastine is used in Hodgkin’s disease and 
choricarcinoma. 
2.5.2 Taxane alkaloids: 
Another class of alkaloid belongs to the taxane skeleton. These compounds have a 
novel diterpenoid tricycle[9.3.1.0]pentadecene skeleton. Such alkaloids exist in the 
family taxaceae which has five genera: (1) Amentotaxus, (2) Austrotaxus, (3) 
Pseudotaxus, (4) Taxus and (5) Torrya. Out of these the mostly studied and 
investigated genus is Taxus. These alkaloids show a wide range of pharmacological 
properties including antitumour and antileukemic.  
2.5.3 Steroidal alkaloids 
Another important class of alkaloids is steroidal alkaloids. These compounds possess 
the basic steroidal skeleton (often in modified form) with the nitrogen incorporated 
as an integral part of the molecule, either in the ring or in the side chain. Such 
alkaloids exist both in plants and animals and display a wide range of 
pharmacological and chemical properties and some of them can be converted into 
steroidal hormones by simple chemical or microbial treatment (Pelletier, 1999).  
2.5.4 Classification of alkaloids according to their occurrence in nature 
1.The Dogbane botanical family (Apocynaceae) 
2.The Aster botanical family (Asteraceae) 
3.The Logan botanical family (Loganiaceae) 
4.The Poppy botanical family (Papaveraceae) 
5.The Citrus botanical family (Rutaceae) 
6.The Nightshade botanical family (Solanaceae) 
7.The Coca botanical family (Erythroxylaceae) 
8.The Borage botanical family (Boraginaceae) 
9.The Legume botanical family (Fabaceae) 
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10.The Monseed botanical family (Menispermaceae) 
11.The Berberry botanical family (Berberidaceae) 
12.The Buttercup botanical family (Ranunculaceae) 
13.The Lily botanical family (Liliaceae) 
14.The Coffee botanical family (Rubiaceae) 
15.The Amaryllis botanical family (Amaryllidaceae) 
16.The Oleaster botanical family (Elaeagnaceae) 
17.The Caltrop botanical family (Zygophyllaceae) 
18. Mushroom Alkaloids 
19. Moss Alkaloids 
20.Fungus and bacter Alkaloids 
21.Alkaloids that are found in the animal kingdom. 
2.5.5 Monoterpenoid-derived indole alkaloids 
Indole alkaloids are so-called because they incorporate an indole ring system (Figure 
 2.4) in their molecular structure. All indole alkaloids are biogenetically derived from 
tryptophan (Figure  2.4) and therefore contain two nitrogen atoms, one of which is 
contained within the five-membered part of the indole nucleus. In a few instances, 
notably the pharmaceutically important alkaloids such as quinine(Figure  1.1) from 
Cinchona species and camptothecin from Camptotheca acuminata, this five-
membered ring is expanded by the inclusion of an extra carbon and the alkaloids 
chemically are classified as quinolines (Figure  2.4) rather than indoles, although their 
biogenetic origins are the same. 
The chemistry and biological activity of indole alkaloids have received much 
attention over the last 50 years and several monographs1,2 and detailed reviews* 
have been published. 
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Figure  2.4: The mother compounds of monoterpenoid derived alkaloids (Pelletier, 
1999). 
The alkaloids of principal therapeutic importance are shown in the Table below, 
together with their sources. 
Three major types of indole alkaloids are recognized by most natural product 
chemists although several other indole alkaloids are known which do not fit neatly 
into these three categories. The three major categories are the ‘‘simple’’ indoles that 
are formed from tryptophan without the addition of other C-skeletal moieties [e.g., 
harmine (Figure  2.5)], the tryptamine-amino acid congeners found particularly in 
fungi such as ergot (), and the largest group, numbering several thousand, where the 
tryptophan skeleton is linked with a monoterpene unit derived from the iridoid 
secologanin. Because of different rearrangements of the iridoid moiety after 
conjugation, three major groups of this type of indole alkaloid are generally 
recognized, these being the Corynanthe-type (e.g., ajmalicine, Figure  2.5), the Iboga-
type (e.g., catharanthine, Figure  2.5), and the Aspidosperma-type (e.g., tabersonine, 
Figure  2.5). In some cases two types are linked together to form bisindoles [e.g., 
vincristine, (Fig. 5.2)], which consist of an Aspidosperma-type linked to an Iboga-
type. 
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Figure  2.5: Structure of some Indole alkaloids (Pelletier, 1999). 
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2.6 Occurrence of Indole Alkaloids in Higher Plants 
The simple indoles occur sporadically in fungi and flowering plants and also in 
animals, since it could be argued that the mammalian neurotransmitter serotonin is 
also a simple indole and others are found in the skin of certain amphibians (e.g., 
bufotenine found in toads, Bufo spp.). The fungal genus Psilocybe contains alkaloids 
such as psilocybin, while harmane alkaloids such as harmine 4 are found in 
flowering plant species. Fairly simple indole alkaloids are found in the seeds of some 
members of the Fabaceae, physostigmine 13 probably being the bestknown 
compound of this type. The tryptophan–amino acid alkaloids are often called the 
ergot alkaloids, since many of them were first isolated from Claviceps spp., fungal 
parasites of grasses that are commonly called ergots. There was considerable surprise 
when, in the 1960s, they were also found in the seeds of some genera of the 
Convolvulaceae, considered to be one of the most evolutionary-advanced families of 
the dicotyledons. The large number of terpenoid–tryptamine alkaloids is largely 
confined to some genera of three evolutionary-advanced dicotyledonous flowering 
plant families (i.e., the Apocynaceae, Rubiaceae, and Loganiaceae). An amazing 
variety of structures belonging to this group have been determined in the last 50 
years and they all arise from a Mannich-like condensation between tryptamine and 
the iridoid secologanin, with subsequent rearrangement of the iridoid components 
(Cordell, 1981; Pelletier, 1999; Sultana, 1992). 
2.7 Biogenetic Classification of Indole Alkaloids 
The fundamental building blocks for monoterpene indole alkaloids are tryptamine 
(tryptophan)(Figure  2.4) and the iridoid, secologanine. (Figure  2.6) The units 
combined to form (in vivo) strictosidine (Figure  2.6). The nitrogenous glycoside 
which is the key intermediate in biosynthetic elaboration which subsequently occurs.  
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Table  2.1: Some monoterpenoid Indole alkaloids of pharmacological significance. 
Compound Source Pharmacologic Activity 
Ajmalicine Catharanthus roseus Hypotensive 
Ajmaline Rauwolfia sp. Antiarrythmic 
Camptothecine Camptotheca acuminate Anticancer 
Deserpidine Rauwolfia canescens Hypotensive 
Ibogaine Tabernathe iboga Psychomimetic 
Leurocristine Catharanthus roseus Anticancer 
Quinidine Remijia sp. Cardiac depressant 
Quinine Cinchona sp. Antimalarial 
Rescinnamine Rauwolfia sp. Hypotensive 
Reserpine Rauwolfia vomitoria Hypotensive 
Strychnine Strychnos nux vomica CNS depressant 
Vincaleukoblastine Catharanthus roseus Anticancer 
Vincamine Vinca major Hypotensive  
 
Figure  2.6: Tryptophan and Secologanine combine to form Strictosidine (Cordell, 
1981). 
 
16 
 
Indole alkaloids are divided to five classes and within each class several subclasses 
have been developed based on their biosynthesis (Table  2.2) (Cordell, 1981). 
Table  2.2: Classification of Indole alkaloids based on their biosynthesis. 
Class 1 Alkaloids containing a nonrearranged secologanin skeleton 
1.1 Strictosidine group 1.11 Picraline group 
1.2 Coryantheine group 1.12 Corymine group 
1.3 Vallesiachotamine group 1.13 Ajmaline group 
1.4 Adifoline group 1.14 Perakine group 
1.5 Talbotine group 1.15 Oxindole group 
1.6 Stemmadenine group 1.16 Pseudoxindole group 
1.7 Mavacurine group 1.17 Condylocarpine group 
1.8 Cinchonamine group 1.18 Akuammicine group 
1.9 Sarpagine group 1.19 Strychnine group 
1.10 Peraksine group   
Class2 Alkaloids containing an open secologanin skeleton 
2.1 Secodine group   
Class 3 Alkaloids containing a rearranged secologanin skeleton 
3.1 Quebrachamine group 3.6 Vindolinine group 
3.2 Aspidospermine group 3.7 Pleiocarpine group 
3.3 Schizophylline group 3.9 Oxindole group 
3.5 Schizozygine group   
Class 4 Alkaloids containing a rearranged secologanin skeleton 
4.1 Fruticosine group   
Class 5 Alkaloids containing a rearranged secologanin skeleton 
5.1 Catharanthine group   
5.2 Pseudooxindole alkaloids   
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Figure  2.7: Main classes of Indole alkaloids (Cordell, 1981). 
Some other sources classify Indole alkaloids according to their skeleton properties. 
Based on these data sources Indole alkaloids with a C9- or C10- monoterpene moiety 
are classified into the subgroups shown in Fig. 2.8. (Pelletier, 1999):  
2.8 Pharmacologıcal Importance of Indole Alkaloids 
The biological activity of some fungi and plants containing indole alkaloids has been 
known for a very long time, particularly those that have a severe effect on humans or 
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animals, and the elucidation of the structure of the alkaloids responsible is a 
comparatively recent event. 
 
Figure  2.8: The chemical structure of some examples of main classes from Indole 
alkaloids (Cordell, 1981). 
Ergot contamination in rye consumed by humans, and in grasses consumed by 
domestic grazing animals, has been known to be associated with miscarriage, 
gangrene, and CNS disturbances for hundreds of years and the effects of the 
contained alkaloids were exploited in central European traditional medicine for 
helping in childbirth. Ergot contains several indole alkaloids and two of them have 
found extensive use in pharmacy. 
Ergometrine (Figure  2.10) is mainly used in childbirth because of its ability to cause 
contraction of the uterus and contract blood vessels, thus reducing bleeding, while 
ergotamine has a stronger dopaminergic effect and is mainly employed in treating 
migraine because it reduces vasodilation. 
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Several semisynthetic compounds based on ergotamine have been developed for 
treating Parkinsonism and related neurological disorders. 
 
Figure  2.9: Classification of Indole alkaloids according to their structure (Cordell, 
1981). 
In southern Asia, the toxic nature of Strychnos nux vomica was well known and other 
species of the genus were known as a source of arrow poisons in Africa and South 
America. Many fungi and plants containing indole alkaloids have been used as 
hallucinogens or in religious rites because of their effect on consciousness and these 
include the Psilocybe fungi in Oaxaca (Mexico) which were known as 
‘‘teonanácatl’’; the roots of Tabernanthe iboga in west central Africa known as 
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‘‘iboga’’; and the seeds of Ipomoea spp., known in Mexico as ‘‘ololiuqui.’’ 
Physostigmine (also called eserine) is an interesting example of an indole alkaloid 
that was discovered because of the use of the seeds of a plant Physostigma 
venenosum, in southeastern Nigeria as an ordeal poison. It was the first 
acetylcholinesterase inhibitor to be discovered and has been used to treat glaucoma 
and myasthenia gravis. Analogues have been developed as insecticides as well as 
drugs, the most recent being rivastigmine, which is used for symptomatic relief in 
Alzheimer’s disease. 
 
Figure  2.10: Two alkaloids with significant pharmacological activity 
(Mukhopadhyay, 1981). 
Other plant species containing indole alkaloids were widely used in traditional 
medical systems (e.g., Rauwolfia serpentina roots), known as ‘‘sarpagandha’’ in 
Ayurvedic medicine have a long tradition of use as a treatment for snakebite and 
some psychiatric diseases. Rauwolfia species contain many indole alkaloids but the 
one which was most widely used in the mid 20th century was reserpine (Figure  1.2), 
which was the first tranquilizing drug but also extensively used at one time as a 
hypotensive. Ajmaline 16 is another Rauwolfia indole alkaloid, which is used to treat 
cardiac arrhythmia in some countries. Yohimbine (Figure  2.11) from Pausinystalia 
yohimbe, the bark of which has a reputation as a male aphrodisiac, has been used to 
treat erectile dysfunction. Extracts from barks of Cinchona spp. were introduced in 
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Europe for the treatment of malaria not long after the conquest of much of South 
america by the Spanish in the 16th century and the major alkaloid quinine (Figure 
 1.1), which contains a quinoline ring system rather than indole, has been used for 
many years as an antimalarial drug although now used only where other antimalarials 
are ineffective. 
Possibly the indole alkaloids that are most important clinically are the anticancer bis-
indoles vinblastine(Figure 5.2)  and vincristine (Figure 5.2), which are found in 
Catharanthus roseus. These were introduced in the 1960s and have made a marked 
impact on remission of childhood leukemia and some other cancers. Other anticancer 
alkaloids derived from tryptophan are the indole ellipticine 20 and the quinoline 
camptothecin 21, the latter having greater importance as a template for analogues 
such as topotecan. 
Many other types of alkaloids, their bitter taste is thought to act as a feeding deterrent 
to mammals, as they are often concentrated in parts of the plant vulnerable to attack 
(e.g., the high percentage of alkaloids in the bark of Rauwolfia roots). The deterrent 
property has been demonstrated for the simple indole gramine as regards sheep. It 
has also been pointed out that gramine has antifeedant activity against aphids, an 
example of general antifeedant activity regarding insects, shown by 
alkaloids.(Mukhopadhyay, 1981). 
2.9 Chemosystematic Importance of Indole Alkaloids 
Waterman has pointed out that the chemosystematic importance of the alkaloids is 
not great. The major interest concerning Indole alkaloids is that the Indole– 
secologanin Indole alkaloids are found in assorted genera of the Apocynaceae, 
Loganiaceae, and Rubiaceae of the Gentianales, with the Iboga type restricted to the 
Apocynaceae. These compounds are also found in the lesser families Alangiaceae, 
Nyssaceae, and Icacinaceae of the Cornales.(Sultana, 1992) 
2.10 Alkaloids of Yohimbe 
We are presenting the isolation and structure elucidation of constituents of 4 Vinca 
species occuring in Turkey, one of which (Vinca herbacea) has previously been 
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studied by our group (Boga, 2011) One of these species has recently been introduced 
to the world of botany by Koyuncu M (Koyuncu, 2011) and is endemic to Turkey.  
During the chemical identification of this plant we obtained α- and β-Yohimbine 
which previously have not been isolated from Vinca species. Since the the occurance 
of a certain class of chemical compound in a plant family and/or species has a 
significant importance in plant taxonomy it will be useful to mention on the structure 
of “Yohimbinoids” in this chapter. 
Yohimbehe bark, originally believed to be derived from a species of 
Taberncemontana (Apocynaceae), but now assigned to Pausinystalia yohimba, 
Pierre (Fam. Rubiaceas; syn. Corynanthe yohimbe, Schum.), a tree native to the 
Cameroons and French Congo, contains alkaloids on which pioneer work was done 
by Spiegel Some of the alkaloids are of uncertain individuality, e.g., Spiegel's " 
yohimbenine "(Spiegel, 1915, 1926) and the unnamed base described by Danckwortt 
and Luy (Ohem, 1896)  
The yohimbines comprise a group of natural, pentacyclic Indole alkaloids containing 
five chiral centers illustrated by Figure  2.11 (Ohem, 1896). 
 
Figure  2.11: Chemical structure of Yohimbine (Ohem, 1896). 
The Indole alkaloids under consideration have been categorized in the past on the 
basis of their ring D stereochemistry in terms of normal Figure  2.12(A), pseudo 
Figure  2.12(B), allo Figure  2.12(C), and epiallo Figure  2.12(D) configurations. 
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Figure  2.12: The categorization of Yohimbine alkaloids based on stereochemistry of 
ring D (Henry, 1949). 
Normal type Yohimbine alkaloids includes: yohimbine; Figure  2.13(A), β-
yohimbine; Figure  2.13(B), coryanthine; Figure  2.13 (C), Yohimbanr; Figure  2.13 
(D) and Yohimbinone; Figure  2.13 (E). 
 
Figure  2.13: The members of normal type Yohimbine alkaloids (Henry, 1949). 
Pseudo type Yohimbine alkaloids includes: Pseudoyohimbine; Figure  2.14 (A) and 
Pseudoyohimbone; Figure  2.14 (B). 
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Figure  2.14: Pseudo type Yohimbine alkaloids (Henry, 1949). 
Allo type Yohimbine alkaloids includes: α-Yohimbine; Figure  2.15 (A), 
Alloyohimbine; Figure  2.15 (B), Alloyohimbane, Figure  2.15 (C), Isoreserpine, 
Figure  2.15 (D). 
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Figure  2.15: Allo Type Yohimbine alkaloids (Henry, 1949). 
Epi-Allo type Yohimbine alkaloids includes: 3-Epi-α-yohimbine; Figure  2.16 (A), 
Reserpine; Figure  2.16(B), Raunescine; Figure  2.16 (C), Isoraunescine; Figure  2.16 
(D), Epialloyohimbane; Figure  2.16 (E), and Reserpate; Figure  2.16 (F). 
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Figure  2.16: Epi-Allo Type Yohimbine alkaloids (Henry, 1949). 
Table  2.3: Physical properties of some yohimbinoid alkaloids. 
Name Crystals and Solvent of 
Crystallisation 
m.p. [α]D 
Py = 
pyridine 
A = alcohol 
Yohimbine 
(quebrachine)  
Needles; 234-235° +84 to 
108°(Py) 
+50 to 55° A) 
α-Yohimbine Polyhedral: 
MeOH or 
EtOH + H20 
234-235° -22° to -28° 
(A) 
-9.3° (Py) 
β-Yohimbine Leaflets : H2Oor 2MeOH 235-236° -54° (dry : Py) 
allo Yohimbine Leaflets ; 1 or 3 H2O. B. H2O, 135-140°; 
B.3H2O, 
98-99° or 
104-105° 
-72-7° or 
-73-6° (Py) 
Corynanthine Hexagonal; 
2H2O 
241-242° 
(dry) 
-125° (A) 
- 73° (Py) 
2.10.1 Pharmacological action  
Yohimbine lowers blood pressure, increases the depth and frequency of respiratory 
movements and in toxic doses paralyses respiration, death being due to this cause in 
mammals, the heart remaining active for some time longer. It possesses local 
anaesthetic properties and resembles ergotoxine and ergotamine in sympatholytic 
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action. Though quebrachine has been shown to be identical with yohimbine, 
differences in pharmacological action have been noted. The other alkaloids of the 
group are stated to resemble yohimbine qualitatively in action, but Raymond-Hamet 
has observed differences in the action of Aspidospermine. Dawes (Dawes, 1946);. 
According to Edmunds, and Gunn (EDMUNDS, 1934) yohimbine is the most active 
of the group, closely followed by Aspidospermine; Quebrachamine and 
Aspidosamine. Kreitmair (Kreitmair, 1928) found α-yohimbine less toxic than 
yohimbine, equally potent as a local anaesthetic and similar in action on the genital 
organs of the dog. Various authors (Kreitmair, 1928) have stated that yohimbine 
exerts no estrogenic activity (Raymond, 1937). For method of evaluation also found 
that orynanthine is more active on the genital organs of the dog (Raymond, 1937) 
and on those of the rabbit cornea. The local anaesthetic action of yohimbine, cocaine 
and corynanthine is of the order 2 : 1 : 0.25 (Henry, 1949). 
2.11 Vallesiachotamine 
As mentioned in chapter condensation of secologanine with tryptamine affords 
strictosidine (3H-α) and vincoside (3H-β) (Figure  2.17). 
 
Figure  2.17: Chemical composition of Strychnine, the mother compound of 
Vallesiachotamine and Vincoside, (Arbain D, 1992). 
Removal of sugar from Strictosidine under mild condition affords Vallesiachotamine 
and likewise Vincoside spontaneously gives its 3β epimer.  
Vallesiachotamine was isolated from Vallesia dichotoma Ruis et. Pav. (Holker, 1959; 
Walser, 1965) and has been classified in modified Corynanthe (Hunterburine type) 
(Mukhopadhyay, 1981) alkaloids. 
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However duplication of some peaks in the NMR spectrum of Vallesiachotamine 
could be seen which has been attributed to the E\Z isomerization of the ethylidene 
group of vallesiachotamine. When some references mention on that 
Vallesiachotamine is a mixture of these two geometrical isomers (J. Edwin Saxton, 
1983 ), some papers name them as Vallesiachotamine and Isovallesiachotamine 
(Figure  2.18) (Arbain D, 1992; Bolzani VS, 2001). 
 
Figure  2.18: Chemical structure of Vallesiachotamine and its “Iso”mer  (Bolzani 
VS, 2001). 
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3. Vinca L.  
The genus Vinca L. (Apocynaceae) is native to Europe, northwest Africa and 
southwest Asia and comprises six species: Vinca difformis Pouret, V. erecta Regel & 
Schmalh, V. pubescens d’Urv., V. herbacea Waldst. & Kit., V. major L. and V. minor 
L.; the last three occur in Turkey (Stearn, 1973, 1978) 
Low creeping evergreen or deciduous perennial subshrubs or herbs. Leaves opposite. 
Flowers large, solitary in leaf axils on long pedicels. Corolla infundibular, lacking 
appendages in throat but with a zone of hairs above insertion of stamens and a low 
ridge connecting corolla lobes at base, lobes spreading. Stamens included, inserted c. 
halfway up corolla tube; filaments short, bent forward the back; anthers with flat 
flap-like appendage at apx. Disc glands 2. Seeds glabrous, oblong, not comose. 
3.1 V. herbacea  
Vinca herbacea (Herbaceous Periwinkle) is a flowering plant native to eastern and 
southeastern Europe, from Austria south to Greece, and east to the Crimea, and also 
in southwestern Asia east to the Caucasus and Alborz mountains. It grows mainly in 
steppe habitats. 
Herbaceous perennial, dying back completely top rootstock each winter, with 
ascending shoots to 20 cm, trailing shoots to 60 cm. leaves herbaceous, deciduous, 
very variable, narrowly elliptic, elliptic, lanceolate to ovate, 0.6-5x0.2-3 cm, base 
cuneate, apex acute, margin smooth, scabrid or shortly ciliate, with inconspicuous 
venis ascending at 10-35o from midrib; petiole 1-4mm. Calyx  3-10mm; lobes 
shortly ciliate or glabrous and smooth. Corolla pale blue to purple-blue; tube 1-2 cm, 
lobes 1-2 cm. Follicles 2.5-3.5 cm. Seeds 11-14 mm. Fl.3-5. Open sunny slopes, on 
sand, gravel, scree, fallow fields, rocks, scrub, very open woodland, 400-2000 m. 
Scattered throughout Turkey & Islands: Tekirdağ: 14km E. of Tekirdağ, Istanbul: 
Değirmenköy, Bolu: Abant, Kastamonu: Kastamonu, Samsun: Havza (Sekizgöz), 
Gümüşhane: Gümüşhane, Çoruh: Artvin, Erzurum: S. Of Đspir, Đzmir: Tahtalı Daç 
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above Đzmir, Eskişehir: 56 km from Eskişehir to Sivrihisar, Ankara: Ankara, Niğde: 
Malatya to Akça Da., 1000 m, Malatya: Baştaş, Maghda Da., Van: Bitlis, Antalya: 
S.W. of Avlan, Antalya: Hafis Paşa, Mut: Mağras Da., Đçel: N. Side of Gülek Boğazı, 
Maraş: 10 km S. Of Maraş, Urfa: E. of Urfa (Figure  3.1). 
 
Figure  3.1: Vinca herbacea (Url 1). 
3.2 V. major  
Vinca major, with the common names Large Periwinkle, Greater Periwinkle and 
Blue Periwinkle, is a flowering plant native to southern Europe, from Spain and 
southern France east to the western Balkans, and also in northeastern Turkey and the 
western Caucasus. 
Evergreen subshurb, with arching shoots rising to 30 cm then curving downwards, 
trailing shoots to 100 cm. Leaves evergreen, blade mostly ovate but varying from 
broadly ovate to lanceloate, 2.5-9 x 2-6 cm, base cordate or turncate-rounded, apex 
acute or obtuse, margin ciliate, with veins spreading at 40-50o from midrib; petiole 
5-15 mm. Calyx 6-18 mm; lobes ciliate. Corolla violet; tube 1.2-2 cm; lobes 1.2-2 
cm. Follicles 2.5-3.5 cm.  
Cultivated as an ornamental plant and sometimes naturalized: Đstanbul: Yıldız Parkı, 
Đstanbul: Ömerli to Şile, 10 km to Heriz, Bursa: Kumla, Hatay: Harbiye. 
Subspecies 
There are two subspecies, with geographically separate ranges: 
•Vinca major subsp. major. Leaf petioles finely hairy, hairs short. Southern Europe. 
•Vinca major subsp. hirsuta (Boiss.) Stearn (syn. V. pubescens d'Urv.). Leaf petioles 
densely hairy, hairs longer; petals much narrower. Caucasus, northeastern Turkey. 
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The closely related species Vinca minor is similar but smaller, with narrower, 
hairless leaves (Figure  3.2). 
 
Figure  3.2: Vinca major(Url 1). 
3.3 V. minor L.  
Vinca minor, Lesser periwinkle and Dwarf periwinkle, is a plant native to central and 
southern Europe, from Portugal and France north to the Netherlands and the Baltic 
States, and east to the Caucasus, and also in southwestern Asia in Turkey. Other 
vernacular names used in cultivation include Small periwinkle, Common periwinkle, 
and sometimes in the United States, Myrtle or Creeping myrtle, although this is 
misleading, as the name myrtle normally refers to the Myrtus species. Wikipedia 
Evergreen subshurb with flowering shoots to 15 cm, trailing shoots to 60 cm, making 
densely interwoven masses. Leave evergreen, blade mostly elliptic or lanceolate (but 
often oveate on trailing shoots), 1.5-4.5 x 0.5-2.5 cm, base usually cuneate, 
sometimes rounded, apex acute or obtuse, margin smooth and glabrous, with venis 
spreading from midrib at 40-60; petiole 2-10 mm. Calyx 3-4 mm, glabrous. Corolla 
usually blue-violet, sometimes white or reddish-purple; tube 9-11 mm, lobes 10-15 
mm. Follicles 1.5-2 cm; seeds 6-9 mm.Cultivated and sometimes naturalized. 
Đstanbul: Büyükdere, Park Camara, Đstanbul: Kınalıada, Bolu: Abant(Figure  3.3). 
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Figure  3.3: Vinca minor (Url 1). 
Ethnomedicine 
Ethnomedically, the dried leaves, aerial parts, and in some cases the entire plant of 
Vinca minor, are used to enhance blood circulation, including that of the brain, 
enhance metabolism in the brain, and to treat cardiovascular disorders.(Stearn, 1978) 
3.4 V. soneri (Figure  3.4) 
Perennial subschrubs with woody rootstock. Stem erect, simple, pilose, 25-50 cm. 
Trailing shoots absent. Leaves opposite, sessil or shortly petiolate, simple, entire, 
ovate-elliptic, 5-8 x 2.5-3.5 cm, base and apex acute, margine smooth and glabrous, 
beneath puberulant only on nerves-with veins spreading at 10-12 from midrib, petiol 
0-1 mm long. Calyx 8-10 mm, lobes linear, glabrous. Corolla blue or pale-blue, lobes 
white-blue, tube 2-2.5 cm, lobes 1- 1.5 cm. Folicle 5-7 cm, seeds 10-12 mm, 
tuberculate. Flowering time: 5- 6. Dry stony slopes, 1200- 2800 m (Koyuncu et al.).  
 
Figure  3.4 :Vinca soneri 
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Table  3.1: The morphological differences between Vinca soneri and V. herbacea. 
Characters Vinca soneri Vinca herbacea 
Stem 25-50 cm to 20 cm 
Trailing shoots absent to 60 cm 
Leaves 5-8 x 2.5-3.5 cm 0.6-5 x 0.2-3 cm 
 
eliptic-ovate narrowly elliptic, 
elliptic-lanceolate 
Petiol 0-1 mm 1-4 mm   
Calyx 8-10 mm 3-10 mm 
Tube of corolla 2-2.5 cm 1-2 cm 
Follicles 5-7 cm 2.5-3.5 cm 
Flowering time May-June March-May   
3.5 Indole Alkaloids Isolated from Vinca herbacea, Vinca major and Vinca 
minor 
A literature summary of Indole alkaloids that have been isolated from three Vinca 
species are given in APPENDIX F  
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4. NANO MEDICINE 
4.1 Introduction to Nano-Medicine 
Nanotechnology is an area of science devoted to the design, construction, and 
utilization of functional structures on the nanometer scale (often 100nm or smaller). 
At the nanoscale, the properties of materials often differ from those of the 
corresponding bulk materials. In fact, fundamental characteristics of a given material 
can be precisely controlled by nanotechnology without changing its chemical 
composition—such as melting point, magnetic properties, or even a characteristic as 
basic as color. There are numerous applications for nanotechnology. Among them, 
the treatment, diagnosis, monitoring and control of biological systems have recently 
been referred to as ‘‘nanomedicine’’ by the National Institute of Health (Bethesda, 
MD, USA). Nanomedicine may involve a number of different types of nanodevices, 
including nanoparticles, nanomachines, nanofibers, sensors, and other nanoscale 
microfabrication-based entities .  
Nanotechnology is now frequently used for various applications in fiber and textiles, 
agriculture, electronics, forensic science, space and medical therapeutics. However, 
biodegradable nanoparticles are frequently used to improve the therapeutic value of 
various water soluble/insoluble medicinal drugs and bioactive molecules by 
improving bioavailability, solubility and retention time. These nanoparticle–drug 
formulation reduces the patient expenses, and risks of toxicity. 
Nanoencapsulation of medicinal drugs (nanomedicines) increases drug efficacy, 
specificity, tolerability and therapeutic index of corresponding drugs. These 
nanomedicines have many advantages in the protection of premature degradation and 
interaction with the biological environment, enhancement of absorption into a 
selected tissue, bioavailability, retention time and improvement of intracellular 
penetration. 
Several disease related drugs/bioactive molecules are successfully encapsulated to 
improve bioavailability, bioactivity and control delivery. Nanomedicines of the 
dreadful diseases like cancer, AIDS, diabetes, malaria, prion disease and tuberculosis 
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are in different trial phase for the testing and some of them are commercialized 
(Weili Qiao, 2010). 
4.2 Introduction to Nano-Drug Delivery Systems 
Nanotechnology has opened the possibility of controlling and manipulating 
structures at the molecular level and led to the creation of novel surface architectures 
and materials. 
Traditional biomedical applications incorporated the use of nanotechnology in a 
broad spectrum of areas. Among them, biosensors, tissue engineering, intelligent 
systems and nanocomposites are used in implant design and controlled release 
systems. Several nano-oriented approaches are being intended (e.g. nanoparticle 
engineering) in order to optimize the technological aspects of drugs. The use of these 
processes has dramatically enhanced dissolution rates in vitro and bioavailabilities in 
vivo of many drugs. Another important strategy is the design of nanocarriers. From 
the first liposomes developed by Gregoriadis and colleagues more than three decades 
ago until the current state-of-the-art, a pronounced increase in the variety of 
macromolecular-based approaches for drug delivery was observed. Among the 
technological alternatives, the most broadly implemented are polymeric 
nanoparticles, dendrimers, polymeric micelles and polymersomes.  
Drug nanoformulations (nanodrug) are superior to traditional medicine with respect 
to control release, targeted delivery and therapeutic impact. These targeting 
capabilities of nanomedicines are influenced by particle size, surface charge, surface 
modification, and hydrophobicity. Among these, the size and size distributions of 
nanoparticles are important to determine their interaction with the cell membrane and 
their penetration across the physiological drug barriers. The size of nanoparticles for 
crossing different biological barriers is dependent on the tissue, target site and 
circulation. For the cellular internalization of the nanoparticles, surface charge is 
important in determining whether the nanoparticles would cluster in blood flow or 
would adhere to, or interact with oppositely charged cells membrane. Cationic 
surface charge is desirable as it promotes interaction of the nanoparticles with the 
cells and hence increases the rate and extent of internalization. For targeted delivery, 
persistence of nanoparticles is required in systemic circulation of the body. But 
conventional nanoparticles with hydrophobic surface are rapidly opsonized and 
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massively cleared by the fixed macrophages of the mononuclear phagocytic system 
(MPS) organs. For increasing circulation time and persistence in the blood, surface 
of conventional nanoparticles are modified with different molecules. Coating of 
hydrophilic polymers can create a cloud of chains at the particle surface which will 
repel plasma proteins. Finally, the performance of nanoparticles in vivo is influenced 
by morphological characteristics, surface chemistry, and molecular weight. Surface 
modified nanoparticles have anti-adhesive properties by virtue of the extended 
configuration on the particle surface which acts as steric barrier reducing the extent 
of clearance by circulating macrophages of the liver and promoting the possibility of 
undergoing enhanced permeation process. 
 
Figure  4.1 Different nanotechnology-based carrier systems (Weili Qiao, 2010). 
Release mechanism can be modulated by the molecular weight of the polymer used. 
Higher the molecular weight of polymer slower will be the in vitro release of drugs. 
Careful design of these delivery systems with respect to target and route of 
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administration may solve some of the problems faced by new classes of active 
molecules. Biodegradable polymeric nanoparticles based drug delivery systems. 
4.3 Different Nanotechnology-Based Nanocarrier Systems 
Based on nanotechnology, nanocarriers synthesized from organic and inorganic 
materials have been developed, such as nanoparticles, micelles, carbon nanotubes, 
dendrimers and nanofibers (Figure  4.1). They have shown great potential in cancer 
therapy by enhancing the performance of medicines and reducing systemic side 
effect in order to gain therapeutic efficiency (Weili Qiao, 2010).  
4.3.1 Micelles formed from amphiphilic block copolymers 
The application of polymer made particles (micro and nano) as means for drug 
vehiculization was one of the most broadly investigated strategies during the last 
decades. Depending on the production methodology, nanocapsules or nanospheres 
can be obtained. While the former are vesicular systems where the solid or 
solubilized drug is surrounded by a polymeric membrane, the later comprise a solid 
matrix with different levels of porosity where the molecules are homogeneously 
distributed across the bulk or attached to the surface The different aspects of 
nanoparticles as well as the biomaterials employed for their production have been 
comprehensively reviewed by several research groups.  
The general synthesis and encapsulation of biodegradable nanomedicines are 
represented in (Fig. 4.2). The drug molecules either bound to surface as nanosphere 
or encapsulated inside as nanocapsules (Kumari, Yadav, & Yadav, 2010). 
The most broadly investigated polymers include the natural chitosan, alginate, 
gelatin and albumin and the synthetic polylactic acid (PLA), poly (lactic-co-glycolic) 
acid (PLGA), polycaprolactone (PCL), poly (cyanoacrylate) (PCA), poly 
(methacrylic acid-co-ethylacrylate) block copolymer as well as combinations with 
other materials such as poly(ethylene glycol) (PEG). 
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Figure  4.2: Type of biodegradable nanoparticles (Kumari et al., 2010). 
Also, inorganic nanoparticles have been developed. In the case of highly 
hydrophobic drugs, increased entrapment can be also attained. From a 
pharmaceutical perspective, the application has been extended to formulations for a 
broad spectrum of administration routes including intravenous injection and 
pathologies (e.g., cancer). Polymeric micelles are nano-structures formed by the self-
assembly of amphiphiles in water, above a minimal concentration called the critical 
micelle concentration or CMC. Polymeric micelles are composed by internal and 
external zones named core and shell, respectively. Due to the high molecular weight 
of the amphiphiles, they display higher stability (slower dissociation upon dilution) 
than micelles formed by regular surfactants (e.g. polyethoxylated castor oil or 
 
According to the structural organization biodegradable nanoparticles are classified as nanocapsule, and 
nanosphere. The drug molecules are either entrapped inside or adsorbed on the surface. Biodegradable 
polymeric nanoparticles based drug delivery systems 
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Cremophor® EL, polysorbate 80 or Tween® 80), even at concentrations below the 
CMC, extending their circulation times in blood. Based on the core-drug interactions 
through chemical and physical forces, drugs display different release profiles. Also, 
polymeric micelles containing poly(ethylene oxide) as the hydrophilic component 
evade opsonization and uptake by the macrophages of the reticuloendothelial system 
(RES), prolonging circulation times in blood. Another aspect of relevance is the 
inhibition of efflux transporters like PGP. 
Micelles formed from amphiphilic block copolymers have recently attracted 
significant attention in diverse fields of medicine and biology. In particular, 
polymeric micelles have been developed as drug and gene delivery systems as well 
as carriers for various contrasting agents in diagnostic imaging applications. In an 
aqueous environment, the hydrophobic blocks of the copolymer are expected to 
segregate into the core of the micelle, whereas the hydrophilic blocks form the 
corona or outer shell. Such a core-shell architecture of the polymeric micelles is 
essential for their utility as novel functional materials for pharmaceutical 
applications. The hydrophobic micelle core serves as a microenvironment for the 
incorporation of various therapeutic compounds; the corona, or outer shell, serves as 
a stabilizing interface between the hydrophobic core and the external medium.  
As a result, polymeric micelles can be used as efficient containers for reagents with 
poor solubility and/or low stability in physiological environments. Interest in 
polymeric micelles for drug delivery has increased rapidly since the late 1980s. Most 
of the work has focused on classical micelles formed by intermolecular aggregation 
of amphiphilic polymers as the drug delivery vehicle, and the advantages of using 
micelle structures as a drug delivery system have been demonstrated. 
The major factors that influence the performance of polymeric micelles for drug 
delivery are loading capacity, release kinetics, circulation time, biodistribution, size, 
and stability. Micelle stability is particularly important. Recent studies have shown 
that the in vivo antitumor activity of a drug incorporated into the polymer micelles is 
positively correlated with the stability of micelles in vitro. The formation of classical 
micelles is thermodynamically favorable only above a specific concentration of the 
amphiphilic molecules (Critical Micelle Concentration, CMC). Above the CMC, 
micelles are in dynamic equilibrium with the free copolymer molecules (unimers) in 
solution, continuously breaking and reforming. When the concentration of the 
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copolymer is below the CMC, micelles tend to disassemble. Such thermodynamic 
instability of micelles below the cmc is one of the concerns for their application in 
vivo. A delivery system is subject to a severe dilution upon intravenous injection into 
an animal or human subject. 
In the bloodstream, under dilution, micelles begin to disassemble, causing changes in 
micelle structure and size. Therefore, controlling the release rate of drugs is difficult. 
Sudden dissociation of micelles may cause serious toxicity problems due to 
potentially large fluctuations in drug concentrations. The problem associated with the 
classical micelle structure can be overcome by developing molecules in which the 
lipophilic components are covalently bound together within the micelle core. Core 
polymerization is an effective method to prevent dissociation of the block copolymer 
micelle. Kataoka’s group has successfully employed this idea. In their study, the 
micelles were prepared from an amphiphilic block copolymer in which the 
hydrophobic block contained a polymerizable end group. After micellation, the end 
groups on the hydrophobic block were polymerized to form a stable core for the star-
shaped polymer structure. The resulting micelles showed fairly high stability and 
maintained small size. As anticipated, the core polymerized micelle showed excellent 
solubilization of rather large molecules such as Taxol. Another approach developed 
recently by Uhrich et al. with a three-arm star polymer composed of mucic acid 
substituted with fatty acid as the lipophilic inner block and with PEG as the 
hydrophilic outer block. This new type of molecule was capable of encapsulating a 
hydrophobic model drug in aqueous media. However, due to the structural 
constraints, the free volume of the hydrophobic core was limited, and only one or 
two drug molecules could be encapsulated in each micelle. A series of star block 
copolymers with the number of arms ranging from three to eight has also been 
synthesized. The arms were composed of block copolymer with PEG as the inner 
hydrophilic block and PCL as the outer hydrophobic block. The application of this 
type of copolymer as an injectable drug delivery system was reported. It was found 
that a reversible sol-gel transition process exists for this system, which is useful for 
drug delivery. However, such star copolymers do not form micelles in aqueous 
media because the hydrophilic block is located in the interior of the star. A recent 
paper described the synthesis of a four-arm star block copolymer of PCL and PEG by 
the same route and similar chemistry as reported in this paper. Another paper 
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described the preparation of a four-arm star PCL-b-PEG polymer with diethylzinc 
catalyst. However, the molecular weight distribution of the block copolymer was 
unacceptably wide. Many studies have been carried out using dendrimers as drug 
delivery systems. Star polymers with a dendrimer as the hydrophobic core and 
multiple PEG chains as the hydrophilic arms have been synthesized and investigated 
as unimolecular micelles for drug delivery by Fre´chet and Kono. It has been 
demonstrated that the micelles with larger dendrimer core have a higher 
encapsulation capability than those with smaller cores. However, due to the structural 
limitations involved in the synthesis of dendrimers of  higher generation, and the 
relatively compact structure of the dendrimers, it is difficult to increase significantly 
the size of the hydrophobic dendritic core in the dendrimer-PEG star polymer. 
Therefore, such dendrimer systems have limitations in terms of drug-loading 
capacity and delivery of compounds of large size. In this paper, we describe the 
synthesis and micellar characterization of a novel amphiphilic star polymer. The core 
of this star polymer is a polyamidoamine (PAMAM) dendrimer; the inner block in 
the arm is lipophilic poly- (ε-caprolactone) (PCL), and the outer block in the arm is 
hydrophilic poly(ethylene glycol) (PEG). First, a star PCL polymer was synthesized 
using the PAMAM-OH dendrimer as the initiator for ring-opening polymerization of 
ε-caprolactone. A PEG polymer was then attached to the terminal group of PCL by 
an ester-forming reaction. In this star polymer the arms consist of polymers that are 
biocompatible and biodegradable. The star structure of the polymers was confirmed 
by several physicochemical methods. To establish this system as a suitable drug 
carrier, the micellar properties of the star amphiphilic polymer in aqueous media 
were studied by fluorescence techniques and dynamic light scattering. The 
solubilization capacity of star-PCL-PEG micelles was evaluated using several highly 
hydrophobic compounds, such as pyrene and water-insoluble dye molecules. A series 
of entrapment experiments showed that various drugs could be incorporated in such 
micelles. These results indicate that the star-PCL-PEG micelle system is a promising 
drug carrier for the delivery of lipophilic drugs (F. Wang, Bronich, Kabanov, Rauh, 
& Roovers, 2005). 
Polymeric micelles, characterized as core-shell structured nanosize aggregations of 
amphiphilic polymer chains with hydrophobic inner core and hydrophilic corona, 
have aroused tremendous interest in pharmaceutical research. Generally, there are 
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two main principles for polymeric micelles to conduct drug delivery. First the 
hydrophobic core of micelles can act as the reservoir of drugs and meanwhile the 
hydrophilic corona has the capacity to stabilize micelles. Secondly, polymeric 
micelles are small enough (<200 nm) to evade from bioclearance, therefore have 
long blood circulation time which helps drug-loaded micelles to reach the action site 
or conduct controlled drug release. Furthermore, compared with lipid-based vectors 
such as liposomes and lipid nanoparticles, synthetic polymeric micelles have brilliant 
advantages in molecule design. By controlling the composition and the length of 
polymer chains, a variety of sized and shaped micelles could be obtained, which 
develop towards advanced drug delivery systems. Currently, a majority of 
explorations in polymeric micelles for drug delivery focuses on cancer therapy. 
Based on the well-known enhanced permeability and retention (EPR) effect, drug-
loaded micelles could be accumulated around tumors and perform high tumor 
inhabitant. For this aim polymeric micelles should be carefully designed to achieve 
the appropriate size, stability and drug loading efficiency under control. 
Polymer base is fundamental for the design of polymeric micellar drug delivery 
systems. Ideally polymers chosen for drug delivery should be biocompatible and can 
be easily tailored or functionalized. Polyphosphazene is a novel biocompatible and 
biodegradable inorganic polymer with two active chlorine side groups on each repeat 
unit. Compared with those popular biomaterials such as polycaprolactone (PCL) and 
poly(lactic acid) (PLA), the distinct advantage of polyphosphazene for drug delivery 
is the chlorine side groups on polyphosphazene can be readily substituted by other 
molecule/macromolecules, therefore, multi-functionalized polyphosphazenes with a 
variation of physical and chemical characteristics could be obtained. Pioneer 
researchers have fabricated several series of polyphosphazenes, and the 
biodegradation and biocompatibility of polyphosphazenes have been demonstrated. 
Other researchers further studied the biomedical application of polyphosphazenes 
such as nano-fibers and hydrogels (Zheng, Qiu, Yao, & Zhu, 2009). Our group has 
been focusing on the micellization of amphiphilic PCL-PEG polymers. In present 
work, we aim to construct a micellar system based on Star and Y shape amphiphilic 
PCL-PEG micelles for tumor targeting treatment. 
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Poly-ε-caprolactone (PCL) 
PCL (poly-ε-caprolactone) is degraded by hydrolysis of its ester linkages in 
physiological conditions (such as in the human body) and has therefore received a 
great deal of attention for use in drug delivery. In particular, it is especially 
interesting for the preparation of long-term implantable devices, owing to its 
degradation slower than that of polylactide. PCL nanoparticles have been prepared 
mostly by nanoprecipitation, solvent displacement and solvent evaporation. Some of 
the molecules that have been successfully incorporated into PCL nanoparticles to 
increase their therapeutic value are described in Table  4.1 (Kumari et al., 2010).  
Table  4.1: Some of the molecules that have been successfully incorporated into PCL 
nanoparticles to increase their therapeutic value. 
Polymer Encapsulant Encap. 
effic. Synthesis methods 
Therapeutic 
improvement 
Release 
mechanism 
Surface 
modificati
on 
in vivo 
Poly-ε-
caprolactone 
(PCL) 
Tamoxifen 90% Solvent displacement 
Preferrential 
tumor targeting 
and circulating 
drug reservoir 
 pluronics 
Increased level of 
accumulation of the 
drug within tumor 
with time and 
extended their 
presence in 
circulation 
 Clonazepam 72.6-95.1% 
Solvent evaporation 
method 
Drug release 
behaviour can be 
modulated by 
introducing 
thermo sensitive 
polymer 
Diffusion   
 Saquinavir 60% 
Solvent 
displacement 
method 
Higher intra 
cellular 
saquinavir conc. 
Diffusion PEO 
Rapid cellular 
uptake of 
rhodamine-123 
encapsulated PEO-
PCL nanoparticles 
was observed in 
THP-1 cells 
 
 Taxol 20.79% micelles Higher taxol loading  MePEG 
Decreased fasted 
glycemia in a dose 
dependent manner 
and nanoparticle 
strongly adhered to 
intestinal mucosa 
 
 Đnsulin 96%  
Preservation of 
insulins’ 
biological 
activity 
Diffusion   
 Docetaxel 90% Nanoprecipitaion 
method 
Higher 
antitumor effect Diffusion  
Effectively kills 
BIG cells 
 
 Vinblastine 48% Emultion method 
Slow drug 
release up to 20 
days 
Diffusion  
Breast cancer cell 
line (MCF-7) 
showed efficient 
uptake 
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4.3.2 Micelles formed from phospholipids 
Phospholipids are natural compounds consisting of a glycerol backbone linked by 
ester bonds to two fatty acid chains and one phosphoric acid. Phospholipids have two 
distinct regions – a long non-polar hydrocarbon tail and a polar phosphate head 
group. This gives the molecules amphiphilic properties. Amphiphiles are molecules 
characterized by the presence of both a hydrophilic and a hydrophobic region within 
a single molecule (Florence & Attwood, 2006). At low amphiphile concentrations in 
an aqueous medium, the amphiphiles exist as monomers in the bulk and the interface. 
As the amphiphile concentration increases, self-association occurs to minimize the 
unfavorable interactions between the aqueous phase and the non-polar region of the 
amphiphiles (Arleth, 2005; C. Lizano & Garc´ıa-P´erez, 2003 ). The type of 
aggregate formed depends on the numerous characteristics of the molecule like 
charge distribution, length of acyl chains, degree of unsaturation and size of the polar 
head group. When the amphiphiles have a large head group, they tend to have a more 
conical shape. These molecules self-assemble spontaneously above a certain 
concentration of the amphiphiles called the critical micellar concentration to form 
micelles, with their hydrophobic tails oriented towards a central hydrophobic core 
and the hydrophilic heads facing outwards (Arleth, 2005). Micelles are in dynamic 
equilibrium with their monomers in solution resulting in a constant exchange 
between monomers in solution and in those of the micelles (Florence & Attwood, 
2006). It is the central hydrophobic core of these micelles that can be taken 
advantage of in delivering water insoluble drugs. 
4.3.3 Sterically stabilized micelles 
Phospholipids like distearoyl phosphatidylethanolamine (DSPE) conjugated to 
polyethylene glycol (PEG) at the polar head were synthesized and used to modify the 
surface of liposomes in the 1990’s (Allen, 1991; Klibanov, Maruyama, Torchilin, & 
Huang, 1990; Sejourne, Rubinstein, Suzuki, & AlkanOnyuksel, 1997; Sejourne, 
Suzuki, et al., 1997). This pegylation of DSPE in addition to making the molecule 
more water soluble also renders a more conical shape to the structure. This facilitates 
the formation of micelles when the concentration of monomers is above CMC 
(Arleth, 2005; Lasic, 1992; Lasic et al., 1992; Needham, McIntosh, & Lasic, 1992). 
PEG chains with molecular weight of 2000 and 5000 are typically used for this 
46 
 
purpose. The reason is PEG chains with MW less than 1000 do not provide sufficient 
polarity to the phospholipid molecule to form micelles, while chains with MW 
greater than 5000 make the phospholipid head group too bulky and water soluble. 
The structure of DSPE-PEG2000 is shown in (Figure  4.3).  
 
Figure  4.3: Chemical structure of DSPE-PEG2000 (Ashok, 2004). 
 DSPE-PEG2000 micelles also known as sterically stabilized micelles which offer 
numerous advantages as a carrier for the delivery of water-insoluble drugs. Firstly, 
SSM display high kinetic and dynamic stability due to very low CMC values of 
around 1µM (Ashok, 2004). This low CMC ensures thermodynamic stability even 
upon large dilution that occurs when administered into the body. Additionally, low 
CMC also ensures low monomer concentration. Since monomers of surfactants are 
primarily responsible for the toxicity caused, PEGylated lipids are safer compared to 
conventional surfactants such as bile salts, Tweens (20, 60 and 80) and Pluronics 
(Alkanonyuksel, 1994; Kabanov & Alakhov, 2002). Secondly, PEGylated lipids have 
a steric barrier on the surface due to the PEG shield. This steric barrier prevents the 
adsorption of proteins such as opsonins onto the particles, thus elongating the 
circulation half-life by reducing reticuloendothelial system (RES) uptake (H. 
Onyuksel, 2005; Lukyanov, 2002; Weissig, Whiteman, & Torchilin, 1998). Thirdly, 
SSM due to their small size with an average diameter of ~16 nm (Ashok, 2004; 
Dagar, 2003) are ideal for passive targeting to cancer tissue due to the (H. Onyuksel, 
2005) Enhanced Permeation Retention (EPR) effect (Matsumura, 1986). This aspect 
will be discussed in further detail in section I.B.3.a. The PEG on the surface of SSM 
also provides the opportunity to surface graft targeting ligands for active targeting. 
Fourthly, SSM provide a unique hydrophobic gradient for the solubilization of drugs 
without the need for any chemical modification. Also SSM can be easily freeze-dried 
and reconstituted without the need for additional lyoprotectants and cryoprotectants, 
ideal for convenient manufacture and long term storage (H. Onyuksel, 2005). Finally, 
SSMs can be easily prepared from the PEGylated phospholipids which are 
biocompatible, biodegradable, relatively non-toxic and FDA approved for human use 
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(Working & Dayan, 1996). DSPE-PEG micelles have recently been studied as 
delivery systems for small molecules, peptides and imaging agents (Ashok, 2004) 
(Dagar, 2003; H. Onyuksel, 2005; Lukyanov, 2002; Y. Wang et al., 2010; Weili 
Qiao, 2010)  
 
Figure  4.4: Formation of sterically stabilized micelles(Ashok, 2004). 
4.3.4 Sterically stabilized mixed micelles 
Sterically stabilized mixed micelles are a novel second generation modification of 
sterically stabilized micelles. They are prepared by the incorporation of a water 
insoluble phospholipid such as phosphatidyl choline (PC) into micelles formed from 
DSPE-PEG2000 (Figure  4.4). This results in an increased core fluidity providing an 
improved solubilization potential for certain drugs like paclitaxel (Dagar, 2003).  
 
Figure  4.5: Formation of sterically stabilized mixed micelles (Ashok, 2004). 
Depending on the ratio of PEGylated lipids and PC used, different morphological 
structures can be formed. Mixtures of low PC content along with PEGylated lipids 
form spherical micelles. As the PC content is increased there is a change from the 
spherical shape to rod-like micelles to disc-shaped aggregates. Further increase in the 
PC content causes micelle to vesicle transition observed by the formation of bi-
layered vesicles (Arleth, 2005; Edwards, 1997; Hjelm, 1992; Hristova, 1995). It has 
been found that in case of DSPE-PEG2000 micelles, an increase of PC content 
greater than 25% led to the formation of rod-shaped particles (Ashok, 2004). To 
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achieve maximum solubilization using spherical mixed micelles alone, a molar ratio 
of 90:10 DSPE-PEG2000: E-PC was selected. Previous work using small angle 
neutron scattering (SANS) and small angle X-ray scattering (SAXS) have 
demonstrated that SSMM composed of DSPE-PEG2000 and E-PC (90:10) have 
aggregation number, size and shape similar to that of simple micelles composed of 
DSPE-PEG2000 alone (Ashok, 2004).  
4.4 Pharmacokinetics and Biodistribution of Nanoparticles 
The pharmacokinetic profiles of the parent drug and the drug encapsulated in the 
nanoparticles are often different. Therefore, it is very important to monitor the 
pharmacokinetics (PK) and biodistribution of nanoparticles to understand and predict 
their efficacy and side effects. The PK profile of the nanoparticles is mainly 
determined by their chemical and physical properties, such as size, charge, and 
surface chemistry. 
4.4.1 PK study 
PK study involves measuring drug concentrations in all major tissues after drug 
administration over a period of time until the elimination phase. It is necessary to 
monitor the drug concentration long enough to fully describe the behavior of the drug 
or nanoparticles in vivo (usually 3 × half-life). The PK profile in the blood can be 
fitted using various programs to obtain key PK parameters that quantitatively 
describe how the body handles the drug or nanoparticles. Important parameters 
include Cmax (maximum concentration), t1/2 (half-life), Cl (clearance), AUC (area 
under the curve), and MRT (mean resident time, average time that a molecule of a 
drug stays in the body). When a drug formulation shows prolonged blood circulation, 
an increased t1/2, a reduced Cl, an increased AUC, and an increased MRT are 
usually observed. On the other hand, if a formulation is quickly eliminated from the 
body, a low t1/2, a high Cl, a low AUC, and a low MRT are often obtained. PK data 
not only can help describe, but also can help predict the behavior or profile of the 
drug or nanoparticles. PK data are often used in deciding the dose and dose regimen 
for maintaining a desirable blood concentration for improved therapeutics with 
minimal side effects. The blood concentration of drugs is highly correlated with their 
efficacy and toxicity in most cases, especially for free drugs. However, to gain 
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insight into how the body handles the drug formulation and how the formulation may 
affect the efficacy and adverse effects, it is essential to obtain the tissue distribution 
information for the drug. A high level of accumulation of a drug in the target tissue 
often results in an enhanced therapeutic effect, and oppositely, a large amount of 
drug distributed to nontarget organs may cause unwanted toxicity. PK and tissue 
distribution studies that allow investigators to screen formulations for a given drug 
are extremely important during drug development. By optimizing the drug 
formulation, investigators can improve the drug delivery to the target tissue and 
reduce drug distribution to the nontarget tissues to obtain increased therapeutic 
activity with minimal side effects (Li & Huang, 2008). 
4.4.2 Comparison of PK of free drugs and drugs encapsulated in nanoparticles 
When a hydrophilic drug is intravenously (i.v.) injected into the body, without much 
protein binding, the drug is often quickly eliminated from the blood by renal 
filtration into the urine. In the case of a hydrophobic drug, the renal clearance is 
significantly reduced compared to that of the hydrophilic drugs due to an increased 
level of serum protein binding. The hydrophobic drugs are often transformed into 
hydrophilic metabolites in the liver and excreted into the bile or eliminated into the 
urine. When the drugs are encapsulated in nanoparticles, the drugs are protected from 
metabolizing enzyme in the liver before they are released and as well as from renal 
clearance due to the increased size. The cutoff size for renal excretion is 
approximately 5.5 nm according to recent research using quantum dots,1 and the 
nanoparticles are usually much larger. Reduced liver metabolism and renal clearance 
of drugs encapsulated in the nanoparticles often result in prolonged blood circulation 
with an increased chance of accumulation in the target tissue (Li & Huang, 2008). 
4.4.3 Tissue selectivity of nanoparticles 
The limited pore size of the endothelial wall in the tissue is the primary delivery 
barrier for nanoparticles but also allows selective accumulation in certain tissues. 
Unlike small molecule drugs that can diffuse through the capillary wall into the 
tissue, nanoparticles rely on the gaps between the endothelium to pass through the 
barrier. Tissues with a leaky endothelial wall usually contribute significant uptake of 
nanoparticles, including tumor, liver, spleen, and bone marrow. The increased rate of 
tumoral uptake of nanoparticles is based on a phenomenon termed the “enhanced 
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permeability and retention” (EPR) effect2 due to the increased capillary permeability 
in the tumor tissue (Li & Huang, 2008).  
The Enhanced Permeability and Retention (EPR) effect is the property by which 
certain sizes of molecules (typically liposomes, nanoparticles, and macromolecular 
drugs) tend to accumulate in tumor tissue much more than they do in normal tissues. 
The general explanation that is given for this phenomenon is that, in order for tumor 
cells to grow quickly, they must stimulate the production of blood vessels. VEGF 
(Vascular endothelial growth factor ) and other growth factors are involved in cancer 
angiogenesis. Tumor cell aggregates of size as small as 150-200 µm, start to become 
dependent on blood supply carried out by neovasculature for their nutritional and 
oxygen supply. These newly formed tumor vessels are usually abnormal in form and 
architecture. They are poorly-aligned defective endothelial cells with wide 
fenestrations, lacking a smooth muscle layer, or innervation with a wider lumen, and 
impaired functional receptors for angiotensin II. Furthermore, tumor tissues usually 
lack effective lymphatic drainage. All these factors will lead to abnormal molecular 
and fluid transport dynamics, especially for macromolecular drugs. Namely, this 
phenomenon was coined “enhanced permeability and retention (EPR)-effect” of 
macromolecules and lipids in solid tumors. The EPR-effect is even more enhanced 
by many pathophysiological factors involved in enhancement of the extravasation of 
macromolecules in solid tumor tissues. (Matsumura, 1986).The enhanced uptake in 
the liver, spleen, and bone marrow is largely attributed to the macrophages residing 
in the tissues, which are responsible for clearing particulates and macromolecules 
circulating in the blood. 
 
Figure  4.6: The illustration of EPR effect (Matsumura, 1986). 
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When nanoparticles are i.v. administered, a variety of serum proteins bind to the 
surface of the nanoparticles, which are recognized by the scavenger receptor on the 
macrophage cell surface and internalized, leading to a significant loss of 
nanoparticles from the circulation. The serum proteins binding on the nanoparticles 
are also termed “opsonins”,and the macrophages contributing the major loss of 
injected dose are also known as the reticuloendothelial system (RES) or mononuclear 
phagocyte system (MPS). Minimizing protein binding is the key point for developing 
a long circulation nanoparticle formulation.(Li & Huang, 2008) 
4.5 Factors Influence PK of Nanoparticles 
Opsonization is the major factor that induces MPS uptake of nanoparticles, and 
therefore, surface characteristics of nanoparticles greatly influence their PK. 
Generally, nanoparticles that have a mean diameter of approximately 100 nm with a 
neutral and hydrophilic polymer-extended surface exhibit prolonged blood 
circulation and an increased level of tumor delivery. 
4.5.1 Surface-engineered nanoparticles as drug carriers 
Over the last 12 years there has been a growing interest in the develpment of a drug 
carrier that is small enough for intravenous administration and has the ability to 
bypass the normal physiological defense processes of the organism.  
The main challenge for administering particulate drug carriers into the vascular 
compartment is the achievement of sitee-specific drug delivery. Indeed, following its 
intravenous administretion, a drug substance will distribute through the body. As a 
consequence the amount of drug will reaching th target site maybe a only small 
fraction of the administered dose. Morover, adverse side effects may occur at 
nanotarget site. 
Active research has been pursued since Ehlrich first considered the concept of 
“magic bullets” for the eradications of disease. For site-soecifirc drug delivery, 
should avoid indiscriminate inreactions with the Mononuclear Phagocyte System 
(MPS), selectively reach the disease site of action, and release the drug in its active 
form at suitable rate and in therapeutic amounts. The nanoparticles should be 
nontoxic elements. Such drug carriers could be of highest interest in cancer 
chemotherapy.  
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Many efforts have concentrated in recent years on the design of submicronic long-
circulating drug carriers such as liposomes, lipid emultions, micelles, solid lipid 
nanoparticles. Among all of these systems we will focus on lipid base and polymeric 
nanoparticles which both are counted as solid colloidal particules ranging in size 
from 10 to 1000nm in which the drug is entrapped (Li & Huang, 2008). 
4.5.2  Factors affect the fate of intravenously administered particles   
Particle siz eand shape greatly influence organ distribution. To circulate through the 
smallest cappilaries, the particle size should be less than 5µm, and to avoid spleen 
filtering effects, the diameter should be less than 200 nm. Carrier surface properties 
such as charge and hydrophobicity play a major role in the interaction with the living 
organism. Đt was established that hydrophobic particles are more avidly taken up by 
macrophages than by hydrophilic ones.  
4.5.3 The role of Mononuclear Phagocyte System (MPS) in removing injected 
particles 
The cells of MPS previously known as the reticuloendothelial system (RES) play a 
key role in the clearence of and body distribution of these particles. They are actively 
endocytic and posses on their surface a number of receptors for plasma proteins that 
are likely to adsorb on particles’ surface. Among their variety of important biological 
functions MPS cells play a role in removing from blood invading bacteria, fungi and 
viruses or protein aggregates derived from tissue destruction. However MPS cells 
also recognise as foreign and efficiently clear injected particles from blood. This fast 
process can occur by an apperently nonspecific phagocytosis. However, uptake is 
tremendously triggered if the particles’ surface is “decorated” with ligands that bind 
to one of the many receptors on the MPS cell surface. 
The most preferred strategy to avoid the MPS phagocytic “barrier” are particle 
camouflage from MPS, for example by modifying the surface to allow a particle to 
“stealthily” circumvent phagocytic cells. To achieve this type of surface-engineered 
drug carrier interactions between carriers and blood should be taken into account(Li 
& Huang, 2008) 
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4.6 Nanoparticle Interactions With Blood  
4.6.1 Opsonins 
Immediately after intervenous administration, the nanoparticles encounter a high 
concentration of hundreds of plasma proteins. The adsorption of protein ligands that 
are capable of interacting with one or more receptors on MPS cells, thus promoting 
the particle uptake by these cells is called opsonization. In some cases plasma protein 
adsorption can also lead to exchange of lipid components with blood cells and 
lipoproteins. This phenomenon is believed not to take place with nanospheres which 
have rigid polymeric cores. 
It is recognized generally that the fate of the injected particles is regulated by the 
composition and by the conformation of the protein layer that typically begins to 
form within seconds after contact with blood.  
The phagocytosis is an irreversible process with mainly three steps: 1)Recognized by 
opsonins such as the complement protein, immunoglobulins G and M, fibronectin 
and apolipoproteins, or by specific or nonspecific receptors present at the surface of 
the macrophage plasma membrane; 2)Then adsorbed by these opsonins; 3)Finally, 
eliminated by the mononuclear phagocyte system (MPS). That means if wecould 
prevent the complement protein from activation, the phagocytosis may be inhibited 
subsequently. It was first pointed out by Vorman and Adams (Vorman, 1969) that the 
hundreds of proteins in plasma experience very different collision frequencies with 
respect to the exposed surface, depending on the concentration and diffusion 
coefficient of each protein ( Table 4.1 ).   
Table  4.2: Concentration (c) and diffusion coefficient (D) of some of the most 
concentrated plasma proteins. 
Protein Concentration, c, (µM) D (10-7cm2s-1) 
Albumin 600 6.1 
IgG 100 4.0 
Α-Antitrypsin 40 5.2 
Transferrin 30 5.0 
HDL 18 4.6 
IgA 15 4 
Complement3 9 4.5 
Fibrinogen 7.5 2 
LDL 2 2 
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If adsorption occurs, the protein can be more or less readily displaced by another 
one. As a consequence, the most abundant plasma proteins, such as albumin, adsorb 
first and as time progresses, are replaced by athers with a lower collision frequency 
but with a higher affinity for the surface. 
More recently it has been pointed out that the collision and reversible attachment of 
protein to a substrate are followed by a series of conformatioanal adjustment to the 
surface, eventually ending with a quasi-irreversible fixation. The gain in entropy 
resulting from chain unfolding was found to be driving force behind adsorption, at 
times overwhelming charge repultions between the protein and the surface. As a 
consequence, the strucrural stability characterizing each protein has a strong 
influence over its adsorption. Hydrophobic surfaces have an ability to stabilize the 
nonpolar protein cores as they become exposed to water during water during 
unfolding. Fibrinogen is one of the most active plasma proteins. It becomes a 
powerful cell activator once it has undergone even modest conformatioanl changes.  
The complement is generally considered to be one of the main opsonins involved in 
the uptake of intravenously adminstered particles. The complement system 
comprises about 20 blood proteins that can interact in a complex cascade involving 
specific binding and proteolytic activation steps. Complement can be activated by 
two major pathways. The “classical” pathway is initiated by the formation of an 
antigen/antibody complex; the “alternative” pathway involves the accelation of the 
spontaneous process of conversion of component C3 into its active form C3b; 
From the immunological point of view, C3, as a major complement protein, plays a 
significant role in complement system. After opsonization, cleavage of C3 by C3 
convertase would be activated into a large fragment of C3b and a small fragment of 
C3a. C3b provides specific recognition by type CR1 receptor on macrophages  thus 
the evidence of C3 cleavage was obtained by quantified the C3 concentration, which 
was used as a way to characterize the avoidance of complement activation by NPs. 
(Shan et al., 2009) 
Fibronectin has also a well-documented role in the uptake of particles. Đt has been 
shown to bind to bacteria and to a variety of macromolecules, such as collagen, actin, 
DNA, or heparin. Some other reported opsonins are tuftsin and clotting factors.   
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4.6.2   Dysopsonins 
In contrast to the opsonin family, certain blood components called dysopsonins were 
shown to inhibit phagocytic ingestion. Therefore, preadsorbing dysopsonins on 
nanoparticles prior to their i.v. administration appear to be a very attractive means of 
achieving long blood circulation times. 
It has been shown that the presence of immunoglobulin IgA on surfaces inhibits 
ingestion by neutrophils and macrophages. The high hydrophilicity of this molecule 
was suggested to be apossible explanation its dysopsonic action. However the 
dysopsonic effects reported in vitro could not be confirmed in vivo. Precoating 
polystrene nanospheres with IgA did not reduce the uptake by peritoneal 
macrophages or the hepatic deposition. 
Muir et al. (Moghimi, 1991; Muir, 1991)suggested that the principal factors that 
result in a dysopsonic action are two serum components, one with a molecular 
weight below 30,000 and another one with a molecular weight higher than 100,000. 
The competition between the two opposite phenomena, the reduction in opsonin 
adsorption and the selective adsorption of dysopsonins, is believed to be the key in 
controlling the particle uptake and hence their biodistribution (Baraton, 2003). 
4.7 Role of Target Geometry in Phagocytosis 
Exclusive use of spherical particles in drug delivery systems originated partly 
because of a presumption that size is the principal parameter of interest and partly 
because of difficulties in fabricating nonspherical particles of controlled dimensions. 
Use of spherical particles not only concealed the role of particle shape in 
phagocytosis but also created an inaccurate picture of the actual role of particle size 
because all parameters that describe size (volume, surface area, etc.) scale with 
particle radius, leaving one wondering as to which parameter is of fundamental 
consequence in phagocytosis.  
A paper is reporting the results of investigation of the role of target geometry in 
phagocytosis using alveolar macrophages as model phagocytes and polystyrene (PS) 
particles of various sizes and shapes as model targets, that target shape at the point of 
first contact by macrophages, not size, decisively determines whether cells will 
proceed with phagocytosis or simply spread on the particle. Size, on the other hand, 
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primarily impacts the completion of phagocytosis when the target volume is larger 
than the macrophage volume. 
This paper is reporting the synthesis of particles with 6 different shapes;  
spheres (radius 1.0–12.5 µm), oblate ellipsoids (major axis 4 µm, aspect ratio 4), 
prolate ellipsoids (major axis 2–6 µm, aspect ratio 1.3–3), elliptical disks (EDs) 
(major axis 3–14 µm, aspect ratio 2–4, thickness 400–1,000 nm), rectangular disks 
(major axis 4–8 µm, aspect ratio 1.5–4.5), and UFOs (sphere radius 1.5 µm, ring 
radius 4 µm). 
The paper reports that, Opsonized or nonopsonized particles were incubated with 
alveolar macrophages and observed under a light microscope (×100) with time-lapse 
video microscopy. 
 
 
 
 
 
 
 
 
 
Figure  4.7: Scanning electron micrographs and 3D illustrations of PS particles 
created for phagocytosis experiments ) (Champion & Mitragotri, 2006).  
IgG-opsonized particles are phagocytosed via Fc receptors, whereas nonopsonized 
particles adsorb proteins from the culture medium supplemented with heat-
inactivated FBS during incubation and are phagocytosed through nonspecific 
scavenger receptors. In both cases internalization of particles is an actindependent 
process.Internalization of both opsonized and nonopsonized particles exhibited a 
strong dependence on local particle shape from the perspective of the phagocyte. 
Local shape varies not only for different particles but also for different points of 
initial contact on the same particle, except for spheres. For example, macrophages 
 
 
 
(A) Spheres. (B) Oblate ellipsoids (13%). (C) Prolate ellipsoids (7%). (D) Elliptical disks (9%). (E) 
Rectangular disks (5%). (F) UFOs (12%). Particles are monodispersed with average standard deviations of 
measured dimensions for each shape listed in parentheses. Aportion of this variation is due to2–5%standard 
deviation in the diameter of spheres used as starting materials. (Scale bars: 5 µm.) 
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that attached to EDs (major axis 14 µm, minor axis 3µm) along the major axis 
(discussed quantitatively below) internalized them very quickly, in <6 min (Figure 
 4.8 A). The macrophage membrane can be seen moving along the length of the 
particle in a coordinated, unified fashion. On the other hand, cells that attached to the 
same EDs along the minor axis or flat side did not internalize them, even after 2 h 
(Figure  4.8 B). They did, however, spread on the particle surface but with 
nonsynchronized, separate fronts moving in different directions at different times. 
Macrophages attached to the flat side of IgG-opsonized EDs exhibited more 
spreading than those attached to nonopsonized EDs, but the final result was the 
same: no phagocytosis. Because the particles used for these studies possessed 
identical properties (dimensions, surface area, volume, and chemistry), observations 
in Figure  4.8 A and B clearly show that the local particle shape at the point of initial 
contact, not the overall size, determined their phagocytic fate. Similar results were 
seen for all shapes including UFO-shaped particles, where internalization does not 
occur when cells attach to the concave region but internalization does occur after 
attachment to the dome or ring regions.  
 
 
 
 
 
 
 
 
 
 
Figure  4.8: Time-lapse video microscopy clips spanning 39 min of macrophages 
interacting with identical nonopsonized ED particles (major axis 14 µm, 
minor axis 3 µm) from two different orientations (Champion & 
Mitragotri, 2006).  
Furthermore this study reports Scanning electron microscopy images that provided 
more evidence for this orientation bias. As can be seen in the micrographs, the cell 
 
 
 
(A) Cell attaches along the major axis of an ED and internalizes it completely in 3 min. (B) Cell attaches to the 
flat side of an identical ED and spreads but does not internalize the particle. Continued observation indicated 
that this particle was not internalized for ~110 min. (Scale bars: 10 µm.) At least three cells were observed for 
each orientation of each particle type and size. Similar results were observed in all repetitions. 
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membrane showed marked progression on EDs when approached along the major 
axis .In contrast, cells that attached to the flat side of EDs exhibited spreading but no 
engulfment of particles, even after 2 h .As a reference point, consistent engulfment 
was observed on spheres ( Fig. 4.9). 
Further insight into orientation-dependent particle phagocytosis was gained by 
staining macrophages for polymerized actin at various times during phagocytosis. 
Actin polymerization is the principal mechanism by which macrophages push the 
leading membrane edge and engulf particles. Initially, an actin cup, comprised of a 
dense actin network, forms beneath the particle. 
As additional actin polymerization and remodeling occur and the membrane 
progresses, the actin cup is transformed into an actin ring around the particle that 
pushes the membrane along the particle until it is internalized (14–16). Spheres and 
EDs that attached to macrophages along the major axis exhibited an actin cup at 
short times that later transformed to a ring around the particle as phagocytosis 
progressed (Figure 4.9, F and D, respectively). 
Macrophage attachment to the flat side of EDs, despite actin polymerization at points 
of contact and spreading, did not exhibit an actin cup or ring .Formation of an actin 
cup is a clear indicator of initiation of internalization and was observed only at 
certain local shapes. 
This phase diagram shows whether or not internalization was initialized and 
completed for particles with different combinations of Ω and V*, the ratio of particle 
volume to macrophage volume.  The authors indicate that initiation of internalization 
could be judged by formation of an actin cup or ring (( Fig. 4.9 E and F), and 
completion could be judged by closure of the membrane. The diagram shows three 
regions: the successful phagocytosis region (Ω≤45°, V* ≤1) where phagocytosis is 
initiated and completed quickly, the attempted phagocytosis region (Ω≤ 45°, V* > 1) 
where phagocytosis is initiated but not completed within the period of observation, 
and the spreading region (Ω> 45°) where particle attachment takes place and 
macrophages spread on the particle but phagocytosis is not initiated. This diagram 
clearly shows that initiation of phagocytosis is governed by Ω whereas V* primarily 
influences completion. 
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Figure  4.9: Scanning electron micrographs and actin staining confirm time-lapse 
video microscopy observations (Champion & Mitragotri, 2006).  
Macrophages phagocytosed particles as large as themselves when approached from 
the preferred orientation (Ω≤45°). However, when approached from the undesired 
orientation (Ω>45°), they did not internalize particles with volumes as small 
as 0.2% of the cell volume. Similar bias has also been seen during phagocytosis of 
pathogens based on limited anecdotal literature. It remains to be seen whether the 
orientation bias of phagocytosis disappears at extremely small particle volumes 
(V*<< 0.002) (Champion & Mitragotri, 2006). 
4.8 Modeling The Interaction Between Proteins and PEG-Grafted Surfaces 
Several methods of camouflaging or masking NPs (NPs) have been employed for 
particles surface modification through physical or chemical attachment in terms of 
neutralize the NPs surface charge or provide a repulsive steric barrier to prevent the 
flocculation of particles and decrease opsonization by blood components. 
Poly(ethylene glycol) (PEG) has uncharged hydrophilic characteristic, and high 
 
Micrographs (A–C) of cells and particles were colored brown and purple, respectively. (A) The cell 
body can be seen at the end of an opsonized ED, and the membrane has progressed down the length of 
the particle. (Scale bar: 10 µm.) (B) A cell has attached to the flat side of an opsonized ED and has 
spread on the particle. (Scale bar: 5 µm.) (C) An opsonized spherical particle has attached to the top of 
a cell, and the membrane has progressed over approximately half the particle. (Scale bar: 5 µm.) (D–
F) Overlays of bright-field and fluorescent images after fixing the cells and staining for polymerized 
actin with rhodamine phalloidin. (D) Actin ring forms as remodeling and depolymerization enable 
membrane to progress over an opsonized ED by new actin polymerization at the leading edge of the 
membrane. (E) Actin polymerization in the cell at site of attachment to flat side of an opsonized ED, 
but no actin cup or ring is visible. (F) Actin cup surrounds the end of an opsonized sphere as 
internalization begins after attachment. (Scale bars in D–F: 10 µm.) At least five cells were observed 
for each orientation of each particle. Similar results were observed in all repetitions. 
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steric stabilization with non-toxic resulting in dramatically changing the charge of 
biomaterials, which thus has been a major strategy to decrease the nonspecific 
interactions of complexes with serum components, and thereby increase blood 
circulation time.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  4.10: Definition of Ω and its relationship with membrane velocity(Champion 
& Mitragotri, 2006).  
Previously PEG chains has been introduced into hydrophobic poly(ε-caprolactone) 
(PCL)  Nanoparticles (NPs) to improve the hydrophilicity of NPs and prolong the 
longevity of polymeric NPs in blood stream. In this study Results have been showen 
that, after intravenous (i.v.) administration, the longevities of PCL-PEG NPs in blood 
circulation were prolonged approximately 7.2-fold as long as that of the naked 
nanoparticles.  
Some studies (Shan et al., 2009) found that the negative charge on the particles 
surface may be a potential activator of human complement system. Therefore, the 
PEG chains on the NPs surface neutralized the zeta potential, the results of 
mentioned study are shown in Table  4.3 . 
 
 
 
(A) A schematic diagram illustrating how membrane progresses tangentially around an ED. T represents the 
average of tangential angles from θ=0 toθ=2. Ω is the angle between T andmembranenormal at the site of 
attachment, N. (B) Membrane velocity (distance traveled by the membrane divided by time to internalize, n 
≥ 3; error bars represent SD) decreases with increasing Ω for a variety of shapes and sizes of particles.  
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Table  4.3: The neutralization of surface of nano-particle by PEG. 
Samples Size distribution (nm) PDI ζ potential (mV) 
PCL 183.4±10.7 0.188±0.029 −27.17±2.92 
PCL-PEG 159.6±15.8 0.159±0.020 −6.046±3.76 
resulting in suppressing complement activation. On the other hand, it has been 
conformed that the brush-like PEG chains may sterically prevent the deposition of 
C3b onto the surface of NPs and reduce interaction with phagocytic cells membrane. 
The results of that study is demonstrated in Figure  4.11.  
 
Figure  4.11:Complement C3 concentrations of human serum after incubation with 
PCL or PCL-PEG NPs. *p<0.05 .vs. PBS (Shan et al., 2009). 
 It has been mentioned that the PCL NPs were prone to cause complement activation. 
On the contrary, compared with naked PCL NPs, the PEG copolymers had a lower 
degree in C3 cleavage than the negative control PBS did (Shan et al., 2009).  
As discussed before, the RES tissues play an important role in determining the 
disposition of NPs, which are expected to be involved in the tissue uptake, retention, 
andmpossible metabolism of PCL and PCL-PEG NPs. The above preliminary 
investigations in biodistribution has been provided important information that the 
hydrophilic PEG chains mask NPs from the plasma protein. The trend showed that 
naked PCL NPs accumulated more in liver, but with the PEGylation NPs, this final 
accumulation was shift toward the spleen. 
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Figure  4.12:  The accumulation for the naked PCL (a) and PCL-PEG (b) NPs in 
various organs at predetermined time (5 min, 30 min, 2 h, 6 h, 24 h 
and 48 h) (Shan et al., 2009). 
In the case of naked PCL NPs, the sequestration in the RES tissues is very rapid and 
considerable, typically in a first 5 min, 90% of NPs were captured by phagocytosis. 
Furthermore, the uptake NPs were eliminated by metabolism rapidly, with only 25% 
of original injected dose residual after 48 h later, decreased for 65%. On the contrary, 
PEGylated NPs had a more steady experience with 45% found in the RES in 5 min 
after injection. 
During 48 h of blood circulation, the accumulation in the RES decreased for 33%. 
The in vivo biodistribution data accompanied with the evidence of uptake by 
macrophages showed substantial difference in phagocytosis uptake between PCL and 
PCLPEG NPs. During the formation of PCL-PEG NPs, the hydrophobic chain of 
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PCL can incorporate with each other, while the hydrophilic chain of PEG chain, 
remaining on the surface, protrude to the outer phase and form a conformational 
hydrophilic “cloud-layer” over the NPs that protect the particles from each other and 
various plasma proteins. 
As a result, the PEGylation NPs could avoid uptake by mononuclear phagocyte 
system (MPS). Indeed, the most marked inhibition of phagocytosis was owing to the 
hydrophilicity and steric effect of PEG chains, which ensure the particles a longer 
half-life time in blood stream. 
Although the description of the adsorption protein is unknown, these observations 
imply that, under the protection of PEG chains to NPs, quiescent macrophages are 
not sufficiently activated yet by some blood component adsorb on NPs surface. 
Nanoparticles That Have a Mean Diameter of Approximately 100 nm Show 
Prolonged Blood Circulation and a Relatively Low Rate of MPS Uptake. 
Liu et al. (D. Liu, Mori, & Huang, 1992) have investigated the biodistribution of 
liposomes of different sizes (30-400 nm) in blood, liver, spleen, and tumor. They i.v. 
injected the radioisotope-labeled liposomes into the mice and examined the 
recovered dose in those tissues 4 h later. It was found that  approximately 60% of the 
injected liposomes between 100 and 200 nm in size were detected in the blood, while 
only 20% of the ID for liposomes greater than 250 nm or less than 50 nm in size was 
recovered in the blood. For liver uptake, liposomes of approximately 100 nm 
exhibited only 20% ID accumulation, and particles greater than 250 nm in size had 
∼25% ID found in the liver. 
Approximately 60% ID was recovered in the liver for liposomes with a diameter of 
less than 50 nm, which was smaller than the pore size of liver fenestrae (100 nm), 
and easily penetrated through the endothelial wall, resulting in an enhanced liver 
uptake. In the case of spleen uptake, liposomes less than 100 nm in size exhibited 
minimal spleen uptake, whereas an increase in particle size led to an increase in the 
rate of spleen uptake. For the liposomes approximately 400 nm in size, 40-50% ID 
was found in the spleen 4 h after injection. The tumoral uptake data were tightly 
correlated to those of the blood PK, in which liposomes with a diameter between 100 
and 200 nm showed a 4-fold higher rate of uptake in the tumor compared to the 
liposomes greater than 300 nm or less than 50 nm in size. 
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Allen’s group also demonstrated (Moreira, 2001)a similar result, in which liposomes 
with a diameter of approximately 120 nm exhibited a 10-20-fold increase in the rate 
of tumoral uptake compared to those with a diameter of approximately 170 nm.19 In 
this particular tumor model, the cutoff size range was even narrower. Torchillin et al. 
found that using micelles with a mean diameter of 10 nm to deliver paclitaxel did not 
show any EPR effect compared to the free drug. However, when the micelles were 
modified with a targeting antibody, significantly improved tumoral uptake was 
discovered. For very small particles, they can easily pass through the leaky capillary 
wall in the tumor but can also be easily pushed out from the tumor into the blood. 
Therefore, small particles have good permeability but poor retention. After 
conjugation with a targeting ligand, the retention in the tumor was greatly enhanced, 
leading to improved tumoral uptake.  
Figure  4.13 summarizes the effect of size on the tumor targeting of nanoparticles. 
The research into the influence of size on PK was mainly studied in the liposome 
field since liposomes of a certain size can be prepared with a narrow size distribution 
by the membrane extrusion method (Li & Huang, 2008). 
 
Figure  4.13: The effect of size on the tumor targeting, (Li & Huang, 2008). 
4.9 Drug Loading and Release Mechanisms 
A successful nanoparticle system may be the one which has high loading capacity to 
reduce the quantity of the carrier required for administration. Drug loading into 
nanoparticles is achieved by two methods: one by incorporating the drug at the time 
of nanoparticle production and second by adsorbing the drug after the formation of 
nanoparticles by incubating them in the drug solution. Drugs can be loaded onto 
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nanoparticles by adding them to a solution that contains previously prepared 
nanoparticles or by adding them to the reaction mixture during the polymerization 
process. These two methods provides solid solution for the drug encapsulation in the 
polymer, dispersion of the drug in the polymer, adsorption of the drug onto the 
surface of the nanoparticles and chemical binding of the drug to the polymer. The 
amount of bound drug and the type of interaction of drug and nanoparticles depend 
on the chemical structure of the drug as well as the polymer and the conditions of 
drug loading. The determination of the adsorption isotherm is one possible way to 
detect the type of binding and the binding rate (mg drug/mg nanoparticle). 
Adsorption isotherms for the nanoparticle/drug delivery system is used to give vital 
information on the best possible formulation, the drug binding capacity onto the 
surface of nanoparticles and the drug adsorbed. Linear sorption isotherms 
characterize solid solutions and Langmuiror S-type isotherms characterize surface 
adsorption. Because nanoparticles are colloidal systems, precise determination of the 
drug content is a major problem. Therefore, the most reliable way to separate 
thenano particles from the solution containing unbound drug is ultracentrifugation or 
gel filtration. From the amount of drug bound, the encapsulation efficiency (EE) of 
the drug can be calculated by using the formula: 
 
(4.1) 
The drug release mechanisms are equally important as the drug polymer formulation 
because of the proposed application in sustained drug delivery. For manipulation of 
the rate and the timing of the drug release from nanoparticles, a good understanding 
of the mechanisms of drug release is needed. There are five possible methods for 
drug release: (a) desorption of drug bound to the surface, (b) diffusion through the 
nanoparticle matrix, (c) diffusion through the polymer wall of nanocapsules, (d) 
nanoparticle matrix erosion, or (e) a combined erosion–diffusion process. The kinetic 
analysis of drug release from nanoparticles can be described by a biexponential 
function 
C=Ae-αt + Be-βt (4.2) 
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where C is the concentration of drug remaining in the nanoparticles at time t, A and 
B are system characteristic constants (A is used for diffusion control system and B 
for erosion control system), and ˛ and ˇ are rate constants that can be obtained from 
semilogarithmic plots. In general drug release rate depends upon solubility, diffusion 
and biodegradation of the matrix materials. The drug release mechanisms can be 
modified by the choice of polymer matrices.  
Drug release also depends upon the loading efficiency of drug and size of 
nanoparticles. Larger particles have a smaller initial burst release than smaller 
particles. The drug loading capacity is directly proportional to burst and release rate 
of nanoencapsulated drug molecule. In the case of nanospheres, where the drug is 
uniformly distributed, the release occurs by diffusion or erosion, of the matrix under 
sink conditions. If the diffusion of a drug is faster than matrix erosion the mechanism 
of release is largely controlled by a diffusion process. The rapid initial release or 
burst is mainly attributed to weakly bound or adsorbed drug to the large surface of 
nanoparticles. The addition of other polymers to PLA based polymers can also be 
used to control drug release. For example, PEG has been polymerized into a PLA 
homopolymer creating a PLA–PEG–PLA copolymer. The drug release continued to 
increase as the total molecular weight of the copolymers decreased. The initial burst 
can be decreased in the absence of lower molecular weight polymers (Kumari et al., 
2010). 
4.10 The Importance of Cancer Therapy Based on Nanomaterials and 
Nanocarrier Systems 
Cancer is one of the leading causes of death worldwide; it claimed 7.6 million deaths 
(13.1%) in 2005 out of 58 million deaths from all causes. In 2002, estimated 6.72 
million people worldwide were newly diagnosed with any the most 10 prevalent 
forms of solid cancers; of these, 4.15 million died within the same year. 
Based on projections, the death toll will rise to 9 million cancer deaths in 2015.  
Chemotherapy, surgery and radiotherapy continue to be the mainstay treatments of 
cancer. Over 700 FDA approved drugs have entered into clinical practice during the 
last 30 years; these are classified into six major groups that include the platinum 
coordination complex, antimicrotubule agents (vinca alkaloids, taxanes), 
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antimetabolites (methotrexate, fluoropyrimidines, cytocine arabinose, gemcitabine),  
antitumor antibiotics (actinomycin D, mitomycin C, bleomycin, anthracyclines, 
podophylotoxines, camptothecines),  alkylating agents, and  others including a 
number of biological drugs or monoclonal antibodies that target specific pathways 
such as EGFR or angiogenesis (Boulikas, 2008).  
Cancer occurs at a molecular level when multiple subsets of genes undergo genetic 
alterations, either activation of oncogenes or inactivation of tumor suppressor genes. 
Then malignant proliferation of cancer cells, tissue infiltration, and dysfunction of 
organs will appear. Tumor tissues are characterized with active angiogenesis and 
high vascular density which keep blood supply for their growth, but with a defective 
vascular architecture. Combined with poor lymphatic drainage, they contribute to 
what is known as the enhanced permeation and retention (EPR). Tumor genes are not 
stable with their development and often show genovariation. The inherent 
complexity of tumor microenvironment and the existence of P-glycoprotein (Pgp) 
usually act as barriers to traditional chemotherapy by preventing drug from reaching 
the tumor mass. Meanwhile, delivery of the therapeutic agents in vivo shares 
physiological barriers, including hepatic and renal clearance, enzymolysis and 
hydrolysis, as well as endosomal/lysosomal degradation. In addition, the efficiency 
of anticancer drugs is limited by their unsatisfactory properties, such as poor 
solubility, narrow therapeutic window, and intensive cytotoxicity to normal tissues, 
which may be the causes of treatment failure in cancer. 
Accordingly, there is a great need for new therapeutic strategies capable of delivering 
chemical agents and other therapeutic materials specifically to tumor locations. 
With the development of nanotechnology, the integration of nanomaterials into 
cancer therapeutics is one of the rapidly advancing fields. It can revolutionize the 
treatment of cancer. Nanotechnology is the creation and utilization of materials, 
devices, and systems through the control of matter on the nanometer scale. 
Nanocarrier systems can be designed to interact with target cells and tissues or 
respond to stimuli in well-controlled ways to induce desired physiological responses. 
They represent new directions for more effective diagnosis and therapy of cancer. 
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4.10.1 The importance of nano-micelles in cancer therapy 
Nano micelles are usually formed into core-shell structures by spontaneous assembly 
when their concentration is above critical micelle concentration (CMC). They have a 
number of unique features, including nanosize, easy manipulation of surface 
chemistry, core functionalities, as well as ease of fabrication, making them suitable 
as carriers for encapsulation, and delivery of water insoluble agents. The micelles 
have a solid-like inner core, which serves as a potent nanocontainer of hydrophobic 
compounds for solubilization of chemotherapeutics, including docotaxel (B. Liu et 
al., 2008), paclitaxel (Park, 2008) camptothecin (H. Onyuksel, 2005) ,and 
dequalinium (DQA) (Lizano et al., 2003) While polyionic complex micelles and 
cationic polymer micelles can incorporate and protect anionic gene or protein with 
low rate of cellular uptake and low physiological environment stability, such as 
vascular endothelial growth factor (VEGF), siRNA (Kim, 2009)and luciferase 
reporter gene.  
 Thanks to their hydrophilic shell, polymer micelles play an important part in 
escaping the recognition of RES and prolonging the blood circulation of drugs. The 
small size (<100 nm) allows micelles for efficient accumulation in pathological 
tissues with permeabilized vasculature via the enhanced permeability and retention 
(EPR) effect. However, the physiological factors, such as the density and 
heterogenesity of the vasculature at tumor sites, interstitial fluid pressure, and 
transport of macromolecules in the tumor interstitium, are responsible for the extent 
of micelles extravasations. 
Stimuli-responsive polymeric micelles are often designed for controlled release of 
drug into tumor tissue with external stimuli trigger, like temperature, pH, ultrasound, 
and special enzymes (Weili Qiao, 2010). 
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Table  4.4. Stimuli that can be utilized to control the behavior and properties of 
micelles. 
Stimuli Stimuli origin Examples References 
pH Decreased pH in cancer 
site caused by hypoxia 
and massive cell death 
Tumoral acidic 
extracellular pH targeting 
of pH-responsive micelles 
encapsulated doxorubicin 
for cancer therapy 
(J. Ko, 
2007) 
Temperature Increased temperature in 
cancerous tissues owing 
to their high metabolic 
activities. External 
applied heating 
Self-assembled,  
thermosensitive micelles 
for controlled doxorubicin 
delivery 
(Nakayama, 
2006) 
Magnetic 
field 
Locally applied 
magnetic field 
Folate-encoded and Fe304-
loaded polymeric micelles 
for dual targeting of cancer 
cells 
(Yang, 
2008) 
Ultrasound Locally applied 
ultrasound 
Ultrasonic release of 
doxorubicin from pluronic 
P105 micelles 
(Husseini, 
2002) 
Redox 
potential 
Increased concentration 
of glutathione inside 
many cancerous cells 
Poly(ethylene glycol)-
modied thiolated gelatin 
nanoparticles for 
glutathione-responsive 
intracellular DNA delivery 
(Torchilin, 
2009) 
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5. VINORELBINE (VLB) 
The Vinca alkaloids are a subset of drugs that are derived from the periwinkle plant, 
Catharanthus roseus (also Vinca rosea, Lochnera rosea, and Ammocallis rosea). 
There are four major Vinca alkaloids in clinical use: Vinblastine, vinorelbine, 
vincristine, vindesine and newly synthesized one; Vinflunine (Figure 5.2 ).   
Since we were trying to upload one of these Vinca alkaloids to nano-micelles in 
which the core part is consisting of nonpolar environment, we had to choose the most 
nonpolar one in order to place the drug in the core of formulation, otherwise 
localization of the drug in the shell would have lead to the fast release of drug from 
carrier which is not favorable in cancer targeting. 
Table  5.1: Water solubility of Vinca alkaloids calculated by a software 
(Development, (© 1994-2010 ACD/Labs)). 
Alkaloid Solubility in pH7 
µg/ml 
Vincristine 20 
Vinblastine 6.3 
Vinorelbine 0.75 
Vinorelbine has the least functional groupin among mentioned Vinca alkaloids so 
seems to be the most nonpolar one. Along with this, its side effects in chemotherapy 
(below) makes it the most appropriate candidate to use it in preparing the new 
targeting nano-formulation to use in cancer therapy. 
Lung cancer is one of the most commonly diagnosed malignancies in developed 
countries and is a growing problem in developing countries. There are two major 
types of lung cancer: non-small cell lung cancer (NSCLC) and small cell lung cancer 
(SCLC). NSCLC makes up approximately 80% of all lung cancer cases and has a 
limited response rate to current chemotherapeutic agents, with tumor shrinkage in 
only 20% of patients and a two-year survival rate between 10% and 16%. One major 
reason for this unsatisfactory outcome of chemotherapy is compromised drug 
delivery to the lung cancer tissues due to high interstitial fluid pressures (IFP) within 
the tumor. Systemically administered chemotherapy cannot be adequately delivered 
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into solid tumors because of the immature vasculature with abnormal architecture 
and leaky, heterogeneous vessel walls as well as the high IFP within tumor tissues. 
Furthermore, a lack of tumor specificity allows anti-cancer drugs to distribute 
indiscriminately to normal organs and tissues. Thus, cancer cells are exposed to a 
lower concentration of the drug than normal cells, resulting in not only decreased 
effectiveness but also increased toxicity. Therefore, it is important to develop a 
strategy to enhance the amount of drugs delivered to tumor tissues in a targeted way 
while sparing normal tissues (Chang, 2009).  
Vinorelbine is currently used in salt form (Bitartarate) in chemotherapy, so according 
to our knowledge the water solubility of its base form is not reported in literature. Its 
calculated water solubility and LogP are 0.75mg/ml and 4.69 respectively which 
were satisfying enough to start using this drug in nano formulation investigations. 
However, the real water solubility value was obtained experimentally was 
completely different (mentioned on Results and Discussion). 
In the other hand it is very important for a drug to carry all functional groups on just 
one surface or in a localized position on the whole surface in order to upload 
succesfully to the core. Otherwise, charge distribution will lead to localization on 
shell. Vinorelbine’s structure carries almost all functional (chargable) groups in a 
very localized manner:  
 
Figure  5.1: 3D illustration of the structure of VLB and the localization of its 
functional groups. 
 
So, we chose Vinorelbine to prepare a new targeting nano-formulation for cancer 
therapy.  
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5.1 History 
Vinorelbine was invented by the Pharmacist Pierre Potier and his team from the 
CNRS in France in the 1980s and was licensed to the oncology department of the 
Pierre Fabre Group and was first reported in Onkologie, vol. 4, issue 1, p; 7-12, 1991 
(Krikorian, 1991).  
The drug was approved in France in 1989 under the brand name Navelbine for the 
treatment of bronchial cancer. It gained approval to treat non-small cell lung cancer 
in 1991. The drug is now primarily used to treat this cancer. Vinorelbine received 
approval by the United States Food and Drug Administration (FDA) in December 
1994 sponsored by Burroughs Wellcome Company. Pierre Fabre Group now markets 
Navelbine in the U.S. The drug went generic in the U.S. in February 2003. 
In Europe is approved to treat non-small cell lung cancer, breast cancer and, in some 
countries, prostate cancer. 
Since 2004 an oral formulation has been marketed and registered in Europe for the 
same settings. It has been shown a similar efficacy and safety profile between both 
intravenous and per os formulations, avoiding local toxicity induced by the 
intravenous vinorelbine (Krikorian, 1991).  
5.2 Mechanism of Action:  
All Vinca alkaloids are administered intravenously (IV). After injection, they are 
eventually metabolized by the liver and excreted. They work in a cellcycle specific 
manner, halting mitosis of affected cells and causing cell death. The mechanism of 
action involves binding to the tubulin monomers and keeping the microtubules 
(spindle fibers) from forming (Ngan et al., 2000; Okouneva, 2003). This is where the 
mechanis of action of taxanes are to stabilize tubulin polymers but also to disrupt 
additional cellular processes and to induce apoptosis (X. M. Liu, Wang, L. G., Kreis, 
W., Budman, D. R., & Adams, L. M. , 2001).  
The mitotic spindle is a specialized structure required for exact chromosome 
segregation in mitosis. Spindle formation is dependent on the reorganization of 
interphase microtubule network, regulated by cell cycle-regulatory mechanisms. The 
centrosome (known as the microtubule organizing center) is involved in the 
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formation of spindle poles during mitosis, which ensures the distribution of the 
correct number of chromosomes to daughter cells. Aberrant centrosome duplication 
could cause centrosome amplification and chromosomal instability. 
These alkaloids also seem to interfere with cells' ability to synthesize DNA and 
RNA. Although the plant has medical uses, it can produce many serious side effects 
if smoked or ingested (Boulikas, 2008). 
5.3 Targeting Stem Cells by Vinorelbine 
One of the virtues of vinorelbine is the fact that it may can be easily combined with 
other cytotoxic and may be suitable for use in special populations such as the elderly 
and/or frail patients. Another rationale for using this agent is that, unlike doxorubicin 
or paclitaxel, vinorelbine has not been proven to be the substrate of ABC 
transporters, which are highly expressed in cancer stem cells (cancer stem cells 
express high levels of drug transporters such as ATP-binding cassette (ABC) 
transporters, which actively efflux drugs from cells, thus protecting them from 
cytotoxic agents). However, based on cancer stem cells concept, the effect of 
vinorelbine on malignant stem is still limited since it is a cell-cycle specific drug 
inhibiting cell growth during metaphase. To circumvent the problem, a sesquiterpene 
lactone parthenolide (PTL) is introduced. PTL is derived from feverfew (tanacetum 
parthenium), an herbal medicine that has been traditionally used for the treatment of 
migraine and rheumatoid arthritis. Recent studies have demonstrated that PTL 
possesses anti-tumor property in different cell lines through multiple signal 
pathways. In particular, a study showed that PTL was able preferentially to ablate 
primitive leukemia cells without affecting normal stem and progenitor cells. These 
findings indicate PTL may represent a novel class of agents for targeting cancer stem 
cells (Y. Liu, Lu, W.-L., Guo, J., Du, J., Li, T., Wu, J.-W., Wang, G.-L.,, 2008).  
5.4 Side Effects 
 For the treatment of non-small cell lung cancer NSCLC, VLB is administered at a 
dose of 20 to 25 mg/m2 alone or in combination with cisplatin or gemcitabine. VLB 
is also administered at a dose of 25 mg/m2 alone or combined with cisplatin or 
trastuzumab in patients with inoperable, advanced, and recurrent breast cancer, who 
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have previously received anthracyclines and taxanes. Vinorelbine has been reported 
to cause venous discoloration and chemical phlebitis proximal to the site of injection, 
as well as localized rashes and urticaria, blistering, and skin sloughing. It is a 
vesicant and venous irritant like other Vinca alkaloids. Factors that influence the 
development of phlebitis include the quality of the vein selected, the size and type of 
catheter used, the duration of infusion, and the pH and osmolality of the drug 
solution. The Japanese package insert for VLB recommends dilution with 50 mL of 
normal saline or 5% glucose and administration over less than 10 min, followed by 
flushing of the vein but the effectiveness of this protocol has not been evaluated.  
Vinorelbine has some other side-effects that can limit its use: Lowered resistance to 
infection, bruising or bleeding, constipation, diarrhea, nausea, numbness or tingling 
in hands or feet (peripheralneuropathy), tiredness and a general feeling of weakness 
(asthenia),  granulocytopenia, leucopenia, and thrombocytopenia, with 
granulocytopenia being the primary dose-limiting toxicity.  
Acute reaction, such as dyspnea, chest pain and wheezing has been reported during 
administration but can be prevented in some cases by premedication with 
corticosteroids.   
A stable oral dosage form of vinorelbine (Navelbine Oral) developed in 1994 by 
Pierre Fabre Medicament is also available. However, Depierre et al. (Depierre et al., 
2001)found a high rate of early deaths (10%) due to complicated neutropenia toxicity 
when patients were given a weekly dose of 80 mg/m2 by mouth; accordingly, the 
dose had to be reduced to 60 mg/m2/week to continue the study (Kohno, 2008). 
5.5 Reported Nano Vinorelbine Formulations: 
The company Hanna Biosciences Inc. has prepared a liposomal formulation for 
vinorelbine-tartarate and the phase I studies started in 2006 and is almost enden in 
2010. They have 2 very important disadvantages in comparing with our DSPE-PEG 
and Polymeric Micelles: 
During preparation of this liposomal formulation, they use Inophore and in another 
stage they use MgSO4 which removing both of them is very hard and they add two 
steps of cleaning and purifying these two compounds to the processes (Semple et al., 
2005).  
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Another study is reporting enhanced therapeutic and reduced side effect of 
vinorelbine by using Peptide attached liposomes. This study is only trying to show 
the effect of a very specific peptide; PC5-2 to target breast cancer cells and uses 
Vinorelbine as an example drug to show the efficacy of the mentioned peptide. 
Maybe because of that reason this paper deos not mention of the method of preparing 
liposome so we are not able to compare our formulation with the reported nano-
vinorelbine formulation (Chang, 2009).   
The last study that reports preparing a nano formulation old Vinorelbine is a paper 
presented by Wang et al. This paper is using the water soluble form of Vinorelbine; 
Vinorelbine-tartarate as model water soluble drug. In this study Poly (ethylene 
glycol)-phosphatidylethanolamine (PEG-PE) (we called the same material DSPE-
PEG in our thesis) has been used as drug delivery system. The authors are reporting a 
very high encapsulation efficacy and saticfying in vitro release period.  
Interestingly this study is reporting using micelles for encapsulation of hydrophiic 
drugs. According to our knowledge liposomes are the most appropriate drug delivery 
systems in order to carry water soluble drugs. Although this paper is reporting 
different evidences that proofes the incorporation of the water soluble drugs with the 
hydrophilic head group of phosphatidylethanolamine, the water soluble drug is more 
possible to incorporate with the PEG layer. Unfortunately all results that have been 
mentioned as the evidence of incorporating drug with the core part of micelle could 
be seen when the drug is incorporated with the PEG layer too (Y. Wang et al., 2010). 
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Figure  5.2: Currently used Vinca alkaloids in chemotherapy, (Boulikas, 2008). 
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6. THE BASICS OF THE METHODS USED IN THIS STUDY 
6.1 The Methods Used in Chemical Isolation of Plant Materials 
6.1.1  Chromatography 
Among the chemical methods of plant examination, chromatographic analysis plays 
a very important role, and it has been introduced to all the modern pharmacopoeias. 
Because of numerous advantages of the chromatographic methods (such as their 
specificity and a possibility to use them for qualitative and quantitative analysis), 
they comprise an integral part of the medicinal plant analysis. 
The following chromatographic methods are most frequently applied in 
phytochemical analysis: one- and two-dimensional paper chromatography, one- and 
twodimensional thin layer chromatography (TLC; also called planar 
chromatography), high-performance column liquid chromatography (HPLC), gas 
chromatography (GC), and column chromatography (CC). These methods can also 
be used for the isolation of the individual components from the component mixtures 
on a preparative and micropreparative scale (Waksmundzka-Hajnos, 2008).  
Chromatography is based on differential migration rates of components of a liquid or 
gas as it moves past adsorptive materials. Practically any soluble or volatile 
substance can be purified by chromatography. Some combination of adsorbant, 
conditions and carrier fluid will allow us to apply a mixture of materials to a column 
of adsorbent and to flush so that differential migration rates separate the materials to 
a column of adsorbent and to flush so systems have stationary phase (which can be 
solid or liquid) and a mobile phase (usually liquid or gas) (Raaman, 2006).  
6.1.2 Column chromatography 
In column chromatography both phase are placed in a column container. Column 
chromatography involves ion-exchange, molecular sieve, adsorption and partition 
phenomenon.  
Column chromatography can function with quite impure feed streams, but an 
undesired byproduct in high concentrations may give peaks that overlap with those 
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of the desired product. Loading relates to capacity of the adsorbent, and overloading 
results in dispertion through the column and little or no purification. A run starts with 
concentrate at the top of the column, then a solvent (eluent) flushes materials through 
the column. Molecules have different attractions to the adsorbing materila and move 
at different rates through the column to its exit. 
With light loading of small columns, resolution of peaks is often excellent so that 
very high purity is obtained. Heavier loading produces longer tails so that one 
material contaminates another. The dispertion of flow in large columns can lead to 
severe cross contamination of material (Raaman, 2006).  
6.1.3 Thin layer chromatography:  
TLC is a chromatographic technique widely used for qualitative analysis of organic 
compounds, isolation of the individual compounds from multicomopnent mixtures, 
quantitative analysis, and preparative-scale isolation. Many kinds of TLC and 
highperformance TLC (HPTLC) precoated plates are commercially available, e.g., 
those with the inorganic adsorbent layers (silica or silica gel and alumina); organic 
layers (polyamide, cellulose).  
Sorbents applied in TLC have different surface characteristics and, hence, different 
physicochemical properties. Moreover, there is a wide choice of mobile phases that 
can be used to separate mixture components; these belong to various selectivity 
groups and, thus, have different properties as proton donors, proton acceptors, and 
dipoles. In TLC, ultraviolet (UV) absorption of the mobile phase solvents does not 
play a significant negative role in detection and quantification of the analytes, 
because the mobile phase is evaporated from the plate prior to the detection. High 
viscosity of a solvent can be viewed as a sole property limiting its choice as a mobile 
phase component. These plate and mobile phase characteristics 
allow a choice from among an unparalleled abundance of TLC systems that offer a 
broad spectrum of separation selectivities, which is particularly important when 
complex mixtures of the plant extracts have to be separated. 
The advantages of TLC are particularly important with plant extracts, which are very 
complex mixtures of the structurally differentiated chemical compounds. Such 
extracts very often contain polar (e.g., tannins and phenols) and nonpolar (lipids, 
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chlorophylls, and waxes) ballasts, apart from a fraction of active substances that is of 
main importance for phytochemistry and pharmacognosy. 
TLC enables separation of a crude plant extract without an earlier purification. For 
example, in a normal phase system a nonpolar fraction moves with the mobile phase 
front (or it can be prewashed with a nonpolar mobile phase prior to the development 
of a chromatogram), and the polar fraction remains strongly retained near to the 
origin; then the fraction of interest is separated in the central part of the 
chromatogram (Hajnos, 2008). 
6.1.4 TLC techniques used in identification of Indole alkaloids 
6.1.5  Stationary phases 
Most TLC procedures for separating Indole alkaloids use an adsorbent stationary 
phase such as silica gel G, often with fluorescent agent added, since all Indole 
alkaloids will absorb UV light and can be observed as quenching zones when 
examined under UV light. 
6.1.6 Mobile phases 
A very large number of mobile phases have been used to separate Indole alkaloids 
and can be found in the standard reference sources. Solvents employed reflect the 
polarity of the alkaloids under investigation. The majority of Indole alkaloids are 
tertiary bases with fairly low polarity, so that mixtures containing a major part of a 
less polar solvent (e.g., chloroform, toluene) with a small proportion of a more polar 
solvent (e.g., acetone, ethanol, methanol) are frequently cited. Since tertiary Indole 
alkaloids share the amphiphilic properties of most other alkaloids, resulting in 
elongated ‘‘streaked’’ zones, sometimes called ‘‘tailing,’’ a base is often added to the 
solvent mixture to ensure that the noncharged form of the alkaloids is predominant 
and that the zones are more compact. For less polar systems, diethylamine, in 
proportions up to 10% v:v, is used but in other cases ammonia solution, either 
concentrated (13.5 M) or in a more dilute form can be used, often in conjunction with 
ethyl acetate and propan-2-ol. 
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6.1.7 Detection reagents 
Most detection of Indole alkaloids is carried out by first observing under UV light 
254 nm for the presence of fluorescent or quenching zones. If the latter are sought, 
then a layer with added fluorophor (e.g., silica gel GF254) should be used. The 
Cinchona alkaloids in particular give a very strong bright blue fluorescence under 
UV 365 nm and can be detected at very low concentrations. Many of the ergot 
alkaloids give a blue fluorescence under UV light at both 254 and 365 nm. It is very 
common to follow examination under UV light with the use of a chemical 
chromogenic reagent but there are a few instances of biological detection methods 
also being applied. 
6.1.8 Chemical detection methods 
Dragendorff’s reagent (potassium iodobismuthate solution) will give an orange color 
against a yellow background for all Indole alkaloids, based on the precipitate 
complex of the alkaloid and the bismuth metallic component of the reagent. 
The colors of zones for some Indole alkaloids obtained by spraying with 
Dragendorff’s reagent can be made more intense by subsequent spraying with 10% 
sodium nitrite solution.15 Iodoplatinate reagent works on a similar principle and 
gives a slightly greater range of colors comprising pink, brown, and violet (Hajnos, 
2008).  
6.2 Methods Used in Preparation of Nano Vinorelbine Formulations:  
6.2.1 Surfactant micelle characterization using dynamic light scattering (DLS) 
Dynamic Light Scattering (DLS) is a technique used for particle sizing of samples, 
typically in the sub-micron range. The technique measures the time-dependent 
fluctuations in the intensity of scattered light from a suspension of particles 
undergoing random, Brownian motion. Analysis of these intensity fluctuations 
allows for the determination of the diffusion coefficients, which in turn yield the 
particle size through the Stokes- Einstein equation. 
Conventional DLS instruments use a detection angle of 90° and this optical 
configuration may not be sensitive enough for the successful measurement of 
surfactant micelles. The Zetasizer Nano range of instruments incorporates non-
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invasive back scatter (NIBS) optics . The scattered light is detected at an angle of 
173° and this novel optics arrangement maximizes the detection of scattered light 
while maintaining signal quality. This provides exceptional sensitivity that is 
required for measuring the size of nanoparticles, such as surfactant micelles, at low 
concentrations. 
DSPE-PEG 2000 and Polymeric micellar samples prepared in a concentration 1000 
and 100 times higher than their CMC respectievely (Birdi, 1997; Cosgrove, 2005; 
Everett, 1988).    
6.2.2 The principals of Differential Scanning Calorimeter (DSC) and its 
relation with polymer characterization and drug delivery systems: 
DSC is a technique which is part of a group of techniques called Thermal Analysis 
(TA). Thermal Analysis is based upon the detection of changes in the heat content 
(enthalpy) or the specific heat of a sample with temperature. As thermal energy is 
supplied to the sample its enthalpy increases and its temperature rises by an amount 
determined, for a given energy input, by the specific heat of the sample. Most DSC 
instruments are of the heat-flux design, a schematic of which is shown below. 
Small, flat samples are contained in shallow pans, with the aim of making a good 
thermal contact between sample, pan and heat flux plate. Symmetrical heating of the 
cell, and therefore S and R, is achieved by constructing the furnace from a metal of 
high thermal conductivity. 
Figure  6.1: Basic Components of a DCS Instrument (Kastantin, 2009). 
 6.2.3 Crystallization of a polymer s
using DSC  
Above the glass transition, the polymers have a lot of mobility. They wiggle and 
squirm, and never stay in one position for very long. When they reach th
temperature, they will have gained enough energy to move into very ordered 
arrangements, which we call crystals, of course. 
When polymers fall into these crystalline arrangements, they give off heat. We can 
see this drop in the heat flow as a big 
Figure  6.2: General view of the crystallization thermogram of a p
2009). 
The temperature at the lowest point of the dip is usually considered to be the 
polymer's crystallization temperature, or 
dip, and that will tell us the latent energy of crystallization for the polymer.
6.2.4 The meaning of “crystal” in polymeric materials and the relation of 
crystallization temperature with the loaded drug in drug delivery 
systems:  
The kind of crystal we're talking about here is any object in which the molecules are 
arranged in a regular order and patte
Most of Polymers can't always stretch out so straightly. In fact, very few polymers 
can stretch out perfectly straight, and those are ultra
polyethylene, and aramids like Kevlar and Nomex. Most polymers can only stretch 
out for a short distance before they fold back on themselves. 
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Figure  6.3: Folding of polymers in solid state, (Kastantin, 2009). 
For polyethylene, the length the chains will stretch before they fold is about 100 
angstroms.  
But not only do polymers fold like this. Polymers also form stacks of these folded 
chains. There is a picture of a stack, called a lamella, right below.  
 
Figure  6.4: The stack of polymers which causes the crystallization thermogram in 
DSC spectrum, (Kastantin, 2009). 
This is the point in which we see the Crystallization Temperature. In this 
temperature, (after giving enough heat to the material,) material gains enough energy 
to form stacks of folded chains. 
 Of course, it isn't always as neat as this. Sometimes part of a chain is included in this 
crystal, and part of it isn't. When this happens we get the kind of mess. Lamella is no 
longer neat and tidy, but sloppy, with chains hangin
amorphism causes a decrease in crystallization temperature.
Figure  6.5: The reason of decrease in crystallization t
6.2.5 The partial interdigitation i
evidence in DSC researchs (s
In polymer science plasticization is the inter mingling of the "solvent" between the 
polymer chains causing the polymer to become more flexible.  
Figure  6.6: Adding the plasticizer and reduction in crystallization t
(Whypych 2009). 
According to the free volume theory, the addition of the plasticizer to the polymer 
creates a large free volume in the 
temperature of the plasticized polymer.
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The presence of drug in lipid based lamellar drug delivery systems induces partial 
interdigitation as it is depicted by the increase of ∆H and reduction of crystallization 
temperature. As it is reported in the literature, the main cause of intergiditation is an 
increase in the lateral area between the lipid headgroups with a formation of voids in 
the hydrophobic core. By interdigitation the system gains energy due to the stronger 
van der Waals interactions in the interior of the membrane bilayers and due to an 
entropy gain by replacing the highly ordered water molecules at the interface with 
the polar part of the amphiphilic molecules (Galipeau, 1995; Kastantin, 2009; 
Koukoulitsa, 2006; Lv et al., 2009; Maswadeh et al., 2002; Sullivan, 2004; Ward, 
2005; Whypych).  
6.2.6 Reversed-phase High Performance Liquid Chromatography (RP-HPLC) 
Reversed phase HPLC (RP-HPLC or RPC) has a non-polar stationary phase and an 
aqueous, moderately polar mobile phase. One common stationary phase is a silica 
which has been treated with RMe2SiCl, where R is a straight chain alkyl group such 
as C18H37 or C8H17. With these stationary phases, retention time is longer for 
molecules which are less polar, while polar molecules elute more readily. An 
investigator can increase retention time by adding more water to the mobile phase; 
thereby making the affinity of the hydrophobic analyte for the hydrophobic 
stationary phase stronger relative to the now more hydrophilic mobile phase. 
Similarly, an investigator can decrease retention time by adding more organic solvent 
to the eluent. RPC is so commonly used that it is often incorrectly referred to as 
"HPLC" without further specification. The pharmaceutical industry regularly 
employs RPC to qualify drugs before their release. 
Structural properties of the analyte molecule play an important role in its retention 
characteristics. In general, an analyte with a larger hydrophobic surface area (C-H, 
C-C, and generally non-polar atomic bonds, such as S-S and others) results in a 
longer retention time because it increases the molecule's non-polar surface area, 
which is non-interacting with the water structure. On the other hand, polar groups, 
such as -OH, -NH2, COO– or -NH3+ reduce retention as they are well integrated into 
water. Very large molecules, however, can result in an incomplete interaction 
between the large analyte surface and the ligand's alkyl chains and can have 
problems entering the pores of the stationary phase. 
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Retention time increases with hydrophobic (non-polar) surface area. Branched chain 
compounds elute more rapidly than their corresponding linear isomers because the 
overall surface area is decreased. Similarly organic compounds with single C-C-
bonds elute later than those with a C=C or C-C-triple bond, as the double or triple 
bond is shorter than a single C-C-bond. 
Another important component is the influence of the pH since this can change the 
hydrophobicity of the analyte. For this reason most methods use a buffering agent, 
such as sodium phosphate, to control the pH. The buffers serve multiple purposes: 
they control pH, neutralize the charge on any residual exposed silica on the 
stationary phase and act as ion pairing agents to neutralize charge on the analyte. 
Ammonium formate is commonly added in mass spectrometry to improve detection 
of certain analytes by the formation of ammonium adducts. A volatile organic acid 
such as acetic acid, or most commonly formic acid, is often added to the mobile 
phase if mass spectrometry is used to analyze the column eluent. Trifluoroacetic acid 
is used infrequently in mass spectrometry applications due to its persistence in the 
detector and solvent delivery system, but can be effective in improving retention of 
analytes such as carboxylic acids in applications utilizing other detectors, as it is one 
of the strongest organic acids. The effects of acids and buffers vary by application 
but generally improve the chromatography (S. Ahuja & Dong, 2005; Satinder Ahuja 
& Rasmussen, 2007). 
6.2.7 A short review of MTT assay: 
The MTT assay and the MTS assay are colorimetric assays for measuring the 
activity of enzymes that reduce MTT or close dyes (XTT, MTS, WSTs) to formazan 
dyes, giving a purple color. A main application allows to assess the viability (cell 
counting) and the proliferation of cells (cell culture assays). It can also be used to 
determine cytotoxicity of potential medicinal agents and toxic materials, since those 
agents would stimulate or inhibit cell viability and growth. MTT (3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a yellow tetrazole), is 
reduced to purple formazan in living cells. A solubilization solution (usually either 
dimethyl sulfoxide, an acidified ethanol solution, or a solution of the detergent 
sodium dodecyl sulfate in diluted hydrochloric acid) is added to dissolve the 
insoluble purple formazan product into a colored solution. The absorbance of this 
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colored solution can be quantified by measuring at a certain wavelength (usually 
between 500 and 600 nm) by a spectrophotometer (Mosmann, 1983).  
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7. MATERIALS AND METHODS 
Materials used in Synthesis of PCL4 -PEG4 and PCL2-PEG Polymers are not 
included  
1.1. Materials: 
• DSPE-PEG2000 ; MW2810, Cat #`PE 18:0/18:0-PEG2000, Lot # 882032-
01/907 
• Acetonitrile, Methanol (HPLC grade) Ficsher scientific 
• TFA (HPLC grade) Ficsher scientific 
• Chloroform-Methanol-Ethanol- Acetonitrile, Ficsher scientific 
• Vinorelbine; Cat# AL-4176 Altan Biochemicals. MW: 778.932 
• Plastic cuvettes 
• Amicon® Ultra-4 Centrifugal Filter Tubes (Millipore) 
• Spectra/Por 3 Molecularporous Dialysis Membrane, Spectrum, MWCO 6000-
8000, part no. 132720 
• Spectra/Por 1 Molecularporous Dialysis Membrane, Spectrum, MWCO 3500, 
part no. 132720 
• MCF-7 cell lines (6x104 cells/ml). 
• Media: DMEM Dulbeccos Modified Eagle Medium, High Glucose 1X. Lot# 
12430  
• Phosphate buffer saline (PBS) (preparation method mentioned below) 
• Media: DMEM Dulbeccos Modified Eagle Medium, High Glucose 1X. Lot# 
12430  
• Fetal bovin serum 
• MTT, Sigma Aldrich Cat# M2003 
92 
 
• Merck: 1.07730.1000 Silica gel 60 GF254, 1.07734.1000 Silica gel 60 
(0.063-0.200 mm), Merck 1.05554.0001 TLC Silica gel 60 F254 
• Argon Tube 
Preparation of Reagents and Buffers: 
Table  7.1: Chromogenic Spray Reagents for Indole Alkaloids (Hajnos, 2008). 
Common 
Name 
Formula Treatment 
after 
Spraying 
Notes 
Dragendorff’s 
reagent 
Solution A: 0.85 g basic bismuth 
nitrate dissolved in 10 mL glacial 
acetic acid and 40 mL water with 
Heating Solution B: 8.0 g 
potassium iodide dissolved in 30 
mL water 
Mix solutions A and B in 1:1 
ratio 
then add to glacial acetic acid 
and water in 1:2:10 ratio 
Observe in 
daylight 
 
Gives an 
orange color 
with many 
types of 
alkoloids. 
 
Cerium(IV) 
sulfate 1 g  
Ammonium cerium(IV) sulfate 
dissolved in 100 ms 85% 
phosphoric acid 
Heat at 
1050C for 10 
min; observe 
in daylight 
Variations of 
formula exist 
Table  7.2: The formulation of 1xPBS Buffer (Medicago, 2010). 
1 8 g NaCl  
2 0.2 g KCl  
3 1.44 g Na2HPO4  
4 0.24 g KH2PO4 
5 in 800 ml of distilled H2O 
6 Adjust the pH to 7.4 with HCl. Add H2O to 1 liter. Sterilize by autoclave 
7.1 Instruments: 
• Schimadzu Prominence HPLC unit 
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• HPLC Column: Zorbax-300SB, C18, 4.6x250mm,5µm, 300A, lot# WSB 
0752003, Agilent Technologies.   
• Zeta Potential/Particle Sizer, NICOMP 380 ZLS 
• Labconco Freezone 6 Freezdrier  
• Beckman Coulter /Du 800 Spectrophotometer 
• Beckman Coulter GS-6R Centrifuge (for centrifuging filter tubes) 
• Fischer scientific Micro Centrifuge 235 C (for centrifuging regular tubes) 
• 400 MHz Bruker AVANCE-400 spectrometer (Department of Medicinal 
Chemistry and Pharmacognosy, University of Illinois at Chicago) and Varian 
Mercury (1H: 400 MHz, 13C: 100 MHz) Boğaziçi University Advanced 
Technologies R&D 
• Perkin Elmer, Jade DSC Instrument 
• Eliza Reader Molecular Devices Spectro Max340 PC 
• Rota Evaporator, Büchi and Heidolph 
• Vortex IKA MS3 basic 
• Ultrasonic Bath (Fisher Scientific FB 15051) 
• UV cabin and light (Camag)  
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8. EXPERIMENTAL 
In this study we  
A) Isolated and identified Vinca alkaloids from three Vinca species. 
B) Uploaded the hydrophobic anticancer drug Vinorelbine to 3 different Nano-
Drug Delivery Systems all of wich have the ability of making micelles and 
carrying hydrophobic drugs. These Drug delivery systems are:  
1- Micelles made of the lipid-polymer conjugate Distearoyl 
Phosphatidylethanolamine-PolyEthylene Glycole 2000 (DSPE-PEG 2000). 
The material is obtained commercially.   
2- Star shape Poly- ε-Capro Lactone4 - PolyEthylene Glycole4 (PCL4-PEG4).  
3- Y Shape Poly- ε-Capro Lactone2- PolyEthylene Glycole(PCL2-PEG).  
 
The latter two polymers have been synthesized by “Gürkan Hızal, Ümit 
Tunca Polymer Research Group”, Istanbul Technical University- Faculty of 
Scıence and Letters, Department of Chemistry. So we just give a short 
illustration of the method of synthesizing these two polymers: 
8.1 Methods: 
8.1.1 Methods used in synthesizing star shape PCL4-PEG4 
a-Synthesis of 1-2,2,5-trimethyl [1,3]dioxane- 5-carboxylic acid  
 
(8.1) 
b- benzyl 2,2,5-trimethyl-[1,3]dioxane-5-carboxylate 
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(8.2) 
c- Reduction of Product 
d- Synthesis of 2-(benzoylcarbonyl)-2-metilpropane-1,3-diyl-bis(2,2,5-trimethyl-1,3-
dioxane-5-carboxylate  
 
(8.3) 
e-Reduction of Product 
f- Synthesis of Star PCL polymer 
 
(8.4) 
i-Synthesis of Azide PCL 
 
(8.5) 
j- Synthesis of Azide PEG 
 
(8.6) 
k- Final Synthesis of Star PCL-PEG (A4B4) 
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(8.7) 
8.1.2 Synthesis of Y shaped Polymer 
a- Synthesis of 2,2,5-trimethyl [1,3]dioxan- 5-carboxylic acid 
 
(8.8) 
b- Synthesis of antrasen-9-il-methyl 2,2,5-trimethyl-1,3-dioxane-5-carboxylate  
 
(8.9) 
c- Reduction of Product 
d4- Coupling of PCL 
 
(8.10) 
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e- PEG Modification 
 
 
(8.11) 
f- Synthesis of Poli ε-caprolactone-b-poliethilene glycol co-polymer  
 
(8.12) 
In all steps, synthesized compounds were characterized by NMR, GPC, DSC and 
Mass Spectrometric measurements. 
8.1.3 Methods applied in isolation of alkaloids  
Plant Material: 
Table  8.1: The collected locations of Vinca species. 
Name Plant Part Collected From Weight (kg) 
Vinca soneri Aerial Parts Erzincan-Kemaliye-
Sirakanaklar 
1.2 
Vinca major Aerial Parts The Garden of 
Ankara University, 
Faculty of Science 
0.24 
Vinca minor Aerial Parts The Garden of 
Ankara University, 
Faculty of Science  
0.15 
All plants were dried in shadow and grounded. 
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Extraction:  
The extraction method applied to above mentioned plants is the same. 
Most alkaloids are present in the raw plants in the form of salts of organic 
acids.(Hesse, 2002) The extracted alkaloids may remain salts or change into bases. 
Base extraction has been achieved by processing the raw material with Ethanol twice 
in room temperature. The Ethanolic extract has been evaporated under vacuum. In all 
cases we obtained a green adhesive gum was obtained. The viscous residue dissolved 
in water ( as little as possible, generally around 250ml). The aquous solution treated 
with weak acidic solution (%1 acetic acid in water, obtained pH= 4.2 ). We accept 
that Alkaloids are in salt form in aquous phase so we could extract the non-basic 
content by using an organic solvent like Dichloromethane.  A base is then added to 
convert alkaloids to basic forms (pH= 8.3 by using %25 NH3 in water) which are 
extracted with organic solvent(Hesse, 2002).  The amount of obtained extracts areas 
listed in table below. 
Table  8.2: The amount of the extracts. 
Name Basic Extract 
(g) 
Asidic 
Extract(g) 
Aquous Extract (remaining after 
extractions) 
Vinca 
soneri 
1.29 41.76 59.2 
Vinca 
major 
1.54 10.08 22.36 
Vinca 
minor 
0.54 8.2 15.8 
The basic extract obtained from Vinca sonerii applied to Silica Gel column and the 
basic extracts of Vinca minor and major were applied to Aluminium column 
chromatography. The applied solvent system is as the table below. The amount of 
solvent applied is proportional to the amount of the fractions is being washed from 
the column at moment of application. 
Table  8.3: The applied solvent system in column chromatography of Vinca soneri. 
 Added Solvent Isolated fraction 
DCM* %100 1-5 
Aceton %2 5-8 
Aceton %5 8-11 
Aceton %10 12-13 
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Table  8.4 (Contd.): The applied solvent system in column chromatography of Vinca 
soneri. 
 Added Solvent Isolated fraction 
Aceton %25 13-17 
Aceton %50 17-21 
Aceton %75 21-26 
Aceton %100 26-29 
MeOH %2 29-30 
MeOH %5 31-34 
MeOH %10 34-37 
MeOH %25 38 
MeOH %50 39 
MeOH %75 40 
MeOH %100 41 
  
Table  8.5: The applied solvent system in column chromatography of Vinca minor 
and major. 
 Added Solvent Isolated fraction 
P.E.* %100 1-5 
CHCl3 %2 5-8 
CHCl3 %5 8-11 
CHCl3 %10 12-13 
CHCl3 %25 13-17 
CHCl3 %50 17-21 
CHCl3 %75 21-26 
CHCl3 %100 26-29 
MeOH %2 29-30 
MeOH %5 31-34 
MeOH %10 34-37 
MeOH %25 38 
MeOH %50 39 
MeOH %75 40 
MeOH %100 41 
Alkaloid existance has been surveyed in the obtained fractions by using Dragendorf 
Reagent. Fractions carrying alkaloid were further purified using Praparative Thin 
Layer Chromatography (Preparative TLC). Aluminium based Silica Gel or neutral 
Aluminium precoated sheets have been used. The used plate type and isolation 
solvent has been reported under Results chapter.   
8.1.4 Methods applied in preparation and characterization of Nano-VLB 
formulations: 
As we mentioned in general information part, in order to achieve a succesfull 
targeted drug delivery it is important to obtain micelles with certain physical 
101 
 
properties like size (under 200nm), acceptable CMC, compatibility to industrial 
production processes and the most important stability at in vivo conditions. The latter 
factor is important in targetting cancer side. Since we aim to use EPR effect it is 
important for drug delivery system to carry the drug till the point of cancer tissue.  
 
Figure  8.1: Targeted drug delivery to the tumor side. 
All methods mentioned below have done by considering these factors.   
8.1.5 Nano-VLB-SSM formulation: 
8.1.6 Determination of the purity of commercially available Vinorelbine: 
According to the recorded NMR Spectrum the sample is completely pure.  
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• The most common impurity in natural and/or semisynthetic compound is the 
isomeric form  of  related compound. Generally the concentration of isomeric 
form(s) is less than mother compound and makes bothering little peaks beside 
main peaks. Obviously the sample is purified from isomeric forms during 
production, because all peaks are in the same ratio of height and shape. 
• All peaks are assignable to the protons of Vinorelbine so sample hasn’t been 
contaminated by any non isomeric impurities as well.  
• The table of assigned protons is as follows (Ribet, 2001):  
 
Figure  8.2: The structure of Vinorelbine (Ribet, 2001). 
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Table  8.6: The results of NMR assay to proof the purity of VLB. 
H No Group ppm     H No Group ppm 
21 CH3 0.73     2 CH2  3.73 
21/ CH3 1.08     24 COOCH3 3.78 
 b-20 CH 1.25     25 OCH3 3.85 
a-20 CH 1.72     a-5/ CH 3.85 
2/ CH 1.87     b-5/ CH 3.96 
20/ CH2 2.05     a-7/ CH 4.04 
11 CH 2.05     b-7/ CH 4.44 
a-8 CH 2.59     6 CH 5.27 
a-1/ CH 2.59     4 CH 5.38 
a-19/ CH 2.82     3/ CH 5.77 
b-1/ CH 2.86     6 CH 5.27 
b-8 CH 3.06     4 CH 5.38 
b-10 CH 3.22     3/ CH 5.77 
a-10 CH 3.33     7 CH 5.85 
b-19/ CH 3.64     14 CH 6.09 
23/ COOCH3 3.71     17 CH 6.39 
       
10/ 
11/ 
12/ 
13/ 
14/ 
CH 7.17 
        NH 7.80 
        C3- OH 8.52 
8.1.7 HPLC method optimization for Vinorelbine in base form: 
The aim of this study was to determine the best mobile phase for Vinorelbine (in 
base form) concentration measurements in our lab settings using Schimadzu 
Prominence HPLC unit. 
Applied General Parameters (Jehl et al., 1990; Puozzo, Ung, & Zorza, 2007; 
Robieux, 1996; Vendrig, 1988): 
• Detection wavelength: 267nm 
• Sample concentration: 100µg/ml. 
• Injection volume: 20µl  
• TFA concentration: %0.05 in water and %0.05 in MeOH; Totally 0.1 v/v 
A gradient of MeOH starting from %20 achieving %100 in 20 minutes is applied to 
the system: 
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HPLC Time Table: 
Table  8.7: HPLC program time table for VLB. 
Time Pump Action %MeOH 
0.01 Controller Start  
0.02 Pumps Pump AB Conc 20 
20 Pumps Pump AB Conc 100 
25 Pumps Pump AB Conc 100 
30 Pumps Pump AB Conc 20 
35 Pumps Pump AB Conc 20 
30.01 Controller Stop  
 
Figure  8.3: HPLC chromatogram of VLB 
• The intensity of peak is high enough however a ‘‘pre-peak’’ is seen in base 
part of main peak 
• The retention time is acceptable 
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• The only problem with this mobile phase is the more or less significant ‘‘pre-
peak’’.  
                                     
Figure  8.4: The ghost peak was seen in chromatogram of VLB. 
• Considering that sometimes high concentration of sample causes this problem 
some samples in lower concentrations have been tested but this pre-peak was 
still recognizable. So this has been accepted as the nature of peak of 
Vinorelbine. 
• During the optimization of a mobile phase for VLB a peak was seen around 
24th minute of Chromatogram; 
 
Figure  8.5 The ghost peak was seen in chromatogram of VLB. 
This was accepted as impurity but during the process of obtaining concentration 
curve it has been seen that the height of this peak is always the same and doesn’t 
change with the height of the sample peak. Starting from this point we came to the 
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conclusion that this is not a impurity but maybe it is a “ghost peak” which is popular 
when TFA is included to mobile phase. Generally its common to see those peaks 
when the organic solvent reaches the point %100. To verify this idea a run without 
sample has been done and the same peak in the same point has been recognised. 
So this peak is not an impurity. 
 
Figure  8.6: The ghost peak was seen in chromatogram of VLB. 
8.1.8 Preparation of calibration curve of Vinorelbine (VLB) using HPLC 
• VLB concentrations: 100, 75, 50, 25 and 12.5µg/ml 
• Injection sequences: 3 times each concentration 
• Mobile phase, MeOH and Water, each containing %0.05 TFA (v/v) 
Table  8.8: Absorbance and area under curve per each injection. 
Conc. (µg/ml) Rep. Abs(mAu) Area (%) Average of Areas 
12.5 1 40.23 339737 
339737 12.5 2 36.41 337604 
12.5 3 35.68 315608 
25 1 73.90 711400 
701825 25 2 75.38 708379 
25 3 76.31 685696 
50 1 152.53 1406120 
1417211 50 2 177.39 1434691 
50 3 168.71 1410823 
75 1 234.43 2145092 
2129935 75 2 233.85 2108867 
75 3 228.92 2135847 
100 1 299.00 2710300 
2760766 100 2 338.83 2839339 
100 3 339.14 2732660 
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Figure  8.7: VLB’s concentration curve. 
8.1.9 DSPE-PEG2000 Sterically Stabilized Micelles (SSM)(drug loaded and 
free micelles):  
Sterically Stabilized Micelles’ Critical Micelle Concentration (CMC) has been 
reported as 1µM/ml(Ashok, 2004). In vitro characterization of PEGylated 
phospholipid micelles for improved drug solubilization: effects of PEG chain length 
and PC incorporation (Ashok, 2004). In DLS and Solubility experiments the SSMs 
has been prepared in concentration of 1mM (CMCx1000). In case of release and 
stability investigations this concentration has been scaled up to 10mM. In cell culture 
studies the concentration of SSM has been scaled up proportional to the amount of 
Vinorelbine used in determination of IC50.   
The method for preparing 50 and 500µg VLB in 1mM SSM has been described 
below as two examples:  
Stock solutions to be prepared: DSPE-PEG will be kept constant at 1mM 
(2.81mg/ml) 
Table  8.9: Stock solutions to be prepared to synthesize DSPE-PEG 2000 micelles. 
Stock 
# 
DSPE-PEG2000 
(mg) 
Vinorelbine 
(µg) 
Final volume (ml) (dis. 
in MeOH) Name 
1 9.835 - 3.5 Stock DSPE-PEG  
2 - 560 1.12 Stock Vinorelbine  
  
VLB Concentration Curve y = 27882x + 5084.2
R2 = 0.9995
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Table  8.10: The ratios of stocks to be mixed to obtain 50 and 500ugVLB/1mM 
SSM. 
Sample 
# 
DSPE-
PEG2000 
Stock (ml) 
Amount of 
Vinorelbine  
(ml) 
Amount of 
MeOH will 
be added 
Final 
volume  
 
Final 
Concentration Name 
1 1 1 - 2 500µgVLB/1mM SSM sample 
2 1 0.12 0.88 2 50µgVLB/1mM SSM sample 
3 1 - 1 2  standard 
8.1.10 Preparation of solubilized Vinorelbine in SSM 
The above amounts of Vinorelbine and DSPE-PEG measured into the respective 
100ml round bottom flasks and 1 ml Methanol added to DSPE-PEG standard 
solution. The methanol evaporated in a rotary evaporator, at 45oC, 150rpm and 630 
mmHg preassure under argon. The film obtained further dried in vacuum overnight. 
1ml of isotonic PBS buffer (10mM, pH 7.4) added and flasks vortexed for 2 minutes 
at maximum speed on a thermolyne (maxi mix II) vortex until all the film is 
dispersed. Then bath sonicated for 5 minutes. The sample and standard transferred to 
a NICOMP tube flushed with argon and sealed and left for equilibration in the dark 
at room temperature for 2 hours (25oC). 
8.1.11 Determination of drug delivery system capacity; solubility of Vinorelbine 
(VLB) in SSM: 
The objective of this experiment was to determine the amount of Vinorelbine that is 
solubilized in DSPE-PEG micelles in a concentration of 1mM. Consequently we will 
find the amount of Vinorelbine in buffer. This is the most important part of 
characterization of VLB-SSM formulation. 
Concentrations of prepared samples:  
Table  8.11: Samples prepared to study in DLS investigations. 
Sample 
# 
Amount of Vinorelbine  
(µg/1ml of 1mM DSPE-PEG) 
1 50 
2 100 
3 200 
4 350 
5 500 
6 1000 
7 2000 
8 3000 
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As we will discuss in results part,  generally or normally when we add a certain 
amount of drug to a system which contains any micellar nano-drug delivery system, 
the drug solublizes in buffer in amounts equal to its water solubility. The excess 
amount will be incorporated with micelles and further addings of the drug to the 
system will cause an aggregation or precipitation in system. So by centrifuging the 
system and measuring the amount of drug in supernants we could measure the exact 
amount of solublized drug in Micelles. 
Interestingly even adding 3mg of VLB to the system didn’t make any aggregation. 
So we decided to make more studies to understand what is the position of VLB in 
SSM and waht is its exact amount in SSM and PBS.  
In the other hand we try to understand what prevents the VLB precipitation and what 
makes it such soluble in SSM.     
8.1.12  Investigation of the possibility of forming micelles by free Vinorelbine: 
Sometimes the hydrophobic drug makes its own micellar system and becomes 
soluble in water (Taylor, 1982). To understand if this event comes true in our system 
or not we made one more experiments; searching for drug micelles with DLS. In 
order to understand does the VLB make its own micelles or not a concentration of 
2mg/ml has been prepared. 
8.1.13 Investigation of the solubility of Vinorelbine (VLB) (base form) in PBS 
by pre-solving it in organic solvents 
Previously has been seen that VLB is not soluble in water or PBS (Reported by 
Science Finder using a calculation program). During making the VLB- SSM 
formulation a very high solubility has been seen. To figure out if this is the 
solublization power of SSM or VLB’s water solubility is higher than what references 
report, a solution of VLB in Organic solvent has been prepared by following the 
procedure of making SSM formulation.It is possible that by following the SSM 
preparation procedure, VLB gains a higher solubility than normal conditions. In this 
order certain amounts of VLB has been dissolved in MeOH and evaporated under 
vacuum by using rotary evaporator. The flasks have been kept under vacuum in 
vacuum desiccator overnight.  The day after 1ml of PBS buffer has been added to 
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each sample. Vortexed for 2 minutes and sonicated for 5 minutes. The UV 
absorbance has been measured by using UV spectrophotometer. 
Table  8.12: U.V. absorbance of different concentrations of VLB solublized in PBS 
after making film. 
Sample 
No 
µg VLB ml MeOH 
added 
Total 
vol. 
ml 
Final 
vol. 
ml 
Final 
conc. 
µg/ml 
U.V. 
absorbance 
1 2000 2 2 1 1000 2.7624 
 ml of 
 previous 
slvnt.  
   
  
2 1 1 2 1 500 2.7624 
3 1 1 2 1 250 2.8971 
4 1 1 2 1 125 2.1060 
5 1 1 2 1 62.50 1.0262 
6 1 1 2 1 31.25 0.4494 
7 1 1 2 1 15.63 0.1776 
8 1 1 2 1 7.82 0.1004 
9 1 1 2 1 3.90 0.0677 
10 1 1 2 1 1.95 0.0320 
 As it could be seen in the table above the water solubility of VLB is around 
250µg/ml. To obtain more accurate results the concentrations between 250 and 500 
has been prepared in CHCl3 as below and Again the solubility of VLB is around 
250µg/ml. :  
Table  8.13: U.V. absorbance of different concentrations of VLB solublized in PBS 
after making film. 
Sample No: µg VLB ml CHCl3 added Total ml Final cons. 
µg/ml 
U.V. 
absorbance 
1 
2500 5 5 500 2.8983 Stock Solution 
 ml of stock sl.     
2 0.9 0.1 1 450 2.8605 
3 0.8 0.2 1 400 2.8983 
4 0.7 0.3 1 350 2.8983 
5 0.6 0.4 1 300 3.1616 
6 0.5 0.5 1 250 3.2407 
7 0.4 0.6 1 200 2.9397 
8.1.14 Separation the drug associated with SSM from free drug in buffer by 
centrifuging:   
Using regular centrifuge process:  
Different concentrations of Vinorelbine has been uploaded to 1mM DSPE-PEG200 
and centrifuged for 10 minutes. Samples from supernatants has been collected and 
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injected to HPLC. Also samples from bottom part of tubes have been collected and 
injected as well but at the end of HPLC assay there was no difference between the 
concentration of supernatants and precipitates meaning that nothing is precipitated.  
Using Centrifugal filter tubes: 
As second trial centrifuge tubes with filters in middle has been used. Certain 
concentrations of VLB in 1 mM SSM (1 ml) has been prepared and transferred to 
centrifuge tubes. The best centrifuge period has been calculated considering the 
centrifuge instrument’s radius. The time period is important because we don’t need 
too much centrifuge force. A short period in which only the free drug in PBS finds 
the possibility of passing through filter and the VLB associated with micelle stays 
stable will be enough. 
Certain procedures necessitate precise centrifugation conditions, which must be 
specified in terms of relative centrifugal force (RCF) expressed in units of gravity 
(times gravity or × g). Many microcentrifuges only have settings for speed 
(revolutions per minute, RPM), not relative centrifugal force. Consequently, a 
formula for conversion is required to ensure that the appropriate setting is used in an 
experiment. The relationship between RPM and RCF is as follows: 
g = (1.118 × 10-5) R S2 
Where g is the relative centrifugal force, R is the radius of the rotor in centimeters, 
and S is the speed of the centrifuge in revolutions per minute. Values of RCF in units 
of times gravity (× g) for common microcentrifuge rotor radii appear in the following 
conversion table. As an example, centrifugation of a sample at 5,000 RPM in a 
microcentrifuge that has a rotor with a radius of 7 cm will deliver a centrifugal force 
of 1,957 × g. ("Url- 2 <http://www.piercenet.com>,," accessed at 09.08.2011). 
Filtrates have been injected to HPLC using the method mentioned above. 
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Figure  8.8: The main parts of centrifugal filter tubes (Url- 2). 
The prepared concentrations and obtained results are as below: 
Table  8.14: The prepared concentrations and obtained results of centrifuging VLB-
SSM formulations by using filter tubes. 
Vinorelbine 
(µg/ml) in  
1mM DSPE-
PEG200 (1ml) 
%VLB associating 
with SSM (1mM) 
1st Trial 
%VLB associating 
with SSM (1mM) 
2nd Trial 
%VLB associating 
with SSM (1mM) 
3rd Trial 
50 93.2 94.8 100 
150 92.7 94.7 90.7 
250 91.4 95.0 92.4 
500 90.7 90.9 90.4 
750 84.44 85.4 86.34 
A control sample consisting of 4mgVLB/1ml MeOH has been centrifuged to check 
the error of method and error is near to “0”. No Vinorelbine is absorbed by filter. 
8.1.15 Study the stability of Vinorelbine-SSM formulation after lyophilization 
In case of introducing VLB-SSM as a new cancer therapy agent to the industry, it is 
important to emphesise the method of storing the material. We suggest lyophilizing 
the formulation and rehydrating it before use. The objective of this experiment is to 
measure the amount of Vinorelbine before and after Lyophilization and measure the 
size of SSMs in the same conditions to determine the stability of formulation.   
The amount of Vinorelbine corporated with SSM has been measured by using HPLC 
before and after lyophilization. The HPLC method is mentioned above. The stability 
of size of SSM has been determined by using DLS. The latter assay has been 
repeated 2,3,5,7 and 15 days after Lyophilization and rehydration. 
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8.1.16 Drug release studies by dialysis of Sterically Stabilized Phospholipid 
Micelles containing Vinorelbine (SSM-VLB) 
To perform dialysis, 3 ml of the VLB-SSM dispersion was transferred into dialysis 
membrane tubing, which was then be placed into 300 ml of dialysis medium (PBS 
buffer) at 37oC under constant slow stirring and kept in dark through out the 
experiment.  Two milliliter of dialysis medium was drawn at 0.5, 1, 2, 3, 4, 6, 8, 10, 
12, 20, 22,24, 28, 48, 72 and 90 hours of the experiment.  One milliliter was used for 
immediate drug measurement while the other milliliter saved in case of necessary 
lyophilization to concentrate the sample more for HPLC measurement. Samples will 
also be taken from the dialysis membrane tubing before and after the experiment. 
Release studies will be conducted for 24 hours without any change or replacement of 
dialysis medium (Cho, 2004; Johnston, 2006; Michalowski, 2004; Morris, 2008; 
Zheng, Qiu, Yao, & Zhu, 2009). 
Applied General Parameters: 
• Total PBS media: 300ml 
• Total amount of formulation: 15mg VLB in 30mM SSM, Total Volume 3ml 
• Dialysis temperature: 370C. 
• Sampling periods0.5, 1, 2, 3, 4, 6, 8, 10, 12, 20, 22,24, 28, 48, 72 and 90  
• Sampling volume: 200µl 
• HPLC Method: as mentioned above 
8.1.17 Characterization of Vinorelbine-SSM Formulation by Using Differential 
Scanning Calorimetry (DSC) 
 Previously we showed that the VLB-SSM formulation is stable after lyophilization. 
We assume that in a VLB-SSM formulation, after lyophilization, the amount of drug 
which is associated with micelles will be kept in dry micelle (maybe with some lost). 
Based on this assumption and by following some logical steps we designed the route 
of our investigation: 
The interdigitation of VLB with SSMs will cause a difference in DSC results in 
compare with that of Free SSMs. 
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If we obtain 2 separated crystallization point for DSPE and PEG using DSC, loading 
the drug will cause changes in both or just one of these crystallization points 
according to the settlement of the drug in the core or on the shell of SSMs. 
If we obtain the DSC spectrum of VLB-SSM formulation in buffer prior to 
lyophilization, comparing the crystallization temperature of VLB-SSM in buffer 
(liquid sample) with the solid lyophilized sample will tell us a lot. 
Liquid Samples’ DSC thermogram has been recorded by using special pans are 
available to measure the thermal behaviour of samples in water or buffer.  
 
Figure  8.9: DSC Pans available for A; Solid samples and B; Liquid samples 
(Kastantin, 2009). 
It is noteworthy that in a sample which contains Buffer salts + Drug Delivery 
System+ Drug+ Water, the mass of buffer salts and water covers a very high ratio of 
the mass of total system. So the amount of drug delivery system and drug itself is 
pretty low in comparing with other components of system so it is hard to observe 
very significant and huge peaks as we saw in solid materials. To overcome this 
challenge we made both concentrations in 10 times higher concentration, 500µg and 
5000 µg VLB in 10 mM SSM (in 1ml PBS). 70µl of each formulation has been used 
in DSC assays. 
8.1.18 Cell culture investigation of Vinorelbine in the three different drug 
delivery systems: DSPE-PEG and PCL-PEG polymers.  
The purpose of this experiment is to determine whether Vinorelbine solubilized in 
simple micelles has similar cytotoxic activity against MCF-7 human breast cancer 
cell line, as compared to a solution of Vinorelbine itself.  
Applied General Parameters (Dagar, 2003; Onyueksel, 2009; Onyuksel, 2009): 
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• Complete media has applied to 96 well plates in 190µl volume 
• 3 different drug delivery systems has been used SSMs, Y shaped PCL2-PEGs 
and Star shaped PCL2-PEG2s. 
• The concentration of VLB in SSM is in the same ratio of 500µg VLB/ 1 mM 
Lipid. The concentration of VLB in Polymers is %5 VLB in %95 Polymer 
(w/w). As a result in the highest concentration of formulations, 500ug VLB 
has been uploaded to   
• The final concentration of VLB in all cases were as:16, 8, 0.8, 0.08, 0.008, 
0.0008 µg/ml 
• Before adding VLB-delivery system, all of delivery systems have been 
applied to well plated in amount of 2µl to keep the drug delivery system 
above CMC. The concentration of all delivery systems has been fixed to 100 
times above CMC 
• In case of adding drug in drug delivery system the drug-delivery system has 
added on empty delivery system in 8µl volume  
• VLB in 10% DMSO has been added on complete media in amount of 10 µl 
• All drug delivery systems has been used in their highest concentrations 
(empty) as controls 
• %10 DMSO and PBS are used as Controls too. The amount of all controls 
were 10µl. 
• Measurements were done in 24, 48 and 72 hours and each were repeated 3 
times.  
 
MTT Method Application (Allahverdiyev, 2004; Davydov, 2002) 
• MTT has been applied in the concentration of 1mg/ml in the volume of 100µl 
to each well 
Before applying MTT, the medium has been aspirated from wells and all wells has 
been washed by PBS for three times.   
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8.1.19 Nano-VLB-polymer formulation 
8.1.20 Preparation of polymeric micelles:  
Polymeric Micelles have been prepared by using two different methods. 
8.1.21 Preparation of free polymeric micelles:  
The star-PCL4-PEG4 and PCL2-PEG polymer was dissolved in DMF at ~100 mg/ mL 
and stirred overnight at room temperature. Water was added in a dropwise fashion to 
both of the polymers’ solution in DMF. The addition of water was continued until the 
desired water content was achieved (13% of DMF in the final mixture). The obtained 
solution was stirred overnight and then dialyzed against double distilled water using 
Spectra/Por 1 Molecularporous Dialysis Membrane, Spectrum, MWCO 3500. The 
dialysate water was exchanged every hour for the first 4 h and then every 6 h for the 
next 12 h (Lv et al., 2009; F. Wang et al., 2005; Ward, 2005; Zheng et al., 2009).  
Its noteworthy that the amount of water that must be added on DMF solution of 
polymers prior to dialysis, has been determind by trying different ratios of water/ 
DMF and the ratio %67/ 13 water/ DMF has been found to afford the polymeric 
micelles with the best size and stability. 
8.1.22 Preparation of drug loaded polymeric micelles: 
Solid Extraction: A measured volume of a methanol solution of Vinorelbine (VLB)  
 
Figure  8.10:Preparation of drug loaded polymeric micelles. 
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was added to a 100ml flask and the solvent was removed under vacuum, leaving a 
solid film of Vinorelbine. A pre-prepared polymer micelle solution (by using 
Dialysis) was agitated with VLB for 15 mins mechanically shaked over night. The 
day after dryg loaded micelles were incubated in 25oC for 2 hours (Lv et al., 2009; 
Zheng et al., 2009). 
8.1.23 Determination of the Critical Micelle Concentration (CMC) of polymeric 
micelles. 
 The same method has been applied to determine CMC of both Star and Y Shape 
polymers. The method is briefly as below.  
• The apparent critical micelle concentration was determined using pyrene as a 
fluorescent probe. 
• Sample solutions were prepared by adding known amounts of pyrene in 
acetone to each of a series of empty vials. The amount of pyrene was chosen 
so as to give a pyrene concentration in the final solution of 6x10-7 M. 
• After the evaporation of acetone, solutions of star-PCL4-PEG4 nd Y shaped 
PCL2-PEG of various concentrations in phosphate buffer saline were added to 
the probe. 
• Samples were equilibrated upon shaking overnight at the desired temperature. 
Steady-state fluorescence spectra were recorded at 336 nm for emission iex, 
and for excitation spectra, ìem was 390 nm. 
• From obtained flourescence graphic, the values I3/ I1 has been calculated by 
dividing the height of the peak at 390 to that of 336. 
• The point of crossing of tangents of curve in the graphic of concentration vs 
I3/ I1 gives the point of Critical Micelle Concentration (Lv et al., 2009; F. 
Wang et al., 2005; Ward, 2005; Zheng et al., 2009). 
8.1.24 Determination of Vinorelbine concentration associated with polymeric 
micelles by using Eliza Reader  
During our studies on polymeric formulations of Vinorelbine we had the opportunity 
of measuring the concentration of Vinorelbine in micelle only by using Elisa Reader.  
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Firstly we prepared certain concentrations of Vinorelbine and we obtained the 
concentration curve by reading max. U.V. absorbance at 286nm. Consequently we 
prepared decreasing concentrations of Vinorelbine in vials and evaporated it under 
reduced preassure to obtain a thin film of Vinorelbine in vial. The pre-made 
polymeric micelle in PBS in the constant concentration of 5mg/ml (~CMCx1000) 
has been added on VLB films and agitated for 15 min.s and physically shaked over 
night. 
The day after the polymeric VLB formulations left in 25oC for 2 hours and 
centrifuged at 6000rpm for 30 mins. The supernants transferred to clean holders and 
10 times diluted with methanol to prevent any aggregation of the drug in PBS.  
All other methods used for characterization of polymeric micelles are similar to the 
reported methods used for DSPE-PEG micelles.  
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9. RESULTS AND DISCUSSION 
9.1 Results of Isolation and Structure Elucidation of Vinca Alkaloids from 
Vinca Species 
9.1.1 Identification of some compounds from Vinca herbacea 
This PhD thesis does not cover structure elucidation of Vinca herbacea. However we 
decided to mention our newly published results for identification of chemical 
constituents (Boga et al. 2011) of this species to serve a collected report of all 
structures that have isolated from Turkish Vinca species to the readers.  
An alkaloidal extract of the aerial parts of V. herbacea (herbaceous periwinkle) 
afforded six Indole alkaloids, and their structures were elucidated as 10-
methoxyraucaffrinoline (1) 11-methoxyburnamine (2), picrinine, burnamine, 
caboxine A and elegantine using intensive 1D- and 2DNMR techniques and mass 
spectrometric analyses (Figure  9.1) (Atta-ur-rahman, 1995; Bhattach.J & Pakrashi, 
1972). 
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Figure  9.1: Indole alkaloids isolated from Vinca herbacea. 
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Table  9.1: 1H and 13C NMR spectroscopic data for 10-methoxyraucaffrinoline  and 
11-methoxyburnamine. 
 1 2 
Position 1H-NMR 13C-
NMR 
1H-NMR 13C-NMR 
2 - 181.7  106.9 
3 4.07 d (9.36) 57.4 3.63 brd (2.50)  52.0 
5 3.64 dd (6.24, 4.90) 51.5 4.80 brs   87.8 
6 1.63 d (11.70) 
2.75 dd (11.70, 
4.70) 
38.0 2.4 dd (14.00, 
1.80) 
3.30 d (14.00) 
 45.0 
7 - 65.3 -  54.0 
8 - 138.3 - 126.3 
9 7.02 d (2.73) 111.2 6.73 d (8.40) 125.6 
10 - 158.1 6.68 dd (8.40, 
2.0) 
108.2 
11 6.89 dd (8.58, 2.73) 113.0 - 160.0 
12 7.50 d (8.19) 121.3 6.93 d (2.0)  97.2 
13 - 150.4 - not 
observed 
14 1.53 dd (14.04, 
5.07) 
1.92 dd (14.82, 
9.75) 
22.0 1.98dt (14.40, 
2.50) 
2.05 brd (14.32) 
 22.1 
15 2.47 dd (5.70, 5.07) 26.8 3.49 brt (1.20)   33.8 
16 2.35 dd (6.24, 5.85) 49.6 -  58.1 
17 5.00 s 79.0 3.47 d (12.10) 
3.70 brd (12.12) 
 65.0 
18 1.26 d (7.02) 18.6 1.57 d (6.24)  13.6 
19 3.67 dd (11.0, 8.0) 
3.72 dd (11.0, 5.10) 
62.2 5.37 brq (6.24) 121.1 
20 1.48 ddd (9.10, 8.0, 
5.1) 
46.0 - 138.1 
21 2.52 dd (9.00, 6.90) 53.4 3.14 brd (18.0) 
3.79 brd (18.0) 
 47.2 
OCOCH3 2.17 s 21.4 -  - 
OCOCH3 - 170.1 -  - 
COOCH3 - - 3.72 s  52.4 
COOCH3 - - - 174.1 
OCH3 3.82 s 55.9 3.77 s  54.3 
In another study on Vinca herbacea collected from Ankara (M. Kartal et al.) afforded 
six Indole alkaloids; Reserpinine, Elegantine (isomajidine), Caboxine A, 
Vincamajine, N-methyl, 14-15 dehydroaspidospermidine, Carpanaubine (or iso- 
Carpanaubine) besides a triterpene Ursolic acid ( unpublished data).  
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9.1.2 Identification of Vallesiachotamine 
The fractions 8-9 were obtained by washing the alkaloid extract of Vinca soneri on 
Si-gel column by using Dichloromethane, Acetone (95:5). The combined fractions 
were dried under reduced preassure and the dried residue was dissolved in 
dichloromethane by mild heating. Cooling down the solvent afforded crystals of Vis-
1. 
The alkaloid extract of Vinca minor subjected to a si-gel column resulted in obtaining 
40 fractions.  The 17th fraction was obtained by proceeding the column by using 
Petroleum ether, chloroform (P.E., CHCl3 (50:50)). The obtained fraction was further 
purified on prep. TLC, and mobile phase was CHCl3. The purified compounds were 
named Vim-1 (and its structure was characterised as Vallesiachotamine) and Vim2, 
(its structure was characterised as iso-Vallesiachotamine) 
Vis-1(8mg) and Vim-1(4mg). 
Vallesiachotamine,  
 
 
Figure  9.2: Vallesiachotamine and its isomer. 
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Table  9.2: 1H-NMR and 13C-NMR assignment of Vallesiachotamine and iso-
Vallesiachotamine (Appendix A). 
C No 
1H-NMR Multiplicity 
J (Hz) 
13C-NMR 
Vallesiachotamine 
 
HMBC 
Vallesiachotamine
 
Vallesiachotamine 
iso-
Vallesiachotamine 
2 -  - 132.4 - 
3 4.48 4.16 brd (1;11) 49.2 - 
5α 3.73 3.73 dd (4;11) 51.06 - 5β 3.70 3.70 dd (4) - 
6α 2.94 2.94 m 22.02 - 6β 2.81 2.81 brd (1;15) - 
7 -  - 108.53 - 
8 -  - 136.2 - 
9 7.30 7.30 dd(1;8) 110.9 C-8, C-10 
      
10 7.11 7.11 brt(1;7) 119.81 C-8, C-9 
      
11 7.16 7.16 brt(1;7) 122.13 C-13, C-12 
      
12 7.48 7.48 d(1;8) 118.15 C-13, C-11 
13 -  - 136.2 - 
      
14α 1.94 1.74 dt(7;13) 34.14 - 14β 2.18  brt (13;1) - 
      
15 4.02 4.02 brd (6) 28 - 
16 -  - 168.3 - 
17 7.68 6.10 s 147.4 COH, C-5, C-3, C-15 
      
18 2.10 2.03 d(7) 15.02 C-19, C-20 
      
19 6.68 6.47 q (7) 152.6 C-18, COH 
      
20 -  - 146.4 - 
OCH3 3.64 3.64    
 
The first isolated alkaloid from V. soneri and V. minor identified as an di-substituted 
Indole alkaloid by the observation of four aromatic methine proton signals, resonated 
at δ 7.11, 7.16. 7.30 and 7.48. The characteristic two broadened triplets and two 
broadened doublets indicated a non-substituted benzene of the Indole ring.  The 
presence of a double bond was observed by a methine proton signal at δ 7.68 (s) and 
its corresponding carbon signal at δ 147.4 based on an HMQC correlation. Since 
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there was no second olefinic proton in the 1H-NMR spectrum, the trisubstituted 
nature of the double bond was deduced and located between C-16 and C-17 which 
clearly followed by 13C- NMR and HMBC experiments.  In the presence of a 
carbonyl moiety, such as a carboxymethyl attached to the olefinic proton at C-16 led 
to the observation of a significant down field chemical shift of H-17, resonated at 
about δ 7.68 as a singlet besides a methoxy signal at 3.64 which could be attributed 
to Vallesiachotamine. One of the other most characteristic signal of 
Vallesiachotamine is aldehyde proton observed at δ 9.4, besides a neighbooring 
olefinic proton appeared at 6.68 as a quartet with a J value of 7Hz, indicating a 
coupling with a methyl protons at 2.10 ppm.  This aldehyde bearing ethylenic side 
chain must be attached to C-15. Indeed H-15 signal was observed as a broadened 
doublet at 4.02 (J=6 Hz) confirming Vallesiachotamine structure (Mukhopadhyay, 
1981; Sultana, 1992). All the spectral data and literature comparision verified of Vis-
1 to be Vallesiachotamine which was isolated from both Vinca species V. soneri and 
V. minor for the first time. 
9.1.3 Identification of α-Yohimbine 
The fractions 21-26 were obtained during elution dichloromethane, acetone (DCM, 
Ace (25:75)) of the alkaloid extract of Vinca soneri on Si-gel column and purified 
through preparative thin layer chromatography.  DCM, Ace (70:30) was used as a 
mobile phase which afforded four different pure compounds, named as: Vis.2, 3, 4 
and 5.   
Vis 3(5mg): 
1H-NMR of the alkaloid exhibited four aromatic methine signals resonated at δ 6.95, 
7.025, 7.27, 7.37 which indicated a possible Indole ring moiety in the structure 
attributing to H-10, H-11, H-12 and H-9, respectively. Their corresponding carbons 
were assigned by HMQC experiment, observing the signals at δ 118.30, 120.47, 
110.61 and 117.09. Its skeleton followed by all carbon signals as well as proton 
signals and deduced to be a yohimbine type alkaloid. The lack of a skeletal methyl 
moiety was supported yohimbine structure. 
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Figure  9.3: α-Yohimbine. 
The most characteristic signals were observed at δ 3.41 as a broaden doublet (J 
=11Hz) for H-3, and δ 4.24 as a doublet of doublet (2.7 and 5.6 Hz). The former was 
significant for C-3 proton with α-stereochemistry. The latter was assigned to H-17 
which should be attached to an oxygenated carbon. H-16 was determined based on J 
coupling values of the signal appeared at δ 2.35 and a COSY experiment. H-16 and 
H-17 signals were significant signals which indicated a yohimbine structure of this 
alkaloid. Their carbons were observed at δ 52.41 and 67.22. The presence of an 
carboxy methyl ester group at C-16 followed by 1H-NMR (δ 3.76 as a singlet) and 
13C-NMR (δ 50.75) and carbonyl signal at 173.92 ppm. The carbon NMR 
experiments (BB and APT) displayed 21 carbon signals consisting of six methylene, 
nine methyne, five quaternary carbon atoms and one methoxyl methyl carbon. The 
methoxyl carbon was observed at 50.75 ppm. 
Besides Indole skeleton’s nitrogen, the presence of a second N atom clearly followed 
by its neighboring three carbon atom signals at δ 60.49 (C-3), 52.79 (C-5) and 60.93 
(C-21) and they were assigned by HMQC and HMBC experiments. This carbon 
frame was supported the yohimbine skeleton. 
As indicated  in previous pages yohimbine alkaloids categorized into four different 
type of configurations (normal, pseudo, allo and epi-allo). Among them, β-
yohimbine belongs to normal type yohimbin alkaloids while α-yohimbine included to 
allo-type alkaloids. 
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Table  9.3: 1H-NMR and 13C-NMR assignments of α-Yohimbine (Appendix B). 
C No 
1H-
NMR 
Multiplicity 
J (Hz) 
13C-
NMR COSY HMBC 
2   134.17   
3 3.41 brd (11) 60.49 H-14α,14β  
5α 2.62 d of t (4; 12) 
52.79 
H-5β C-3 
5β 3.1 dd (6;11) H-5α C-3,C-2,C-1,C-7 
6α 2.98 m 20.96   6β 2.72 dd(5;15)  C-7 
7   106.31   
8   126.91   
9 7.37 d(8) 117.09 H-10  
10 6.95 t(8;1) 118.30   
11 7.025 t(8;11) 120.47   
12 7.27 d(8) 110.61   
13   136.69   
14α 1.17 q(11;7) 
32.24 
H-14β,H-3 C-2,C-134,C-
15 
14β 2.46 td (3;1) H-14α,H-3,H-15 
 
15 2.00 dq (2.7; 3) 36.02 H-14β  
16 2.35 dd(11.7;2.7) 52.41   
17 4.24 dd(2.7;5.6) 67.22 H-16,H-18  
18α 1.9 dd(4;13.5) 32.03   18β 1.66 m(2;4;13.3)   
19 1.36-1.39 
m 22.82   
20 1.52 dpentet(2.6;11.0) 39.76 H-21α  
21α 2.26 t(10.9) 60.93 H-21β  21β 2.92 dd(3;11.4) H-21α,H-20  
COOCH3 3.76 s 50.75   
COOCH3   173.92   
 
The only skeletal difference between normal- and allo-type yohimbines is the 
configuration of hydroxyl group at C-17. In this structure, to identify its 
configuration we have considered coupling constant values of H-17 with H-16 
protons and H2-18. The appearance of chemical shift of H-17 at δ 4.24 as a dd and its 
coupling values (Table  9.3) was indicative of β- configuration of H-17. All carbon 
and proton NMR data confirmed the structure to be α- yohimbine (Robert et al., 
1983).   
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9.1.4 Identification of β-Yohimbine 
Vis-5(5mg): 
 
Figure  9.4: β-yohimbine. 
 
Third compound from V. soneri revealed similar spectral data to those of α-
yohimbine. It exhibited 21 carbon signals having the same nature of protonated 
carbons with same numbers. Its Indole ring protons were resonated almost at the 
same frequency (Figure 9.4). C-3 proton was observed at δ 3.3 as an overlapped 
signal by MeOH signal which was determind by an HMQC experiment. Its J value 
followed by coupling constant value of one of C-14 protons at δ 1.20 brt (J = 11.3 
Hz). Consequently the J value of H-3 should be 11.3 Hz which indicated  α-
stereochemistry of H-3. In fact, except for pseudo- and epiallo-yohimbines, normal 
and allo yohimbines always have H-3 with α stereochemistry.  
The main difference between α and β yohimbines was observed for H-17 proton. 
When a β-hydroxyl group was attached to C-17, H-17  was resonated at δ 3.74 as dd 
(J= 3.52 and 10.77Hz) in case of β- Yohimbine while in α-yohimbine (C-17, α-OH)  
it was observed at δ 4.24 with smaller J couplings. 
It should be noted that C-17 signal was observed at 71.58 ppm in β-hydroxylated 
cases in yohimbine structures. Thus, all spectral data confirmed the structure to be β-
yohimbine (Robert et al., 1983). 
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 9.4: 1H-NMR and 13C-NMR assignment of β-Yohimbine (Appendix C). 
C No 1H-NMR 
Multiplicity 
J (Hz) 
13C-NMR 
2   133.89 
3 3.3 Overlapped by MeOH 59.91 
5α 2.64 ddd (4.30;11.3;11.5) 52.77 5β 3.12 dd (5.5;11.3) 
6α 2.96 m 20.98 6β 2.72 dd(4.5;15.4) 
7   106.44 
8   126.87 
9 7.38 d(8) 117.80 
10 6.96 t(8,1) 118.2 
11 7.04 t(8,11) 120.60 
12 7.28 d(8) 110.5 
13   136.69 
14α 1.32 d 33.10 14β 2.16 d 
15 1.52 dd (5) 36.02 
16 2.16 dd (5.7; 10.6) 57.4 
17 3.74 dd(3.52;10.77) 71.5 
18α 2.06 dd(4,14) 33.68 18β 1.4 d 
19α 1.20 dd(3,…) 27.7 19β 1.7 t of d (3,13) 
20 1.48 m 39.4 
21α 2.18 dd(4,10.5) 60.55 21β 2.98 dd(3;10.8) 
CO2CH3 3.80 s 51 
 2.64 ddd(4.30;11.3;11.5)  
 
9.1.5 Identification of Picrinine 
Vis-31 
The positive APCI-MS spectrum of Vis-31 revealed a molecular ion peak at m/z 
339.40  [M+H]+ for C20 H22 O3N2. 
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Figure  9.5. Chemical structure of Picrinine. 
Table  9.5: 1H-NMR and 13C-NMR assignment of Picrinine (Appendix D). 
C No 1H-NMR 
Multiplicity 
J (Hz) 
13C-NMR 
2   106.13 
3 3.68 m 52.75 
5 4.92 m 87.20 
6 2.29 3.42 
dd (3.0; 14) 
d(14) 44.10 
9 6.78 d (7.41) 111.70 
10 6.80 td (1.2; 7.4) 121.66 
11 7.10 td (1.2; 7.4) 128.70 
12 7.13 brd (7.4) 126.6 
     14 1.92 m 21.92 
15 3.31 d (2.5) 32.95 
16 2.45 d (3.5) 58.01 
18 1.49 dd (1.7;7) 14.02 
19 5.44 brq (7) 121.27 
20   137.85 
21 3.16 3.81 
brd (17.6) 
td (18.33) 47.02 
COOCH3 3.66 s 51.13 
COOCH3   174.02 
    N-H 1.84 brs  
 
Its 1H-NMR spectrum exhibited Indole ring protons at δ 6.78, 6.80, 7.10 and 7.13 
with characteristic multiplicities indicating a nonsubstituted benzene of the Indole 
ring. The presence of an ethylenic side chain at C-20 was observed by the signals at δ 
5.44 as br quartet (J =7 Hz)  along with a doublet of doublet at δ 1.49 (J= 1.7 and 7 
Hz) which resembled sarpagine related type indol alkaloids. The smaller J value of 
the latter signal originated from allylic coupling of Me-18 with one of the allylic 
protons. The vinylic proton at δ 5.44 showed three bond away correlation with a 
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carbon, appeared at δ 31.65 assigning to H-15 at δ 3.31 (d, J = 2.6 Hz). This proton 
was also showed a gHMBC correlation with C-19, and vice-versa. Another 
characteristic proton signal was observed at 4.92 ppm as a narrow multiplet, its 
corresponding carbon was determined to be at 87.20 ppm, attributable a carbon 
probably located between a nitrogen and oxygen atoms. The proton signal at 4.92 
showed a three bond correlation with a quaternery carbon signal appeared at 51.25 
which was assigned to C-7, therefore the signal at 4.92 was determined to be H-5. 
Another carbon signal resonated at 106.13 ppm, also assigned to a carbon either 
between two oxygenes or between an oxygen and a nitrogen atoms. Based on g-
HMBC correlation as well as literature data, the signal was deduced to be C-2. In 
fact, it was also located between nitrogen and oxygen atoms, however, its rigid 
situation as a bridge-head carbon caused more downfield resonance compared to C-
5. H-15 also exhibited a three bond away correlation with a carbonyl carbon of the 
ester group indicating location of the ester group at C-16 and verifying the 
assignment of the proton at δ 3.31 belong to C-15 as well as its vicinity to C-20. C-3 
proton signal resonated at δ 3.68 as a broadened doublet (J = 11.20 Hz) which 
coupled to H-14 protons (1.92, m) observed by a COSY experiment. All the 
experimental data allowed to determine of the structure as picrinine (Atta-ur-rahman, 
1995; Batista, 1996) which has been isolated from some Vinca species as well as 
some other Apocynaceae family plants .  
9.1.6 Identification of 11-Hydroxypolyneuridine 
Elution of the alkaloid extract of Vinca major on neutral Aluminium column by 
using EtOAc, MeOH ( 95:5) was afforded fraction 34 which was further purified by 
a second column chromatography. The fraction 19 of the latter column was purified 
by using preparative TLC. The mobile phase was Toluene- Acetone- Diethylamine 
(40:5:5) and 5 compounds were obtained. First compond was named Vmaj-1.     
Vmaj-1(3mg): 
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Figure  9.6: 11-hydroxypolyneuridine. 
This alkaloid has also an Indole skeleton as expected. However it was a mono 
substituted benzene ring exhibiting aromatic signals at δ 6.62, 6.76 and 7.10 
corresponding to H-10, H-12 and H-9, therefore the compound should carry a 
substituent at C-11, probably being a hydroxyl or methoxyl group, but HMBC 
experiments indicated hydroxyl moiety rather than methoxyl moiety.  One of the 
characteristic signal for its skeleton was observed at δ 5.45 as a broadened quartet (J 
=6.7Hz) along with a vinylic methyl doublet appeared at δ 1.70 as a doublet which 
belong to an ethylenic side chain attached to C-20 as seen in sarpagine type Indole 
alkaloids. 
The three carbons attached to the nitrogen atom were observed at δ 50.80 (C-3), 
57.75 (C-5) and 54.53 (C-21). Their protons were assigned by HSQC experiments 
(Table  9.6). In addition, the presence of a hydroxymethylene and carboxy methyl 
groups in the structure followed by 1H and 13C NMR signals (Table  9.6). Based on 
HMBC experiments both their location was deduced to be at C-16.  Particularly C-5 
proton showed three bond correlations hydroxymethylene carbon which appeared at 
67.41 and carboxymethyl carbonyl observed at 173.02 verifying their location at C-
16. All spectral data and literature comparison indicated that Vmaj-1 must be a 
polyneuridine derivative. 
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Table  9.6: 1H-NMR and 13C-NMR assignment of 11-Hydroxypolyneuridine 
(Appendix E). 
C No 1H-NMR 
Multiplicity 
J (Hz) 
13C-NMR COSY HMBC 
2   130.93   
3 4.3 d(10) 50.80   
5 2.9 brd(4) 57.75   
6α 2.81 dd(5,16) 
nd  C-5, C-16, C-7 6β 3.35 dd(2,16)   
7   103.93   
8   131.93   
9 7.1 dd(9) 110.97  C-11, C-13 
10 6.62 dd(2,9) 110.47   
11   149.88   
12 6.76 d(2) 101.86  C-8 
13   127.00   
14α 2.72 q of d (1,5,13) 28.56  C-17 14β 1.92 t (12)   
15 3.27 brd(3) 28.77  C-21, C-3 
16   51.11   
17α 3.78 d(9) 67.41   17β 3.65 d(10)  COCH3 
18 1.7 d (6.7) 11.87  C-19 
19 5.45  117.41   
20   137.22   
21α 3.58 d(16) 54.53   21β 3.69 d(16)   
COOCH3 3.00 s 50.43   
COOCH3   173.02   
 
On the basis of HMBC correlations, a hydroxyl group should be located at C-11, thus 
11-hydroxypolyneuridine was isolated for the first time from nature (Atta-ur-rahman, 
1995; Kogure, 2005; Marinibettolo, 1980).  
 
 
132 
 
9.2 Results of Characterization of Nano-VLB Formulations 
9.2.1 Results of characterization of nano-VLB-SSMs 
9.2.2 Results of solubility of Vinorelbine (VLB) in SSM: 
There was no precipitation in any of samples and time history graphic was so clear 
too.  
A hydrophobic drug has certain water solubility. Normally in a micellar drug 
delivery system drug molecules prefer to be dissolved in water in an amount equal to 
its water solubility. Adding more amount of drug causes the incorporation of 
hydrophobic core of the micelle with the hydrophobic drug. By the addition of higher 
amount of drug causes the precipitation of drug in the holder.  
As it could be seen there is no Vinorelbine agrregation or precipitation even by 
adding 3000µg VLB to the system.  
There are two possibilities:  
1-Since the hydrophilic functional groups on VLB molecule is much localised, it is 
possible for VLB to make its own dimers or micelles in or out of micelle and 
increase the water solubility.  
2- It is noteworthy that micelle size is going smaller and smaller by adding more and 
more vinorelbine. Previously it has been reported that the size of Sterically Stabilized 
Mix Micelles’ (SSMM) is smaller than normal SSMs. The reason is that a “unimer” 
of DSPE localises in between two DSPE-PEG”unimers” in the “polymeric” micelle 
structure and gives the PEG part to fold more than before. We know that the size of 
PEG layer encloses a very important part of the size of all of micell. Therefore more 
folding in PEG layer causes the whole micelle go smaller and smaller.  
We shall pay attention on that some times 2-3 nm difference in size is not important 
in DLS measurements. We repeated our assays at least 3 times and calculated the 
Standard Deviation. The change in size of micelle by addition of more VLB is in 
range of meaningfullness.  
The results has been repeated for 3 times, and particle size measurements have been 
repeated for 3 subsequent days and then one week after. When the particle size was 
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stable for 1mg VLB/1mM lipid, the size of micelles containing 2 and 3 mg VLB 
were increasing after first day. 
It seems that the VLB units settled in between two DSPE unimers, leave their 
position after some days and cause an enlargement in micellar size. 
Starting from this point we need to understand if VLB makes its own micelles or 
incorporates with the DSPE core of the SSMs.  
 
 
Figure  9.7: Localization of VLB in between 2 DSPE-PEG unimers and observation 
of a decrease in size of particle. 
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Table  9.7: The results of particle sizing of different formulations of VLB-SSM by 
using DLS. 
VLB conc.  
in 1mM lipid 
(1ml) 
INT-WT and VOL-WT Time History 
50 
 
 
100 
 
 
200 
 
 
350 
 
 
500 
 
 
1000 
 
 
2000 
 
 
3000 
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Table  9.8: The relationship between amount of VLB associated with SSM and 
micelle size. 
VLB 
conc. 
(µg/1mM 
SSM) 
Micelle 
size 
(nm) 
First 
day  
Micelle 
size 
(nm) 
3rd 
day 
50 14.02 14.2 
100 14.16 14.2 
200 14.42 14.2 
350 14.24 14.2 
500 13.9 14.2 
1000 13.4 13 
2000 12.02 12.9 
3000 11.04 12.1 
 
 
9.2.3 The UV study of VLB associated with SSM:  
We assume that if Vinorelbine associated with SSM is in molecular level  its UV 
absorbance will be equal to that of free VLB in molecular level in in buffer. In this 
assay, we repeated the UV absorbance measurments 3 times in a day and once again 
after three days. The reason is explained under the “Results” part.  
Table  9.9: Free Vinorelbine concentration curve in PBS in UV spectrophotometer. 
VLB Conc. 
µg/ml U.V. absorbance 
125 2.106 
62.5 1.0262 
31.25 0.4494 
15.63 0.1776 
7.82 0.1004 
3.9 0.0677 
1.95 0.032 
0 0 
 
 
y = 0.0169x - 0.0302 
9.2.4 UV Absorbance of 1mM SSM associated Vinorelbine in different 
concentrations: 
After identification of UV absorbance of VLB in PBS, we have measured the same 
concentrations of VLB in 1mM SSM. If the VLB is in molecular level in SSMs we 
should get the same absorbance that VLB showed in PBS with SSM-VLB 
formulation. 
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Table  9.10:  UV absorbance of 1mM SSM associated Vinorelbine in different 
concentrations. 
VLB conc. 
(µg/ml) in  
1 mM DSPE-
PEG 2000 
UV 
absorbance 
First day 
UV 
absorbance 
First day 
(2nd trial) 
UV 
absorbance 
First day 
(3rd trial) 
UV absorbance 
After 3 days 
(the same for all 
formulations) 
50 1.8097 1.2205 1.2264 2.1632 
150 2.8204 3.8698 3.8698 3.1095 
250 3.8996 3.8698 3.8698 3.8876 
350 3.8996 3.8698 3.8698 3.8876 
500 3.8996 3.8698 3.8698 3.8876 
1000 4.5000 4.5000 4.5000 4.5000 
1500 4.5000 4.5000 4.5000 4.5000 
2000 4.5000 4.5000 4.5000 4.5000 
3000 4.5000 4.5000 4.5000 4.5000 
 
 
Figure  9.8: UV absorbance of VLB in 1mM DSPE-PEG 2000. 
As a result of above study, its impossible to use the free VLB conc. curve equation to 
find out the amount of VLB in SSM or to prove that VLB is in molecular level in 
SSM or not. For example if we use the equation to find the amount of VLB 
associated with SSM in the first line equation (50µgVLB/1mM lipid):  y = 0.0169x - 
0.0302, 1.8097= 0.0169x - 0.0302  x= 106.9 µg/ml. But this is impossible because 
we used only 50 µg/ml VLB in making this formulation.  
But starting from this point we could come to the conclusion that in all 
concentrations of VLB a part or all of the drug is associated with SSMs and that is 
why the UV absorption of a certain amount of VLB is much more higher than the 
same amount of free drug. 
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9.2.5 Results of Investigation of the Possibility of Forming Micelles by Free 
Vinorelbine: 
A concentration of 2 mg/ml has been prepared by using the method reported in Table 
 8.9 and Table  8.10, and the existence of particles has been studied in NICOMP 
particle sizer, but no significant result has been obtained: 
 
Figure  9.9: DLS investigation of 2 mg VLB in PBS. 
However in time history diagram some particles with stable sizes (2600 and 1000 
nm) show up but disappear as soon as we dilute this concentration to 1mg/ml: 
 
Figure  9.10: Time history diagram in DLS investigation of 2 mg VLB in PBS. 
But when we incorporate the same amount of drug with 1mM SSM the solvent is 
completely clear and these particles are disappeared: 
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Figure  9.11: DLS investigation of 2 mg VLB associated with DSPE-PEG. 
As a result either Vinorelbine is makes  its own micelles or not, this is a clear proof 
of the association of the drug with micelles. But as we will mention in DSC results, 
eventually we came to the conclusuion that VLB does not make its own micelles in 
water and the particles detected by NICOMP particle sizer are not real particles. 
Generally, this happens in particle sizing assays carried out in highly diluted systems. 
9.2.6 Results of separation of the amount of drug associated with SSM from 
free drug in buffer by centrifuge  
As mentioned in Methods part, using normal centrifuge tubes, no difference was 
observed between the concentration of supernatants and precipitates, which meanes 
there is neither a precipitation during centrifuge procedure nor latent aggregation in 
system.   
By using Centrifugal Filter Tubes the results are as follows: 
 
Figure  9.12: Amount of VLB associated with SSM followed by centrifuge assay. 
Three very important results are obtained: 
1- The more Vinorelbine the more association between SSM and drug. As seen in the left 
hand graphic, increasing the amount of drug causes more association and consequently 
less drug has been filtrated in centrifuge tubes.  
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2- We have calculated the percentage of drug is associated with SSMs, as illustrated in the 
right hand graphic. The amount of VLB associated with DSPE-PEG raises up starting 
from low concentration up to 500µg and faces a little decrease after increasing its 
concentration from 500µg to 1mg. Probably 500µg VLB concentration in the system is 
the highest point of association of SSM with drug and above this point in 1mM SSM 
concentration, the drug delivery system is saturated with with drug and it starts to be 
solved in buffer.  
3- The most important result: If we shall choose the most appropriate formulation 500µg 
VLB in 1mM SSM would be the best in which the physical properties of formulation is 
stable even after 3 days and also is the highest amount of stable incorporation of the 
drug with SSM. 
Earlier reports support our results. Previously by using “Differential Scanning 
Calorimetry” it has been shown that the most favored position of Vinorelbine (VLB) 
in lipid bilayer is at the interface part of polar and non-polar groups of phospholipids 
bilayer (C.Koukoulitsa et al. Chemistry and Physics of Lipids 144 (2006) 85-95). The 
same study exhibited the amphoteric property of Vinorelbine should be a reason for 
its association with model lipid bilayer. According to this study, Vinorelbine is 
characterized by an extensive hydrophobic area covering both catharantine and 
vindoline moieties and hydrophilic groups predominated in vindoline moiety. 
 
Figure  9.13: The amphoteric property of Vinorelbine (Koukolitsa, 2006 ). 
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There is always a second possibility that must be concidered. Sometimes the 
existance of a latent aggregate in the system causes a shift in the size diagram of 
particles. For example if we have two different particles with 20 and 2000 nm 
diameters, the larger particle causes a left hand shift in the size diagram of the 
smaller particle. This causes in measurement of the size of the smaller particle as 18-
17 nm. About our results, it is possible that VLB is making it’s own micelles (or 
soluble aggregates) and this floating aggregates are pushing the DSPE-PEG2000 
micells’ size daigram to left and results in the sizing them as 11-12 nm.  
By using centrifuge assays, we showed that this hypothesis does not really come true. 
However we discard the possibility of presence of latent aggregates in the system by 
choosing the 500 µg VLB/ 1mM SSM as the most stable formulation in which there 
is no decrease in size of micelles.  
9.2.7 Results of the stability of Vinorelbine-SSM formulation after 
lyophilization: 
Concentration changes before anf after lyophilization and rehydration : 
Table  9.11: The amount of VLB in SSM, measured by HPLC. 
VLB amount before lyophilization 
(µg/ml) 
VLB amount after lyophilization 
4487.715302 3992.526628 
4485.582259 3993.453780 
6411.449000 4884.277000 
 
Figure  9.14: Changes in concentration of VLB in SSM after lyophilization. 
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Table  9.12: Size changes before and after lyophilization. 
before lyophilization after lyophilization 
 
 
 
 
 
 
Table  9.13: Differences in size of micelles before and after lyophilization. 
Particle size nm 
before lyophilization 
Particle size nm 
after lyophilization 
10.8 12.3 
11.8 11.8 
10.7 11.7 
Standard Deviation Standard Deviation 
0.60827625 0.32145503 
 
Figure  9.15: Changes in micelle size after lyophilization. 
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Table  9.14: Changes in micellar size in 2,3,5,7 and 15 days after lyophilization. 
2nd day 
 
7th day 
 
3rd day 
 
15th day 
 
5th day 
 
  
The Physical Result of Lyophilization: 
We were also able to get a fluffy material of formulation after lyophilization as could 
seen in photos: 
 
Figure  9.16: The physical results of lyophilization. 
As it could seen there is no significant change in size and amount of Vinorelbine in 
500µg VLB/1mM SSM formulation after and before lyophilization. 
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9.2.8 Results of drug release studies by dialysis of Sterically Stabilized 
Phospholipid Micelles containing Vinorelbine (SSM-VLB) 
First Release Study: 
Table  9.15: First VLB-SSM release results. 
Time(H) % release 
0 0 
0.5 -0.15 
1 1.47 
2 3.11 
3 5.15 
4 6.36 
6 5.7 
12 11.82 
21 16.56 
24 18.79 
30 18.94 
48 25.58 
 
 
As it could seen the very first sample of release (0.5h) was not sufficient to be 
detected. To solve this problem in the second and third trials, 1ml of media has been 
sampled and lyophilized. The lyophilized sample was dissolved in 200µl of MeOH 
to obtain 5 times higher absorbance. Thus, the 5 times concentrated sample was used 
in calculations. 
Second Release Study:  
Table  9.16: Second VLB-SSM release results. 
Time (h) % release 
0 0 
0.5 0.12 
1 1.49 
2 3.50 
3 5.45 
4 6.50 
6 7.10 
12 11.73 
24 15.10 
28 18.30 
48 20.1 
72 22.29 
90 35.71 
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3rd Dialysis Study: 
Table  9.17: Third VLB-SSM release results. 
Time 
(h) % release 
0 0 
0.5 0.7 
1 1.47 
2 4.6 
3 6.15 
4 6.36 
12 11.81 
18 9.61 
22 13.15 
24 15.94 
48 26.42 
53 32.53 
96 82.66 
117 99.06 
 
 
Total Release Results: 
Table  9.18: Total release results. 
Time (h) 0 0.5 1 2 3 4 12 24 48 
%Release 0 0.22 1.47 3.73 5.58 6.40 11.79 16.61 24.03 
STDV 0 0.434319 0.011547 0.772679 0.51316 0.080829 0.051962 1.934089 3.432162 
 
Figure  9.17: VLB-SSM Total release result. 
The release from VLB-SSM formulation is slow enough to keep drug stable until the 
drug delivery system reaches the cancer cell side, and it then releases.  
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Also the “very slow release” period confirms the tight corporation of the drug with 
DSPE part of the micelle. 
9.2.9 Results of DSC assays of SSM-VLB formulation: 
9.2.10  Results of Solid Samples  
 
Figure  9.18: DSC thermogram of PEG 2000. 
As shown in the above  figure, PEG 2000 shows a crystallization temperature at 
56oC. 
The dip point is obtained herein is due to the stock of polymers as seen below and 
mentioned before (Fig.6.4).  
This crystallization temperature decreases to 52oC in case of DSPE-PEG2000 
sample: 
In Figure  9.19 a new peak in 48oC has shown up. We didn’t have naked DSPE to 
compare its Thermogram with obtained spectrum.However the Thermogram of 
Dipalmitoyl Phosphatidyl Choline (DPPC) which is structurally very near to DSPE 
as 41 oC. 
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Figure  9.19: DSC thermogram of solid DSPE-PEG 2000 (obtained commercially) 
before making SSM. 
So it seems that the spectrum in 48 oC is related to DSPE. Probably DSPE is also 
making some stacks possibly not as organized as PEG, but ordered enough to give a 
crystallization thermogram. 
The decrease in crystallization temperature of PEG probably is due to attachment to 
DSPE. During the Click Reaction both materials loose energy equal to the binding 
energy and this causes a reduction in crystallization temperature.  On the other hand 
binding of PEG to DSPE causes a disruption in the structure of above mentioned 
polymeric stock and this is another reason for the decrease in crystallization energy. 
 
Figure  9.20: Unfolding of PEG at the point of attachment to DSPE and decrease in 
crystallization temperature. 
The Illustrated Reason of Reduced Crystallization Temperature of PEG after Binding 
to DSPE  
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A very interesting result is obtained from the Thermogram of DSPE-PEG after 
making SSM. The film making procedure has been followed and the obtained free 
SSM formulation obtained has been freeze dried.  The result is as seen below:  
 
Figure  9.21: DSC Thermogram of solid DSPE-PEG 2000 after making SSM. 
It seems that we lose the crystallization thermogram of DSPE after making film and 
lyophilization. This probably is related to the amorphous shape which hydrophobic 
DSPE gains after dealing with water. As we mentioned on, amorphous material don’t 
show crystallization temperature. 
 Other result which obtained from this thermogram is the second peak related to 
PEG. PEG gave 2 different peaks; 52 oC and 54 oC. The crystallization peak at 52 oC 
is the same with DSPE-PEG before film making and the shoulder at 54 oC is related 
to PEG stocks that found the opportunity of making crystals again after 
lyophilization whole around the micelles.  
Results of Solid Samples of VLB associated with SSM: 
As mentioned above, we measured the water solubility of Vinorelbine (VLB) as 
250µg/ml. In order to determine the behaviour of Vinorelbine in Sterically 
Satabilized Micellar (SSM) system, we chose two different concentrations of VLB, 
one below its water solubility; 50µg/ml and the second above it; 500µg/ml. In both 
cases the concentration of SSM was 1mM. 
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Figure  9.22: The illustration of changes in SSM structure after lyophilization. 
Thermogram of 50µg VLB associated with 1mM SSM:  
 
Figure  9.23: Thermogram of 50µg VLB associated with 1mM SSM after 
lyophilization. 
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The area under peak (∆H) has been enhanced (71.36J/g for Free SSM and 86.24J/g 
for 50µg VLB associated with SSM). Since this is the freez dried sample we assume 
that the enhancement of the thermogram is due to the association of VLB with the 
core part, eventhough there is no significant change in the core part of Thermogram 
(around 46oC).   
 
Figure  9.24: Thermogram of 50µg VLB associated with 1mM SSM  in comparing 
with the free SSM, both after lyophilization. 
 Thermogram of 500µg VLB associated with 1mM SSM: 
The thermogram showes a very significant change both in ∆H (123.99 J/g for 
500µgVLB-SSM and 71.36J/g for the free SSM) crystallization thermogram. This 
indicates the association of VLB with SSM completely in core part since there is a 
significant change in DSPE thermogram at 46oC. 
 
Figure  9.25: Thermogram of 500µg VLB associated with 1mM SSM after 
lyophilization. 
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Figure  9.26: Thermogram of 500µg VLB associated with 1mM SSM in comparing 
with free SSM after lyophilization. 
As we mentioned above the presence of drug in lipid based lamellar drug delivery 
systems induces partial interdigitation as it is depicted by the increase of ∆H and 
reduction of crystallization temperature. 
9.2.11 Results of Liquid Samples 
The Thermogram of the free SSM (10mM) in Buffer: 
 
 
Figure  9.27: The thermogram of free SSM (10mM) in buffer. 
As we mentioned on Figure  9.22 in liquid media DSPE chains are able to make 
stacks and we could see this at 46oC as the crystallization thermogram of core part. 
Also there is a significant decrease in the crystallization thermogram of PEG layer. 
In Figure  6.4, we showed how polymers give crystallization dip and in Figure  9.22 
we saw how PEG chains are sprinkled in water and give crystallization thermogram 
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in lower point. Here in buffer media, obviously PEG layer is freer in comparing with 
its lyophilized shape and exhibits the crystallization temperature at 50oC instead 52 
oC and 54 oC (Figure  9.21). 
The Thermogram of 50µg VLB/1mM SSM (500µgVLB/10mM SSM) in Buffer: 
 
Figure  9.28: The thermogram of 50µg VLB/1mM SSM (500µgVLB/10mM SSM) in 
buffer.  
Because of the low concentration of VLB-SSM in whole system the crystallization 
thermograms are not significant; we assigned the exact temperatures by following the 
similar points in solid samples.   
There is a shift in core part from 46oC to 45oC which could indicate the localization 
of VLB in core. As we mentioned before this could be a sign of intedigitation of 
VLB with the DSPE layer. This is where there is no change in PEG layer’s 
crystallization temperature and this evident confirms the localization of VLB in core 
not on PEG layer (50 and 50oC) (Figure  9.28 and Figure  9.27).  
The Thermogram of 500µg VLB/1mM SSM (5000µgVLB/10mM SSM) in Buffer: 
Using 500µg VLB gives us more significant peaks. Again when there is almost no 
change in PEG layer (50oC in comparing with 50 and 50oC) there is a shift in 
crystallization temperature of DSPE layer; 45oC (46oC in free SSM). 
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Figure  9.29: The thermogram of 500µg VLB/1mM SSM (5000µgVLB/10mM SSM) 
in buffer. 
When we use 500µg VLB in 1mM SSM both in solid and liquid phases we obtain 
very good results which showes a complete incorporation of drug in SSM in core 
part.  
 
Figure  9.30: The thermogram of 500µg VLB/1mM SSM (5000µgVLB/10mM SSM) 
after lyophilization (solid) and in in Buffer (liquid). 
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The Thermogram of solid Vinorelbine:  
To ensure that Vinorelbine’s DSC spectrum does not interfere with SSM’s 
thermogram, we recorded thermal behaviour of the free dug. 
Interestingly no crystallization or melting point was seen in VLB’s thermogram. 
However there was an exothermic peak at 42oC which indicates the “decomposition” 
or “degradation”of the drug during heating. 
 
Figure  9.31: The thermogram of solid Vinorelbine. 
We don’t see this exothermic peak in the thermogram of VLB-SSM samples. This is 
probably due to the protection of the drug by the covering shell of SSM. If this 
assumption is correct this evidence again confirms the incorporation of VLB with 
core part. The settlement of VLB on shell wouldn’t protect the drug from 
degradation and would give us the exothermic peak in all samples. 
In the other hand this thermogram showes us that Vinorelbine has an amorphous 
compound. It is in chrystalline form neither in molecular level nor in drug delivery 
system. 
In solid samples PEG layer finds opportunity to make stacks and gives a high 
crystallization temperature. But, in liquid samples PEG layer is less folded and more 
scattered, so crystallization temperature is lower than solid phase. However, there is 
no significant change in mentioned temps in comparison with free SSM in each case. 
So, VLB is incorporated with PEG layer neither in solid nor in liquid phase. 
 The DSPE layer is able to make kind of stack in water, so gives a crystallization 
peak around 46oC. However, it seems that a kind of deformation happens in the core 
of micelle during the lyophilization and this event prevents the recording of DSPE 
crystallization peak at solid samples (after lyophilization). But, fortunately we see the 
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DSPE crystallization peak when we incorporate 500µg VLB with 1mM micelle both 
in solid and liquid phases. Probably, the interdigitation of VLB with core gives 
enough energy to the system and the DSPE crystallization peak shows up again in 
thermogram. 
As a result, although we were not able to measure the exact amount of VLB 
incorporated with the core of SSM we successfully showed the loading of VLB to 
DSPE part of the micelles. 
9.2.12 Results of characterization of polymeric micelles 
9.2.13 Results of determination of the Critical Micelle Concentration (CMC) of 
polymeric micelles: 
 
Figure  9.32: Excitation vs wavelength in determining the CMC value of Star-PCL-
PEG. 
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Figure  9.33:CMC graph of Star-PCL-PEG. 
 
Figure  9.34: : Excitation vs wavelength in determining the CMC value of Y-Shaped-
PCL-PEG. 
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Figure  9.35: CMC graph of Y shaped-PCL-PEG. 
The CMC of Star Shaped polymer has been calculated as 50mg/l which is in the 
borders of acceptable CMC ranges.   
That was the reason we tried to synthesize the second polymer.  
As we showed in synthesizing part of thesis, we used a benzene ring as dendrimer in 
the 4 arm star shape polymer. Probably this ring is causing a steric hindrance for 
unimers to get along and make micelles.  
 
Figure  9.36: The steric hinderance in making micelles made by benzene rings. 
Although this is a very sofisticated illustration, and in reality the size of benzene ring 
in comparing with the length of PCL and PEG parts is ignorable, we need to consider 
that there is no attracting force in between benzene rings and also in comparing with 
other polymeric micellar systems that have been reported, our unimers do not make a 
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network in the corona of micellar system. So we decided to synthesize a polymer 
with “Chain Form” corona and ended up with Y Shape PCL2-PEG. 
As it could seen the CMC of the second polymer is 1mg/l which is accepted as an 
excellent CMC value in previous papers.  
Although the CMC is very satisfying in Y Shaped Polymer, we faced a problem with 
this material. 
In Pyrene fluorescence of Star Shape polymer there is a point after which pyrene 
shows no fluorescenece. This means all pyrene molecules are aggregated and non of 
them are in molecular level insizde of polymeric micelle (Chattopadhyay, 1984).  
In contrast the fluorescence of pyrene in micelles made by Y-Shaped polymer never 
goes to zero and whatever the concentration of polymer is, pyrene is giving some 
flourescence even under CMC point. That’s the reason the CMC graphic is that odd.  
The reason of this extra ordinary behaviour of pyrene maybe is due to some 
aggregates that are made by Y shaped polymers under CMC. Under CMC although 
there is no Micellar aggregation in system there are some amorph aggregates that 
entrap pyrene and helps it to give fluorescence. This situation has been reported by 
some other groups too (Jones, 1999). This is what nedds to be confirmed by DLS 
assays.  
9.2.14 Results of particle sizing assay of VLB-polymeric micelles formulation: 
The results of DLS assay support the CMC results. The size of Star Shaped polymer 
is 59nm. However under CMC we have aggregations with ~250nm size.   
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Figure  9.37: Results of DLS investigation of the size of Star-PCL-PEG. 
 
Figure  9.38: Results of DLS investigation of the size of Y shaped-PCL-PEG. 
The micellar size is around 114nm and under CMC we find an aggregate at 62 and 
255 nm.  
9.2.15 Results of solubility of Vinorelbine (VLB) in polymeric micelles: 
Dealing with polymers, we didn’t face the extra ordinary solubilization case of 
Vinorelbine in SSM. Vinorelbine reached a certain solubility capacity in Polymeric 
micelles and then started making aggregates.  
The rsults are as below and were similar for both polymers: 
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Table  9.19:Results of Solubility of Vinorelbine (VLB) in polymeric micelles. 
Total VLB (ug/ml)  VLB ug/ml associated with 5mg/ml Polymer 
50 50 
100 100 
150 150 
200 200 
250 250 
300 250 
350 250 
400 150 
500 150 
 
Figure  9.39: The results of determining the max. Amount of VLB carried by 
polymeric micelles 
As a result 5mg Polymer is able to carry 250µg VLB which is equal to %5 of 
Polymer’s mass. 
Table  9.20: The comparision of mass of different drug delivery systems carrying 
500µg VLB. 
 SSM Star- PCL4 -PEG4 Y- PCL2 -PEG 
500µg VLB is 
soluble in: 1mM= 2.81 mg 10 mg 10 mg 
0
50
100
150
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50 100 150 200 250 300 350 400 500
Total VLB added to Polymeric System (ug/ml)
VLB ug/ml associated with 5mg/ml Polymer
VLB ug/ml in supernants
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9.2.16 Results of drug release studies by dialysis of PCL-PEG-VLBs 
The samples obtained from dialysis bath has been diluted using MeOH (x10) and the 
U.V. absorbance has been recorded by using Eliza Reader at 286nm. Since the 
dialysis results of two different polymers are very similar we don’t report the same 
results twice. 
Table  9.21:  Results of Drug Release Studies by Dialysis of Polymeric Micelles 
Containing Vinorelbine (PCL-PEG-VLB). 
% Release VLB/Pol 
micelle 
Hour %Release 
0 0 
0,5 10,32 
1 14,35 
2 16,36 
3 19,68 
4 25,22 
6 32,23 
9 38,45 
12 39,67 
24 42,44 
48 60 
 
 
The release period of VLB-Polymer formulation is slow enough to be used in cancer 
tharapy by using targeted drug delivery.  
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9.2.17 Results of the ınvestigation of cytotoxic activity of Nano-VLB 
formulations: 
9.2.18 VLB-SSM 
Cytotoxic activity of VLB in SSM after 24 hours 
 
Figure  9.40: VLB-SSM cytotoxic activity after 24 h. 
Table  9.22: VLB-SSM cytotoxic activity after 24 h. 
VLB CONC. % CONTROL 24h STDV 
16ug VLB/32uM (89.92ug) SSM 66.9  3.044667 
8ug VLB/16uM (44,96 ug) SSM 65.24297  5.017679 
0.8ug VLB/1.6uM (4,496 ug) SSM  67.18352  3.268222 
0.08ug VLB/0.16  uM  ( 0,496 ug) SSM 79.68791  4.109966 
0.008ug VLB/0.016 uM ( 0,0496 ug) SSM 83.90033  2.155281 
0.0008ug VLB/0.0016 uM (0,00496 ug) SSM 94.38791  4.00357 
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Cytotoxic activity of VLB in SSM after 48 hours 
 
Figure  9.41: VLB-SSM cytotoxic activity after 48 h. 
Table  9.23: VLB-SSM cytotoxic activity after 48 h. 
VLB CONC. % CONTROL 48h STDV 
16ug VLB/32uM (89.92ug) SSM 62.36667 0.665833 
8ug VLB/16uM (44,96 ug) SSM 62.53333 1.28582 
0.8ug VLB/1.6uM (4,496 ug) SSM  65.8 1.915724 
0.08ug VLB/0.16  uM  ( 0,496 ug) SSM 73.56667 2.466441 
0.008ug VLB/0.016 uM ( 0,0496 ug) SSM 77.93333 2.11266 
0.0008ug VLB/0.0016 uM (0,00496 ug) SSM 83.2 2.535744 
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Cytotoxic activity of VLB in SSM after 72 hours 
 
Figure  9.42: VLB-SSM cytotoxic activity after 72 h. 
Table  9.24: VLB-SSM cytotoxic activity after 72 h. 
VLB CONC. % CONTROL 72h STDV 
16ug VLB/32uM (89.92ug) SSM 41.5 8.884256 
8ug VLB/16uM (44,96 ug) SSM 43.5 8.019823 
0.8ug VLB/1.6uM (4,496 ug) SSM  50.6 8.070239 
0.08ug VLB/0.16  uM  ( 0,496 ug) SSM 59.67853 2.790698 
0.008ug VLB/0.016 uM ( 0,0496 ug) SSM 62.90565 2.469391 
0.0008ug VLB/0.0016 uM (0,00496 ug) SSM 69.93202 3.62307 
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9.2.19 VLB-Y Shaped polymer 
VLB-Y Shaped Polymer Cytotoxic Activity after 24 Hours 
 
Figure  9.43: Cytotoxic activity of VLB-Y Shaped PCL-PEG polymer in 24 h. 
Table  9.25: Cytotoxic activity of VLB-Y Shaped PCL-PEG polymer in 24h. 
VLB CONC. % CONTROL 24h STDV 
16ug VLB/320ug Y sh. Pol 72.31111  2.005917 
8ug VLB/160ug Y sh. Pol 73.28018  1.992692 
0.8ug VLB/16ug Y sh. Pol 75.54301  2.081594 
0.08ug VLB/1.6ug Y sh. Pol 77.93651  0.797287 
0.008ug VLB/0.16ug Y sh. Pol 81.36111  1.809108 
0.0008ug VLB/0.016ug Y sh. Pol 86.53147  1.111877 
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VLB-Y Shaped Polymer Cytotoxic Activity after 48 Hours 
 
Figure  9.44: Cytotoxic activity of VLB-Y Shaped PCL-PEG polymer in 48 h. 
Table  9.26: Cytotoxic activity of VLB-Y Shaped PCL-PEG polymer in 48 h. 
VLB CONC. % CONTROL 48h STDV 
16ug VLB/320ug Y sh. Pol 56.76667 4.574203 
8ug VLB/160ug Y sh. Pol 58.2 4.503332 
0.8ug VLB/16ug Y sh. Pol 62.14533 2.8327 
0.08ug VLB/1.6ug Y sh. Pol 66.50059 2.786869 
0.008ug VLB/0.16ug Y sh. Pol 74.5826 1.283188 
0.0008ug VLB/0.016ug Y sh. Pol 82.71622 1.932373 
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VLB-Y Shaped Polymer Cytotoxic Activity after 72 Hours 
 
Figure  9.45: Cytotoxic activity of VLB-Y Shaped PCL-PEG polymer in 72 h. 
Table  9.27: Cytotoxic activity of VLB-Y Shaped PCL-PEG polymer in 72 h. 
VLB CONC. % CONTROL 72h STDV 
16ug VLB/320ug Y sh. Pol 39.79096 7.178032 
8ug VLB/160ug Y sh. Pol 45.47006 5.834016 
0.8ug VLB/16ug Y sh. Pol 53.68362 2.073716 
0.08ug VLB/1.6ug Y sh. Pol 62.25989 4.395596 
0.008ug VLB/0.16ug Y sh. Pol 67.58418 1.358241 
0.0008ug VLB/0.016ug Y sh. Pol 75.58757 2.504597 
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9.2.20 VLB-Star Shaped polymer 
Star Shaped Polymer Cytotoxic Activity after 24 Hours 
 
Figure  9.46: Cytotoxic activity of VLB-Star Shaped PCL-PEG polymer in 24 h. 
Table  9.28: Cytotoxic activity of VLB-Star Shaped PCL-PEG polymer in 24 h. 
VLB CONC. % CONTROL 24h STDV 
16ug VLB/320ug Star sh. Pol 71.13333 1.41892 
8ug VLB/160ug Star sh. Pol 69.03333 2.182506 
0.8ug VLB/16ug Star sh. Pol 71.5 1.322876 
0.08ug VLB/1.6ug Star sh. Pol 74.16667 1.607275 
0.008ug VLB/ 0.16ug Star sh. Pol 81.06667 3.426855 
0.0008ug VLB/0.016ug Star sh. Pol 87.3 2.306513 
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Star Shaped Polymer Cytotoxic Activity after 48 Hours 
 
Figure  9.47: Cytotoxic activity of VLB-Star Shaped PCL-PEG polymer in 48 h. 
Table  9.29: Cytotoxic activity of VLB-Star Shaped PCL-PEG polymer in 48 h. 
VLB CONC. % CONTROL 48h STDV 
16ug VLB/320ug Star sh. Pol 59.6  5.670979 
8ug VLB/160ug Star sh. Pol 62.2  4.084116 
0.8ug VLB/16ug Star sh. Pol 65.48889  2.542382 
0.08ug VLB/1.6ug Star sh. Pol 69.1  1.4 
0.008ug VLB/ 0.16ug Star sh. Pol 75.46667  3.233162 
0.0008ug VLB/0.016ug Star sh. Pol 79.53333  1.501111 
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Star Shaped Polymer Cytotoxic Activity after 72 Hours 
 
Figure  9.48: Cytotoxic activity of VLB-Star Shaped PCL-PEG polymer in 72 h. 
Table  9.30: Cytotoxic activity of VLB-Star Shaped PCL-PEG polymer in 72 h. 
VLB CONC. % CONTROL 48h STDV 
16ug VLB/320ug Star sh. Pol 42.8  5.8 
8ug VLB/160ug Star sh. Pol 46  2.73913 
0.8ug VLB/16ug Star sh. Pol 53.2  5.694212 
0.08ug VLB/1.6ug Star sh. Pol 54.5  3.814149 
0.008ug VLB/ 0.16ug Star sh. Pol 57.2  5.642694 
0.0008ug VLB/0.016ug Star sh. Pol 61.37391  5.301546 
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VLB in %10 DMSO after 24 h 
 
Figure  9.49: Cytotoxic activity of free VLB in 24h. 
Table  9.31: Cytotoxic activity of free VLB in 24h. 
VLB CONC. % CONTROL 48h STDV 
16ug VLB/%10 DMSO 61.34534  4.544604 
8ug VLB/%10 DMSO 63.09525  4.193084 
0.8ug VLB/%10 DMSO 66.84642  7.373908 
0.08ug VLB/%10 DMSO 71.64132  2.183458 
0.008ug VLB/%10 DMSO 78.14511  3.433965 
0.0008ug VLB/%10 DMSO 84.07831  8.065308 
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VLB in %10 DMSO after 48 h 
 
Figure  9.50: Cytotoxic activity of free VLB in 48h. 
Table  9.32: Cytotoxic activity of free VLB in 48h. 
VLB CONC. 
% CONTROL 
48h STDV 
16ug VLB/%10 DMSO 36.74044  3.160696 
8ug VLB/%10 DMSO 51.11143  2.177919 
0.8ug VLB/%10 DMSO 67.24581  1.270171 
0.08ug VLB/%10 DMSO 69.53089  2.615977 
0.008ug VLB/%10 DMSO 70.44066  0.80829 
0.0008ug VLB/%10 DMSO 70.04371  1.305118 
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VLB in %10 DMSO after 72 h 
 
Figure  9.51: Cytotoxic activity of free VLB in 72h. 
Table  9.33: Cytotoxic activity of free VLB in 72h. 
VLB CONC. % CONTROL 72h  STDV 
16ug VLB/%10 DMSO 46  4.71593 
8ug VLB/%10 DMSO 50.6  2.986637 
0.8ug VLB/%10 DMSO 61  6.237788 
0.08ug VLB/%10 DMSO 65.66667  5.040172 
0.008ug VLB/%10 DMSO 72.93333  3.682843 
0.0008ug VLB/%10 DMSO 77.2  10.78518 
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Controls: 
 
Figure  9.52: Cytotoxic activity of different drug delivery systems on MCF-7 in 24 h. 
 
Figure  9.53: Cytotoxic activity of different drug delivery systems on MCF-7 in 48 h. 
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Figure  9.54: Cytotoxic activity of different drug delivery systems on MCF-7 in 72 h. 
Determination of IC50 of 3 Different Formulations of Vinorelbine in 72 h. 
Table  9.34: Determining IC50 of 3 different formulations of Vinorelbine in 72 h. 
Formulation IC50 STDV 
Free VLB 8.127951 0.71593 
VLB-SSM 1.199619 0.309321 
VLB-Y Shaped Pol 1.956646 0.5907 
VLB- Star Shaped Pol 1.337767 0.4173 
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Figure  9.55: IC50 of 3 different formulations of Vinorelbine in 72 h in comparing 
with free VLB. 
Cytotoxic Activity  Discussion:  
The cytotoxic activity of different Nano-formulations of Vinorelbine shows 
improvement comparing with Free Vinorelbine. This improvement is %85.24 for 
VLB-SSM, %75.92 for VLB-Y Shape Pol. and %83.54 for VLB-Star Shape Pol. 
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10. CONCLUSION AND RECOMMENDATIONS 
10.1 Conclusion of Results Obtained from Plant Analysis:  
 
In this study we report the isolation and structure elucidation of Vinca alkaloids 
obtained from Turkish Vinca species which consist of Vallesiachotamine, α-
Yohimbine, β-Yohimbine, Picrinine from Vinca soneri, Vallesiachotamine and iso-
Vallesiachotamine from Vinca minor, and 11-Hydroxypolyneuridine was isolated as 
a new compound from Vinca major. The fourth species growing in Turkey is V. 
herbacea, our investigation on it afforded Indole alkaloids, 10-
Methoxyraucaffrinoline, 11-Methoxyburnamine, Picrinine, Burnamine, Caboxine A 
and Elegantine. Our results on the study of V. herbacea has been just published in 
2011 (Boğa et al.). 
Since Vinca soneri has newly been introduced to the world of science by Turkish 
scientists (Koyuncu, 2011) it was important to confirm the relationship of this 
species to Vinca L. Because α- Yohimbine and β-Yohimbine are being reported for 
the first time from a Vinca species. This could be an evidence for the novelity of V. 
soneri which differed from other Vinca species while the presence of Picrinine which 
is a common chemical constituent of Vinca species, also found in the other three 
species investigated in this study,l verified that the species soneri should belong to 
the genus Vinca L. 
The synthesis of yohimbine derivatives have attracted a significant attention (Brown, 
2000; D. J. Mergott & Jacobsen, 2005; D. J. Z. Mergott, S. J.; Jacobsen, E. N., 2008; 
Mustafa, 2005; Yoshino, 2008) due to their aphrodisiac and CNS stimulant activity. 
Early studies suggest that the alkaloid stimulated the respiratory center in small 
doses, while depressed respiration in large doses. It is generally considered an α2-
adrenergic blocking agent. According to Goodman and Gilman, the activity of 
Yohimbine may arise from being an relatively selective inhibitor of α2-adrenergic 
receptors, enhancing neural release of norepinephrine at concentrations less than 
those required to block postsynaptic α1 receptor. Yohimbine also blocks peripheral 5-
HT receptors. Aphrodisiac activity has also been attributed to the enlargement of 
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blood vessels in the genitalia, transmission of nerve impulses to genital tissue, and an 
increased reflex excitability in the sacral region of the spinal cord. Yohimbine is also 
reported as a monoamine oxidase inhibitor; it also possesses a weak calcium
.
 channel 
blocking effect (Wiley-Blackwell, 2010).  
So, the newly introduced plant Vinca soneri could be presented as a new source of 
Yohimbine derivatives and could further be used in biological and chemical assays. 
10.2 Conclusion of Results Obtained from Synthesis and Characterization of 
nano-Vinorelbine (nao-VLB) Formulations 
In this study we report synthesis and characterization of three different nano-VLB 
formulations. Vinorelbine is a dimeric Vinca alkaloid and is a chemotherapeutic 
agent which is used in the treatment of non-small cell lung cancer and breast cancer 
 0, p.71). This agent has numerous side effects (Chapter  5.4, p.74), therefore we have 
prepared nano-VLB formulations by uploading Vinorelbine to the micellar drug 
delivery systems. By this way, we will be able to target cancer tumors and this will 
cause a reduction in the side effects of commercially available Vinorelbine ( 4.2, 
p.36, Chapter  4.10, p.66).   
It is important to prepare a formulation which has the appropriate size, not detectable 
by MPS, with a prolonged release period, enhancing cytotoxic effect in comparision 
with free Vinorelbine and is not toxic to the healthy cells, as well ( 4.4 p: 48, Chapter 
 4.5, p: 51, Chapter  4.6 p:53, Chapter  4.7 p:55, Chapter  4.8 p:59, Chapter  4.9, p: 64 
and Chaper  4.10, p: 66). 
We then prepared three different nano-VLB formulations all of which form micelles 
in aqueous systems;  
1-VLB-SSM Formulation (Chapter  4.3.3, p:45), Sterically Stabilized Micelles are 
well known targeted drug delivery systems with a very low CMC value (1µM) 
(Chapter  4.3.3, p:45). Their size is ~15 nm (Chapter  4.3.3, p:45), and by uploading of 
the drug the size is reduced to ~11nm  8.1.11, p:108). The most stable formulation 
was found to be 500µgVLB/1mM SSM formulation. In this formulation, release 
period is long enough (%35.7 release after 90h) (Chapter  8.1.16 p: 113) to be 
effective in cancer side. We also showed that it is stable enough after lyophilization 
without using any surfactant which is suitable to store for a certain period  8.1.15, 
p:112). And lastly VLB-SSM formulation has a cytotoxic activity ~6.7 times better 
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than free VLB. Together with all of these results by using DLS and DSC we came 
into a conclusion that VLB settles in the core of sterically stabilized micelle in 
between 2 DSPE units and this property gives an extra ordinary stability to the 
formulation ( 9.2.9, p:145). There is always a second possibility that must be 
concidered. Sometimes the existance of a latent aggregate in the system causes a 
shift in the size diagram of particles. In our results, it is possible that VLB is making 
it’s own micelles (or soluble aggregates) and this floating aggregates are pushing the 
DSPE-PEG2000 micells’ size daigram to left and results in the sizing them as 11-12 
nm.  
By using centrifuge assays, we showed that this hypothesis does not really come true. 
However we could discard the possibility of presence of latent aggregates in the 
system by choosing the 500 µg VLB/ 1mM SSM as the most stable formulation in 
which there is no decrease in size of micelles.  
 2- VLB-star shape PCL4-PEG4 (VLB-Star Poly) and 3- VLB-Y shape PCL2-PEG 
(VLB-Y Poly) formulations: While PCL and PEG are very well known 
biodegradable materials, the synthesis and structure of the unimers are completely 
new  8.1.1, p:95). We measured the CMC value of VLB-Star Poly and VLB-Y Poly  
as 50mg/L and 1mg/L, respectively. Both are acceptable values for polymeric nano 
drug delivery systems. However, the latter CMC value is ideal for a targeted drug 
delivery system  9.2.13, p:154). The size of these two micelles are 59 nm for VLB-
Star Poly and 114 nm for VLB- Y Poly. Both micelles exhibited to have acceptable 
sizes to achieve passive targeting (Chapter 4.3.1, p:43). However, both polymers are 
making aggregates under CMC value which is considered as a handicap for drug 
delivery systems, because the pharmacokinetic of aggregates would be completely 
different from micelles. Both polymeric micelles are able to carry VLB maximum in 
an amount equal to 5% of polymer weight (5% VLB/95%Pol (w/w)). The release 
period is sufficient (%60 release in 48h), but is not as long as VLB-SSM 
formulation. Cytotoxic activity of VLB-Poly formulations are enhanced in 
comparing to the free VLB (~ 4.1 times for VLB-Y Poly and ~6 times enhancement 
for VLB- Star Poly) (Chapter 9.2.19-9.2.20 and p:184).  
As a conclusion, although the characterization of all nano-VLB formulations 
revealed sufficient results, the best results are obtained by VLB-SSM formulation 
which might be due to the lipophilicity of Vinorelbine (Koukoulitsa, 2006). This 
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property causes a high affinity of drug to the sterically stabilized micelles which is 
the main reason of high solubility, prolonged release and a better cytotoxic activity 
of VLB-SSM formulation.    
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APPENDIX A: NMR Spectra of Vallesiachotamine 
 
Figure A. 1: Vallesiachotamine 1H NMR. 
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Figure A. 2: Vallesiachotamine 1H NMR (1.1-3.5 ppm). 
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Figure A. 3: Vallesiachotamine 1H NMR (8.5-10.8 ppm). 
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Figure A. 4: Vallesiachotamine 1H NMR (3.4-4.7 ppm). 
 
195 
 
 
Figure A. 5: Vallesiachotamine 1H NMR aromatic area. 
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Figure A. 6: Vallesiachotamine APT spectrum. 
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Figure A. 7: Vallesiachotamine COSY spectrum. 
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Figure A. 8: Vallesiachotamine HMQC spectrum. 
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Figure A. 9: Vallesiachotamine HMBC spectrum. 
200 
 
APPENDIX B: NMR Spectra of α-Yohimbine 
 
Figure B. 1: α-Yohimbine 1H-NMR Spectrum. 
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Figure B. 2:  α-Yohimbine 1H-NMR (1.0-2.1 ppm). 
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Figure B. 3: α-Yohimbine 1H-NMR (3.3-4.3 ppm). 
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Figure B. 4: : α-Yohimbine 1H-NMR (2.2-3.2 ppm). 
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Figure B. 5: α-Yohimbine 1H-NMR aromatic area. 
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Figure B. 6: α-Yohimbine APT Spectrum. 
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Figure B. 7: α-Yohimbine COSY Spectrum. 
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Figure B. 8: : α-Yohimbine HMBC Spectrum. 
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Figure B. 9: α-Yohimbine HMQC Spectrum. 
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APPENDIX C: NMR Spectra of β –Yohimbine  
 
Figure C. 1: β- Yohimbine, 1H-NMR. 
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Figure C. 2: β –Yohimbine 1H-NMR (1.0-2.5 ppm). 
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Figure C. 3: β –Yohimbine 1H-NMR aromatic area. 
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Figure C. 4: β –Yohimbine APT Spectrum. 
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Figure C. 5: β –Yohimbine BB Spectrum. 
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Figure C. 6: β –Yohimbine HSQC Spectrum. 
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Figure C. 7: : β –Yohimbine HMBC Spectrum. 
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APPENDIX D:  Spectral Data of Picrinine  
 
Figure D. 1: 1H-NMR spectrum of Picrinine. 
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Figure D. 2: Picrinine 1H-NMR (1.0-2.1 ppm). 
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Figure D. 3: Picrinine 1H-NMR Aromatic Area. 
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Figure D. 4: Picrinine MASS Spectrum. 
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Figure D. 5: Picrinine MASS Spectrum 2. 
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APPENDIX E: NMR Spactra of 11-Hydroxypolyneuridine  
 
Figure E. 1: 1 H-NMR-Spactrum of 11-Hydroxypolyneurid. 
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Figure E. 2: 11-Hydroxypolyneuridine 1H-NMR (0.7-2.2 ppm). 
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Figure E. 3: 11-Hydroxypolyneuridine 1H-NMR aromatic area. 
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Figure E. 4: 11-Hydroxypolyneuridine APT Spectrum. 
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Figure E. 5: 11-Hydroxypolyneuridine BB Spectrum. 
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Figure E. 6: 11-Hydroxypolyneuridine COSY Spectrum. 
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Figure E. 7: 11-Hydroxypolyneuridine HSQC Spectrum. 
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Figure E. 8: 11-Hydroxypolyneuridine HMBC Spectrum. 
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APPENDIX F: Indole Alkaloids Isolated from Vinca minor, major & herbacea 
Table F. 1: Indole alkaloids isolated from Vinca minor, major and herbacea. 
Compound Structure Source Year 
Published 
Literature  
Vinoxine 
 
Vinca 
minor 1977 
Vinoxine, A Novel Type of Indole Alkaloid, Voticky, Z. Et al. 
Collection Czechoslov. Chem. Commun., 42, 548-552, 1977 
O-
Acetylvinoxine 
 
Vinca 
minor 1977 
Vinoxine, A Novel Type of Indole Alkaloid, Voticky, Z. Et al. 
Collection Czechoslov. Chem. Commun., 42, 548-552, 1977 
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Table F. 1 (Contd): Indole alkaloids isolated from Vinca minor, major and herbacea. 
16-
epipleiocarpamine 
 
Vinca 
minor 1977 
Vinoxine, A Novel Type of Indole Alkaloid, Voticky, Z. Et al. 
Collection Czechoslov. Chem. Commun., 42, 548-552, 1977 
Pleiocarpamine 
 
Vinca 
minor 1977 
Vinoxine, A Novel Type of Indole Alkaloid, Voticky, Z. Et al. 
Collection Czechoslov. Chem. Commun., 42, 548-552, 1977 
19-
Dihydrovinoxine 
 
Vinca 
minor 1977 
Vinoxine, A Novel Type of Indole Alkaloid, Voticky, Z. Et al. 
Collection Czechoslov. Chem. Commun., 42, 548-552, 1977 
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Table F. 1(Contd): Indole alkaloids isolated from Vinca minor, major and herbacea. 
Vincarubine 
 
Vinca 
minor 1986 
Vincarubine, A Novel Bisindole Alkaloid from Vinca minor, Proksa, B. 
et al. Tetrahedron Letters, 27, 5413-5416, 1986  
(-)-
Vincorine 
 
Vinca 
minor 1962 
Alkaloids from Vinca minor L. Vincadine, minovine and vincorine, 
MOKRY J, DUBRAVKOVA L, SEFCOVIC P. Experientia. 1962 
15;18:564-5. 
 
Vincadine 
 
Vinca 
minor 1962 
Alkaloids from Vinca minor L. Vincadine, minovine and vincorine, 
MOKRY J, DUBRAVKOVA L, SEFCOVIC P. Experientia. 1962 
15;18:564-5. 
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Table F. 1(Contd): Indole alkaloids isolated from Vinca minor, major and herbacea. 
Minovine 
 
Vinca 
minor 1962 
Alkaloids from Vinca minor L. Vincadine, minovine and vincorine, 
MOKRY J, DUBRAVKOVA L, SEFCOVIC P. Experientia. 1962 
15;18:564-5. 
(-)-1-
Norvincorine 
 
Vinca 
minor 1987 
Proksa, B., Uhrín, D., Grossmann, E., & Votický, Z. (1987). (-)-1-
Norvincorine, a New Alkaloid from Vinca minor. Planta Medica, 
53(1), 120. 
Minovincine 
 
Vinca 
minor 1974 
Dopke, W., Meisel,H., Structure and Stereochemistry of Alkaloid 
from Vinca minor, Die Pharmazie, 29, 68, 1974 
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Table F. 1(Contd): Indole alkaloids isolated from Vinca minor, major and herbacea. 
Minovincinine 
 
Vinca 
minor 1973 
Malikov, V.M., Yunusov, S.Y., Vinca Alkaloids, Chemistry 
of Natural Compounds, 5, 597-617, 1977 
Ervinidinine 
 
Vinca 
minor 1973 
Malikov, V.M., Yunusov, S.Y., Vinca Alkaloids, Chemistry 
of Natural Compounds, 5, 597-617, 1977 
11-
Methoxyvincadiformine 
 
Vinca 
minor 1964 
Malikov, V.M., Yunusov, S.Y., Vinca Alkaloids, Chemistry 
of Natural Compounds, 5, 597-617, 1977 
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Table F. 1(Contd): Indole alkaloids isolated from Vinca minor, major and herbacea. 
±Vincadiformine 
 
Vinca 
minor 1973 
Malikov, V.M., Yunusov, S.Y., Vinca Alkaloids, Chemistry 
of Natural Compounds, 5, 597-617, 1977 
11-
Methoxyminovincine 
 
Vinca 
minor 1973 
Malikov, V.M., Yunusov, S.Y., Vinca Alkaloids, Chemistry 
of Natural Compounds, 5, 597-617, 1977 
N-
Methylvincadiformine 
 
Vinca 
minor 1973 
Malikov, V.M., Yunusov, S.Y., Vinca Alkaloids, Chemistry 
of Natural Compounds, 5, 597-617, 1977 
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Table F. 1(Contd): Indole alkaloids isolated from Vinca minor, major and herbacea. 
11-
Methoxyminovincinine 
 
Vinca 
minor 1973 
Malikov, V.M., Yunusov, S.Y., Vinca Alkaloids, Chemistry 
of Natural Compounds, 5, 597-617, 1977 
5-Oxominovincine 
 
Vinca 
minor 1973 
Malikov, V.M., Yunusov, S.Y., Vinca Alkaloids, Chemistry 
of Natural Compounds, 5, 597-617, 1977 
N-
Methylaspidospermidine 
 
Vinca 
minor 1973 
Malikov, V.M., Yunusov, S.Y., Vinca Alkaloids, Chemistry 
of Natural Compounds, 5, 597-617, 1977 
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Table F. 1(Contd): Indole alkaloids isolated from Vinca minor, major and herbacea. 
Picrinine 
 
Vinca 
minor 1973 
Malikov, V.M., Yunusov, S.Y., Vinca Alkaloids, Chemistry of Natural 
Compounds, 5, 597-617, 1977 
Vincoridine 
 
Vinca 
minor 1973 
Malikov, V.M., Yunusov, S.Y., Vinca Alkaloids, Chemistry of Natural 
Compounds, 5, 597-617, 1977 
Vincovine 
 
Vinca 
minor 1971 
Malikov, V.M., Yunusov, S.Y., Vinca Alkaloids, Chemistry of Natural 
Compounds, 5, 597-617, 1977 
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Table F. 1(Contd): Indole alkaloids isolated from Vinca minor, major and herbacea. 
N-
Methylquebrachamine 
 
Vinca 
minor 1973 
Malikov, V.M., Yunusov, S.Y., Vinca Alkaloids, Chemistry 
of Natural Compounds, 5, 597-617, 1977 
Vincaminorine 
 
Vinca 
minor 1973 
Malikov, V.M., Yunusov, S.Y., Vinca Alkaloids, Chemistry 
of Natural Compounds, 5, 597-617, 1977 
Vincaminoridine 
 
Vinca 
minor 1973 
Malikov, V.M., Yunusov, S.Y., Vinca Alkaloids, Chemistry 
of Natural Compounds, 5, 597-617, 1977 
10-
Methoxyvellosimine 
 
Vinca 
minor 1973 
Malikov, V.M., Yunusov, S.Y., Vinca Alkaloids, Chemistry 
of Natural Compounds, 5, 597-617, 1977 
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Table F. 1(Contd): Indole alkaloids isolated from Vinca minor, major and herbacea. 
R=R3=OH; R1=OH; R2=COOCH3 
Vincamine 
 
Vinca 
minor 
1973 
 
Malikov, V.M., Yunusov, S.Y., Vinca 
Alkaloids, Chemistry of Natural Compounds, 5, 
597-617, 1977 
R=R3=H; R1= COOCH3; R2= OH 16-
Epivincamine 
R= R3=H; R1 = R2 =O (±)-Eburnamonine 
R=OCH3, R1 = OH; R2 = COOCH3, R3 =H 
Vincine 
R= R1= R3=H; R2= OH, (-)Eburnamine 
R= R3=H; R1=H;∆16,17 Eburnamerine 
R= R3=H; R1= R2=O, (-)-Eburnamerine 
R= R2= R3=H, R1=OH (+)-Isoeburnamine 
R= OCH3; R1= R2=O; R3=H, 11-
Methoxyburnamonine 
R= OCH3;  ; R1= R2=O; R3=H, 
11,12Dimethoxyeburnamonine 
R=H, R1=OH; R2=COOCH3; R3=O 
Vincaminine 
R=OCH3, R1=OH; R2=COOCH3, R3=O, 
Vincinine 
R=H, R1=R3=OH, R2=COOCH3, 
Hydroxyvincamine 
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Table F. 1(Contd): Indole alkaloids isolated from Vinca minor, major and herbacea. 
Reserpine 
 
Vinca 
minor 1961 
Malikov, V.M., Yunusov, S.Y., Vinca 
Alkaloids, Chemistry of Natural Compounds, 5, 
597-617, 1977 
Dehydroaspidospermide 
 
Vinca 
minor 1973 
Malikov, V.M., Yunusov, S.Y., Vinca 
Alkaloids, Chemistry of Natural Compounds, 5, 
597-617, 1977 
Vinorine 
 
Vinca 
minor 1971 
Malikov, V.M., Yunusov, S.Y., Vinca 
Alkaloids, Chemistry of Natural Compounds, 5, 
597-617, 1977 
R=OCH3; R1=CH2OH, 10-
Methoxydeacetylakyammiline 
 
 
Vinca 
minor 1972 
Malikov, V.M., Yunusov, S.Y., Vinca 
Alkaloids, Chemistry of Natural Compounds, 5, 
597-617, 1977 
R=H, R1=CH2OH, 
Deacetylakyammiline 
R=R2=H, Vincamidine 
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Table F. 1(Contd): Indole alkaloids isolated from Vinca minor, major and herbacea. 
11-
Methoxytetrahydroalstonine 
 
Vinca 
major 1991 
Mukhopadhyay, G., Mukherjee, B., Patra, A., Chatterjee, 
A., Ghosh, R., Roychowdhury, P., & Kawazura, H. (1991). 
11-Methoxytetrahydroalstonine, a heteroyohimbinoid 
alkaloid from Vinca major. Phytochemistry, 30(7), 2447-
2449 
Reserpinine 
 
Vinca 
major 1974 
A.Banerji and M. Chakrabarty, Lochaverine, A New Indole 
Alkaloid of Vinca major, Phytochemistry, 13, 2309-2312, 
1974 
R=H,Vincamajoreine 
R=COMe, O-Acetyl 
vincamajoreine 
 
Vinca 
major 1974 
A.Banerji and M. Chakrabarty, Lochvinerine, A New 
Indole Alkaloid of Vinca major, Phytochemistry, 13, 2309-
2312, 1974 
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Table F. 1 (Contd): Indole alkaloids isolated from Vinca minor, major and herbacea. 
R=OMe,R1=H, R2=CHO, 10-
Methoxyvellosimine 
R=OMe,R1=CH2OH, R2=H, 
Lochvinerine 
 
 
Vinca 
major 1974 
A.Banerji and M. Chakrabarty, Lochvinerine, A New Indole 
Alkaloid of Vinca major, Phytochemistry, 13, 2309-2312, 
1974 
R1=βCHO, R2=Me, 10-
Methoxyperakine 
R1=βCH2-OCOMe, R2=Me, 
Vincawajine 
 
Vinca 
major 1995 
Atta-Ur-Rahman, Sultana A., Nighat, F., Bhatti,M. K., 
Kurucu, S., Kartal, M., Alkaloids from Vinca major, 
Phytochemistry, 38, 1057-1061, 1995. 
10-Methoxyvinorine 
 
Vinca 
major 1995 
Atta-Ur-Rahman, Sultana A., Nighat, F., Bhatti,M. K., 
Kurucu, S., Kartal, M., Alkaloids from Vinca major, 
Phytochemistry, 38, 1057-1061, 1995. 
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Table F. 1(Contd): Indole alkaloids isolated from Vinca minor, major and herbacea. 
Akuammicine 
 
Vinca 
major 1964 
Malikov, V.M., Yunusov, S.Y., Vinca Alkaloids, 
Chemistry of Natural Compounds, 5, 597-617, 1977 
R=OCH3, R1=Ac; R2=R3=H; 
R4=CH3 Majoridine 
R= OCH3, R1= R2= R3=H; R4= 
CH3,  Vincamajoreine 
R= R1= R3=H, R2=COOCH3, R4= 
CH3, Vincamajine 
R= R3=H, R1= Ac, R2=COOCH3, 
R4= CH3, Vincamedine   
Vinca 
major 1977 
Malikov, V.M., Yunusov, S.Y., Vinca Alkaloids, 
Chemistry of Natural Compounds, 5, 597-617, 1977 
Akuammine 
 
Vinca 
major 1964 
Malikov, V.M., Yunusov, S.Y., Vinca Alkaloids, 
Chemistry of Natural Compounds, 5, 597-617, 1977 
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Table F. 1(Contd): Indole alkaloids isolated from Vinca minor, major and herbacea. 
Vincamine 
 
Vinca 
major 1973 
Malikov, V.M., Yunusov, S.Y., Vinca Alkaloids, Chemistry of Natural 
Compounds, 5, 597-617, 1977 
Ervine 
(rauniticine) 
 
Vinca 
major 1977 
Malikov, V.M., Yunusov, S.Y., Vinca Alkaloids, Chemistry of Natural 
Compounds, 5, 597-617, 1977 
Majidine 
 
Vinca 
major 1964 
Malikov, V.M., Yunusov, S.Y., Vinca Alkaloids, Chemistry of Natural 
Compounds, 5, 597-617, 1977 
Majorinine 
 
Vinca 
major 1977 
Malikov, V.M., Yunusov, S.Y., Vinca Alkaloids, Chemistry of Natural 
Compounds, 5, 597-617, 1977 
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Table F. 1(Contd): Indole alkaloids isolated from Vinca minor, major and herbacea. 
Majidine 
 
Vinca 
herbaceae 1968 
I. Ognyanov, B. Pyuskyulev, I. Kompiš, T. Sticzay, G. Spiteller, M. 
Shamma and R.J. Shine, Alkaloids from vinca herbacea The structures and 
stereochemistry of majdine and isomajdine,TetrahedronVolume 24, 1968, 
4641-4648  
Isomajidine 
 
Vinca 
herbacea 1968 
I. Ognyanov, B. Pyuskyulev, I. Kompiš, T. Sticzay, G. Spiteller, M. 
Shamma and R.J. Shine, Alkaloids from vinca herbacea The structures and 
stereochemistry of majdine and isomajdine, Tetrahedron Volume 24, 1968, 
4641-4648 
Akuammicine 
 
Vinca 
herbacea 1964 
Malikov, V.M., Yunusov, S.Y., Vinca Alkaloids, Chemistry of Natural 
Compounds, 5, 597-617, 1977 
Vincanine 
 
Vinca 
herbacea 1973 
Malikov, V.M., Yunusov, S.Y., Vinca Alkaloids, Chemistry of Natural 
Compounds, 5, 597-617, 1977 
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Table F. 1(Contd): Indole alkaloids isolated from Vinca minor, major and herbacea. 
R=OH, Tabersonine 
R=OCH3, Methoxytabersonine 
 
Vinca 
herbacea 1973 
Malikov, V.M., Yunusov, S.Y., Vinca Alkaloids, 
Chemistry of Natural Compounds, 5, 597-617, 1977 
N-Methyl-∆14,15-
dehydroaspidospermidine 
 
Vinca 
herbacea 1975 
Malikov, V.M., Yunusov, S.Y., Vinca Alkaloids, 
Chemistry of Natural Compounds, 5, 597-617, 1977 
Venalstonine 
 
Vinca 
herbacea 1969 
Malikov, V.M., Yunusov, S.Y., Vinca Alkaloids, 
Chemistry of Natural Compounds, 5, 597-617, 1977 
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Table F. 1(Contd): Indole alkaloids isolated from Vinca minor, major and herbacea. 
R= R1=R3=R4=H, 
R2=COOCH3, Vincarine 
R= R1= R4=H, R2=COOCH3, 
R3=OH, Herbaline, 
R= R1=H, R2=COOCH3, 
R3=OH, R4=CH3, Herbamine 
 
 
Vinca 
herbacea 1972 
Malikov, V.M., Yunusov, S.Y., Vinca Alkaloids, 
Chemistry of Natural Compounds, 5, 597-617, 1977 
R=R3=OH; R1=OH; 
R2=COOCH3 Vincamine 
 
 
Vinca 
herbacea 1968 
Malikov, V.M., Yunusov, S.Y., Vinca Alkaloids, 
Chemistry of Natural Compounds, 5, 597-617, 1977 
R=H, Herbaine 
R=OMe, Herbaceine  
 
Vinca 
herbacea 1963 
Malikov, V.M., Yunusov, S.Y., Vinca Alkaloids, 
Chemistry of Natural Compounds, 5, 597-617, 1977 
Reserpinine 
 
Vinca 
major 1974 
A.Banerji and M. Chakrabarty, Lochaverine, A New 
Indole Alkaloid of Vinca major, Phytochemistry, 13, 
2309-2312, 1974 
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Table F. 1(Contd): Indole alkaloids isolated from Vinca minor, major and herbacea. 
Majidine 
 
Vinca 
herbacea 1964 
Malikov, V.M., Yunusov, S.Y., Vinca Alkaloids, 
Chemistry of Natural Compounds, 5, 597-617, 1977 
R=OCH3, 16-
carboxyherbavine 
R=H, Herbaline 
 
Vinca 
herbacea 
1975 
1973 
Malikov, V.M., Yunusov, S.Y., Vinca Alkaloids, 
Chemistry of Natural Compounds, 5, 597-617, 1977 
Skimmianine 
 
Vinca 
herbacea 1971 
Malikov, V.M., Yunusov, S.Y., Vinca Alkaloids, 
Chemistry of Natural Compounds, 5, 597-617, 1977 
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